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Summary 
Prostatic diseases are common; benign prostate hyperplasia (BPH) is almost 
ubiquitous in elderly men (1) and 899,000 men were diagnosed with prostate 
cancer worldwide in 2008.(2)  The incidence of both is increasing and expected to 
continue to rise.(3,4)  Therefore, prostatic diseases represent a considerable 
economic burden, but there are currently no reliable markers available to 
accurately differentiate indolent from aggressive disease nor to predict who will 
benefit from treatment for either BPH or prostate cancer.  This results in over and 
under-treatment of both diseases with consequent patient related morbidity and 
mortality. 
The molecular mechanisms underlying the natural history of prostatic diseases 
remain elusive.  It is accepted that prostate cell growth and survival are 
exquisitely dependent upon activation of the androgen receptor (AR) by androgens.  
Following ligand binding, AR undergoes further phosphorylation at serine residues, 
which inhibit proteolytic degradation, stabilise AR and influence AR 
transactivation.  It is therefore plausible that alterations in AR phosphorylation 
may drive prostatic disease progression.  However, few studies have explored the 
significance of AR phosphorylation, or the kinases driving AR serine 
phosphorylation in the clinical setting. 
The over-riding objective of this study was to establish the clinical relevance of AR 
serine phosphorylation status in prostate tissue in both BPH and prostate cancer.  
The specific aims of the current study were: 
 To firstly establish and validate a panel of AR phosphospecific antibodies. 
22 
 
 To evaluate site specific AR serine phosphorylation expression levels in 
prostate cancer and BPH patient cohorts, with full clinical data and follow-
up. 
 To investigate the expression of candidate kinases mediating such 
phosphorylation. 
This involved establishing tissue banks with linked comprehensive clinical 
databases, and utilising this tissue to establish AR phosphorylation expression 
profiles for each patient. 
Six AR phosphospecific antibodies (pARS81, pARS94, pARS213, pARS515, pARS578, pARS650) 
were verified using peptide competition assays and western blotting.  Cdk1, 
ERK1/2, Akt and PKC were identified as putative kinases mediating AR 
phosphorylation using the online kinase search tool Scansite 2.0. 
Immunohistochemistry was performed on hormone naïve diagnostic prostate 
cancer tissue relating to 90 patients.  High expression levels of AR phosphorylation 
at serine sites 81, 515 and 578 were each associated with a poorer clinical 
outcome.  Following cox regression analysis, cytoplasmic pARS515 expression 
(p=0.038, HR 4.5 (95% CI 1.1–20.6)) and pARS81 nuclear expression (p=0.030, HR 
0.033 95% CI 0.002-0.721) were independently associated with shorter time to 
biochemical relapse and shorter disease specific survival respectively.  Cdk1 
and/or pCdk1161 were significantly associated with pARS81 and pARS515 as predicted 
by Scansite 2.0.  Similarly, nuclear PKC expression was significantly associated 
with pARS578 expression both in the cytoplasm and the nucleus.  In patients with 
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PSA at diagnosis ≤20ng/ml, high cytoplasmic pARS515 expression was associated with 
significantly shorter time to biochemical relapse (p=0.019). This translated into 
significantly shorter disease-specific survival (p<0.001, 10y survival 38.1% vs 100%). 
Prostate cancer patients with a low serum PSA level at diagnosis may be suitable 
for delayed radical treatment via active surveillance.  An investigation was 
therefore undertaken in 51 prostate cancer patients treated by active surveillance.  
Active surveillance is a deferred radical treatment approach which provides a 
potential solution to the problem of over treatment as a result of over-diagnosis.  
However some patients harbour occult aggressive disease and delay in treatment 
may result in disease progression and failure of radical therapy.  Although none of 
the individual AR serine phosphorylation sites were associated with clinical 
outcome measures on univariate analysis, high expression of total AR in the 
cytoplasm (p=0.021, HR 4.6 (95% CI 1.3-16.8)) and presence of perineural invasion 
in the tumour specimen (p=0.003, HR 8.6 (95% CI 2.1-35.7)) were deemed 
independent with regards to shorter time to treatment intervention in a cox 
regression analysis. 
Validation of the results seen in the first active surveillance prostate cancer cohort 
was undertaken in a second prospectively collected cohort consisting of 84 active 
surveillance patients.  The results in the first cohort were not replicated in the 
second.  Although cytoplasmic pARS81 was associated with time to intervention 
(p=0.032) and pARS515 expression trended towards an association (p=0.072), an 
increase in patient numbers in both cohorts may have provided more reliable 
results.  However even with the numbers available in contrast to the first active 
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surveillance cohort, but in line with the pilot prostate cancer cohort, Cdk1 was 
associated with pARS515 expression, and pCdk1161 trended towards an association. 
BPH is also an androgen driven disease dependent upon the AR.  Previous research 
into predictive and prognostic markers in BPH is scant.  Therefore a comprehensive 
analysis of clinical and novel pathological factors, including markers of 
inflammation, was performed in 336 BPH patients.  Following this a complete 
panel of AR serine phosphorylation sites, and associated kinases, was analysed with 
reference to clinical outcome measures in the BPH cohort.  Low expression levels 
of total AR and AR phosphorylated at Ser-81, 515 and 650 were associated with 
poorer clinical outcomes.  Low expression of smooth muscle pARS515 (p=0.029, HR 
0.31 (95% CI 0.10-0.94)) and older age (p=0.004, HR 5.13 (95% CI 1.43-18.41)) were 
deemed independent on cox regression analysis with regards to shorter time to 
postoperative acute urinary retention (AUR).  Furthermore, low expression of 
pARS515 in the smooth muscle was associated with increased incidence of 
postoperative AUR in patients over 70 years old (25.1% vs 2.8% at 10 years 
following transurethral resection of prostate (TUR)), (p=0.002, HR 0.20 (95% CI 
0.06-0.62)).  This may have important clinical implications in postoperative 
counselling of these patients.  In addition it may influence the decision to 
commence early postoperative medical treatment (with 5-alpha-reductase 
inhibitors and/or alpha blockers) on a prophylactic basis in these patients.  
Cytoplasmic pARS650 expression (p=0.010, HR 0.50 (95% CI 0.29-0.86)) and PSA at 
diagnosis (p=0.018, HR 1.89 (95% CI 1.11-3.16)) were independently associated 
with time to failure of surgical intervention.  Furthermore, low expression of 
pARS650 in the cytoplasm was associated with increased failure of surgical 
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intervention in patients with PSA ≥4ng/ml at diagnosis (45.5% vs 13% at 5 years 
post TUR), (p=0.026, HR 0.52 (95% CI 0.29-0.93)). 
This comprehensive study on immunohistochemical expression of site specific AR 
serine phosphorylation and associated kinases fills a gap in the current literature.  
It has demonstrated the clinical significance of AR serine phosphorylation in 
prostate cancer and BPH and uncovered potentially exciting new avenues for 
future investigation.  Site specific serine phosphorylation of the AR may serve as a 
prognostic and predictive biomarker in prostatic disease and has potential as a 
future target for therapeutic intervention. 
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1 Introduction 
Benign prostate hyperplasia (BPH) is the most common urological disease in 
elderly men and prostate cancer is the most common male malignancy in the UK.  
Both of these diseases are increasing in incidence and currently there is no way 
to accurately differentiate indolent from aggressive disease nor decipher who 
will respond favourably to treatment. 
1.1 Normal prostate 
The prostate is a tubulo-alveolar gland which forms part of the male 
reproductive system.  The human prostate is located inferior to the bladder neck 
and anterior to the rectum (Figure 1.1).  The normal prostate weighs 
approximately 20g and is about the size of a walnut.  It is enclosed by a capsule 
composed of collagen, elastin and large amounts of smooth muscle.  In addition 
three distinct layers of fascia cover the prostate on the anterior, lateral, and 
posterior aspects.  The gland is supported anteriorly by the puboprostatic 
ligaments and inferiorly by the external urethral sphincter and perineal 
membrane.(5) 
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Figure 1.1 Anatomical location of the prostate gland in humans (6) 
 
The development of the human prostate begins in approximately the 10th week 
of gestation.  It is dependent upon the production of testosterone by the foetal 
testis at around the 8th week of gestation.  Following this, the growth of 
prostatic buds from the urogenital sinus is dependent upon binding of the potent 
androgen 5α-dihydrotestosterone to androgen receptors (AR) located in the 
surrounding mesenchymal tissue.(7)  Postnatally, under the influence of 
androgens, the ducts form a patent lumen and the acini within the epithelial 
lining differentiate and begin the production of a number of secretory products. 
Figure 1.2 Histology of prostatic glandular epithelium (8) 
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Histologically the prostate glandular epithelium consists of three cell types; 
basal, luminal secretory and neuroendocrine (Figure 1.2).  Basal cells are few in 
number and although their function is not completely understood they are 
known to secrete components of the basement membrane.  Luminal cells 
secrete components of prostatic fluid, including prostate specific antigen (PSA) 
and express the AR.  The prostatic stroma is composed of fibroblasts, smooth 
muscle cells, endothelial cells, dendritic cells, nerve cells and inflammatory 
infiltrates.  Some stromal cells are also androgen responsive and produce growth 
factors which act in a paracrine fashion on the epithelial cells. 
The principal function of the prostate is as a secretory gland.  The prostatic 
luminal cells produce a fluid containing; citric acid, acid phosphatase, PSA and 
zinc.  Prostatic fluid combines with fluid from the seminal vesicles (containing 
fructose and prostaglandins) and spermatozoa from the testes to form the 
ejaculate.(9)  This precise combination of secretions provides a mildly alkaline 
fluid in order to deposit viable sperm into the acidic female reproductive tract. 
Figure 1.3 Crossectional image of prostatic zonal anatomy (10) 
 
Chapter 1 Introduction  29 
 
Anatomically the prostate can be divided into four zones; 1. peripheral zone, 2. 
central zone 3. preprostatic zone and 4. anterior fibromuscular zone (Figure 
1.3).  The peripheral zone surrounds the central and transitional zones 
posteriorly, adjacent to the rectum.  It comprises approximately 70% of prostatic 
volume (11) and is the site of approximately 80% of prostatic cancers. 
The central zone surrounds the transitional zone from the angle of urethra to 
the bladder base. It comprises approximately 25% of prostatic volume and is the 
site of approximately 5% of prostatic cancers. Cancers arising from the central 
zone tend to be more aggressive and more commonly invade the seminal 
vesicles.(12) 
The preprostatic zone consists of periurethral glands and a transitional zone.  
Periurethral glands comprise less than 1% of the mass of the glandular prostate 
and do not possess their own periglandular muscularis and therefore are limited 
to the immediate periurethral stroma and grow proximally towards the bladder 
neck.(13)  A small out-pouching of these periurethral glands is known as the 
transitional zone and is the innermost zone located adjacent to the prostatic 
urethra.  It shows more duct branching and acinar proliferation than the 
periurethral glands.  The transitional zone comprises approximately 5% of 
prostatic volume and is the site of approximately 10% of prostatic cancers.  More 
commonly enlargement of the transitional zone and periurethral glands with 
increasing age via BPH can impinge upon the prostatic urethra leading to 
symptoms of bladder outflow obstruction. 
The anterior fibromuscular zone comprises the entire anterior surface of the 
prostate, is completely non-glandular and equates to approximately 33% of the 
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intracapsular prostatic tissue.  It acts as a shield for the other three glandular 
zones.(13) 
1.2 Benign prostatic hyperplasia 
BPH is one of the most common diseases in elderly men.  Autopsy studies have 
demonstrated a prevalence of 50% in men aged 50-60 years and 90% over 80 
years.(1,14)  BPH is a histological diagnosis associated with unregulated 
proliferation of connective tissue, smooth muscle and glandular epithelium 
within the prostatic transition zone (Figure 1.4).  This may lead to compression 
of the prostatic urethra via an increase in prostatic volume and increased 
smooth muscle tone.  Clinically BPH may cause significant morbidity in the form 
of bothersome lower urinary tract symptoms (LUTS) and complications such as 
acute urinary retention (AUR).  Interestingly, in studies of large numbers of men, 
prostate volume does not correlate directly with symptom severity or urine flow 
rates (15), suggesting other factors are at play.  Similarly not all men with 
histological BPH will experience LUTS and not all men with LUTS will have 
histological BPH. 
Figure 1.4 Haematoxylin and eosin stained BPH section (16) 
 
Chapter 1 Introduction  31 
 
Haematoxylin and eosin stained section of BPH demonstrating both glandular 
and stromal hyperplasia. 
1.2.1 Androgens and the androgen receptor in BPH 
The molecular mechanisms underlying BPH development and progression are 
largely unclear.  Many theories of aetiology have been proposed including; 
embryonic reawakening, aging, androgens, estrogens, oxidoreductase and 
inflammation theories.  However, the presence of androgens in both foetal and 
adult life is known to a pre-requisite for the development and progression of 
BPH.  Men castrated prior to puberty and those with genetic diseases affecting 
androgen production or action do not develop BPH.(17)  Androgens act via the 
AR, a type 1 nuclear transcription factor.  Higher serum concentrations of the 
potent androgen dihydrotestosterone (DHT) have been associated with larger 
prostate volume and higher prevalence of BPH in a cross-sectional study of 505 
men.(18)  In other work, DHT concentration was found to be highest in the 
periurethral area of the transtitional zone in BPH.(19)  Similarly primitive BPH 
nodules in the periurethral transitional zone have been shown to exhibit higher 
nuclear AR expression than in other areas of the prostate.(20)  These results 
indicate that cells in the transitional zone of the prostate may play an important 
role in development of BPH via modulation of androgen/AR signalling. 
1.2.2 Stromal epithelial interactions in BPH 
Continuous stromal-epithelial interactions are critical in prostatic development, 
homeostasis and disease as demonstrated by conditional knockout murine 
models.  Previous work has demonstrated the importance of cell-specific AR in 
smooth muscle AR knockout mice that exhibit smaller prostates, histological 
abnormalities, altered gene expression, inflammation and fibrosis.(21)  Stromal 
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fibroblastic selective AR knockout mice exhibit decreased proliferation of 
epithelial cells with increased apoptosis.(22)  Double stromal knockout mouse 
models (deletion of AR in stromal fibroblasts and smooth muscle cells) 
demonstrated a reduction in the size of the anterior lobes of the prostate, 
decreased proliferation and increased apoptosis of epithelial cells in the anterior 
prostate.(23)  Conditional knockout mice lacking AR in prostate epithelial cells 
however, developed larger, less differentiated prostates with increased cell 
death when compared to wild type.(14)  The importance of stromal-epithelial 
cross talk has been further demonstrated in coculture experiments of primary 
human BPH stromal fibroblasts and epithelial cells whereby cell growth was 
significantly increased when compared to separate cell culture.(24)  Although 
the individual roles of cell-specific AR are appreciated to be important, the 
clinical relevance of cell-specific AR expression has not been previously studied. 
1.2.3 Age and BPH 
AR expression remains high in elderly men despite falling levels of circulating 
androgens, suggesting that other regulatory mechanisms may be at play.(25)  
Alterations in the endocrine microenvironment leading to deregulation of 
prostatic growth have been postulated to account for the age related increase in 
BPH.(25,26) 
1.2.4 Inflammation in BPH 
Inflammation is thought to influence the development and progression of BPH 
although, again, its precise role is uncertain.(27)  Inflammatory infiltrates are 
routinely found in prostate tissue specimens from men with BPH (28,29) and 
have been associated with increased prostate volume and international prostate 
symptom score.(29,30)  In addition systemic measures of inflammation, such as 
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c-reactive protein (CRP), have been associated with development of BPH, 
increased LUTS and residual LUTS following medical treatment.(31-33)  There is 
emerging evidence linking inflammation to AR expression in BPH.(34,35)  Wang 
and colleagues demonstrated that stromal AR could enhance macrophage 
migration and macrophage-mediated stromal cell proliferation in BPH via its 
downstream target the inflammatory chemokine-chemokine (C-C motif) ligand 
3.(34)  Conversely, activation of prostatic smooth muscle cell AR via DHT was 
found to suppress the inflammatory response and reduce secretion of growth 
factors.(35)  The relationship between inflammation and cell-specific AR remains 
unclear and therefore requires further investigation. 
1.2.5 Medical treatment of BPH 
The androgen axis is targeted in the medical treatment of BPH with 5-alpha 
reductase inhibitors which block the conversion of testosterone to DHT.  The use 
of 5-alpha reductase inhibitors has repeatedly been shown to reduce prostate 
volume and symptomatic LUTS.(36)  5-alpha reductase inhibitors are often used 
in combination with α-blockers, which decrease urethral smooth muscle tone in 
the bladder neck, to achieve the best symptomatic response.(37) 
1.2.6 Surgical treatment of BPH 
Unfortunately, medical therapy for BPH often fails and surgical intervention via 
transurethral resection (TUR) of prostate is required, however this is associated 
with complications such as bleeding, urethral stricture and incontinence.  In 
addition, a subset of men will have on-going symptoms despite surgical 
intervention and require further treatment with medication or repeat TUR 
operation. 
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1.2.7 Predictive and prognostic markers in BPH 
1.2.7.1 Age 
As discussed above prevalence of BPH and clinical progression is known to 
increase with increasing age.  Prostate volume also increases with age and data 
suggests a prostate growth rate of 2.0-2.5% per year in older men.(38)  Although 
prostate volume does not directly correlate with symptoms, prostate growth is a 
risk factor for LUTS progression and larger volume prostates are associated with 
increased risks of clinical progression of BPH, AUR and need for prostate 
surgery.(39) 
1.2.7.2 Geographical location 
Studies have shown geographic differences in prostate volume and LUTS.  South 
east Asian and Indian men have been shown to have significantly lower volume 
prostates than western men.(40,41)  Although Indian men had increased 
symptom severity scores than western men.(41) 
1.2.7.3 Genetics 
Studies have shown genetic influences of BPH and LUTS.  Male relatives of men 
aged less than 64 years undergoing surgery for LUTS were four times more likely 
to undergo BPH surgery themselves.(42)  In particular, brothers of the cases 
were six times more likely to undergo BPH surgery.(42)  Monozygotic twin studies 
have shown concordance rates of 62% for LUTS and 26% for BPH.(43,44)  
Inherited forms of BPH tend to have a larger volume prostates and earlier age of 
onset of clinical symptoms than men with sporadic BPH.(45) 
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1.2.7.4 PSA 
Although more commonly associated with prostate cancer, PSA has repeatedly 
been correlated with increased age in parallel with increased incidence of 
BPH.(46-48)  Despite this association PSA has not been used routinely to diagnose 
or monitor treatment of BPH.  It may be that the controversy surrounding PSA in 
prostate cancer has also limited its use in BPH. 
1.3 Prostate cancer 
An estimated 899,000 men were diagnosed with prostate cancer worldwide in 
2008 with most cases in developed countries.(2)  It is the most common cancer 
in Scottish men with 14,819 cases diagnosed and 4,212 deaths between 2008–
2012.(49)  At the end of 2011 there were 21,259 men living with prostate cancer 
in Scotland and this figure is expected to rise 80% by 2022.(49,50)  Prostate 
cancer therefore represents a considerable burden on the health service and 
significant disease-related morbidity and mortality is suffered by patients.  
Treatment of prostate cancer is also costly; men are treated with radiation, 
surgery or hormones, but even surveillance strategies are expensive.  The 
diagnosis, treatment and 5 year follow-up cost of prostate cancer in the UK was 
estimated at £136, 278, 237 in 2010.(51) 
The vast majority of prostate cancers are acinar adenocarcinomas occurring 
within the peripheral zone of the prostate as discussed previously.  Non acinar 
carcinoma variants of prostate cancer comprise 5-10% and include; sarcomatoid 
carcinoma, ductal adenocarcinoma, squamous and adenosquamous carcinoma, 
urothelial carcinoma, small-cell carcinoma, basal-cell carcinoma and clear cell 
adenocarcinoma.(52)  The histological subtype has important implications for 
prognosis and treatment decision making. 
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Early prostate cancer is unlikely to produce any symptoms and men who are 
ultimately diagnosed with prostate cancer usually present in primary care.  
Further investigation may be prompted by an abnormal rectal examination or 
serum PSA testing in at risk individuals.  Patients with progressive prostate 
cancer may present with LUTS similar to those seen in BPH and those with 
metastatic disease may present with bone pain.  However, since the advent of 
serum PSA testing in the 1980s the number of men presenting with metastatic 
disease has significantly reduced.(53) 
Prostate cancer may also be diagnosed secondary to the investigation or 
treatment of BPH.  BPH is associated with a higher serum PSA level which may 
lead to a suspicion of prostate cancer, and pathological analysis of tissue 
resected during a TUR of prostate may result in a diagnosis of prostate cancer. 
The diagnosis of prostate cancer involves investigation most commonly with a 
combination of biochemical, pathological and radiological measures.  Following 
serum PSA testing and rectal examination the diagnosis of prostate cancer is 
usually confirmed via a transrectal ultrasound (TRUS) guided needle biopsy of 
the prostate gland.  The aim of prostate biopsy is to confirm the presence or 
absence of prostate cancer in men suspected of having the disease.  Currently 
approximately 25% of men undergoing TRUS biopsy with abnormal aged-based 
serum PSA levels will have a positive diagnosis for prostate cancer.(54)  
Interestingly detection rates vary dependent upon the number of previous 
biopsies; 14-22% for initial biopsy, 10-15% for second biopsy and 5-10% for third 
biopsy.(55-57)  Radiological imaging may be undertaken following or preceeding 
TRUS guided prostate biopsy.  This may take the form of MRI/CT/bone scan 
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dependent upon the clinical variables of each individual case.  Low risk cancers 
deemed unlikely to have spread may not require any imaging following diagnosis. 
1.3.1 Management challenges of 21st century prostate cancer 
The weight of the economic burden of prostate cancer stems from the inability 
to accurately differentiate indolent cancer, which will never incur clinical 
sequale, from aggressive disease which is invasive and spreads ultimately causing 
death.  Consequently many clinically insignificant prostate cancers are over-
treated and some aggressive cancers are under-treated resulting in high 
morbidity to individual patients and cost to the health services.  This arises 
largely from the inadequacy of the current tools used to risk stratify patients at 
diagnosis.  Prostate biopsy is subject to a significant amount of sampling error 
with one study demonstrating 27% of low grade cancers upstaged or upgraded on 
repeat sample taken at 3 months.(58)  Clearly the current tools available to 
guide treatment of prostate cancer are inadequate and translate into the 
significant morbidity and mortality of patients in Scotland.  Further progress 
must be made in order to accurately identify those men at risk of developing the 
aggressive life shortening form of this disease. 
1.3.2 Current predictive and prognostic markers 
Clinical, pathological, biochemical and radiological markers are used to risk 
stratify patients at diagnosis. 
1.3.2.1 Age 
Advancing age is one of the strongest risk factors for prostate cancer.  Incidence 
is estimated at 0.1% in those men aged under 50 and approximately 85% of all 
cases are diagnosed in those aged over 65 years.  Age at diagnosis has also been 
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shown to be a significant predictor of overall survival in men with prostate 
cancer.  This is likely to be a reflection on the age-related increase in 
comorbidities, susceptibility to major illness, and blunting of the immune 
response.(59) 
1.3.2.2 Genetics 
Family history has been shown to be a risk factor for prostate cancer.(60)  In 
patients diagnosed under 55 years of age predisposing genes are thought to 
account for up to 40% of cases.(61,62)  With each increase in number of first 
degree relatives affected by prostate cancer the relative risk to patient 
increases.(63)  In addition familial prostate cancer has been linked to familial 
breast cancer, thought to be related to the BRCA1 and BRCA2 genes. 
1.3.2.3 Ethnicity 
Ethnicity has repeatedly been shown to be a risk factor for prostate cancer.  
Asian men have the lowest incidence rates of prostate cancer particularly in 
India, China and Japan.  Furthermore south Asian men living in the UK have a 
lower incidence of prostate cancer than Caucasian UK men.(64)  Black men have 
higher rates of prostate cancer, compared to Caucasian men; African-Americans 
have 1.3-2.0 times increased risk and black men have 3-times higher risk of 
developing prostate cancer.(65)  Ethnic origin is also associated with disease 
specific mortality.  Black men have a 30% higher mortality rate than White men.  
The mortality rate in South Asian men was found to be significantly less than in 
Caucasian men.(66) 
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1.3.2.4 PSA 
Prostate specific antigen (PSA) is also known as ‘kallikrein-3’.  It is a 
glycoprotein produced exclusively by the prostate gland and has a role in 
promoting sperm motility and the dissolution of cervical mucus.  Normally the 
basement membrane acts as a barrier preventing circulatory escape of PSA.  
Disruption of the basement membrane by prostatic disease (cancer, BPH, 
prostatitis) and/or manipulation (massage, rectal exam, biopsy) can allow 
leakage of PSA into the systemic circulation which can be measured by a simple 
blood test.  PSA has poor specificity for prostate cancer with 15.2% of men with 
a “normal” level (<4.0ng/ml) demonstrating cancer on biopsy.(67)  PSA 
screening was common place in the USA until relatively recently.  Large 
population based studies have clearly demonstrated that prostate cancer 
screening using PSA increases prostate cancer detection but does not reduce 
prostate cancer deaths.(68)  In addition the European Randomised Study of 
Screening for Prostate Cancer (ERSPC) trial suggested that in order to prevent 
one death from prostate cancer, 1055 men would require screening and 37 men 
would need treated for prostate cancer.(69) 
Serum PSA testing is often used as a marker of response to treatment for 
prostate cancer.  It is utilised to determine and monitor the success of radical 
treatment.  In addition PSA is also used to identify patients who require 
treatment intervention (both radical and non-radical).  In addition it is 
frequently used to monitor patients in whom prostate cancer has been diagnosed 
but treatment has been purposefully delayed either via active surveillance or 
watchful waiting. 
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The introduction of PSA testing in the 1980s has really changed the face of 
prostate cancer and has led to significant stage and grade migration of the 
disease with more clinically insignificant cancers being detected.  The current 
challenge centres around the differentiation of indolent from aggressive prostate 
cancer. 
1.3.2.5 Gleason 
The Gleason grading system for prostate cancer, developed in the 1960s and 
most recently modified in 2005, is still the strongest predictor of outcome in 
men diagnosed with the disease.(70,71)  Gleason grading for prostate cancer is a 
histological score based upon differentiation.  It ranges from 2-5 (well-poorly 
differentiated) and a score is calculated based on the two most predominant 
tumour patterns.  Haematoxylin and eosin staining of high and low Gleason 
prostate cancer tissue is shown in Figure 1.5. 
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Figure 1.5 Haematoxylin and eosin staining of low (A) and high (B) Gleason grade prostate 
cancer (71) 
 
Haematoxylin and eosin staining of prostate biopsy sections.  A: Gleason 
score 6 (3+3) prostatic carcinoma composed of small discrete glands, variable 
in size and organisation.  B: Gleason score 8 (4+4) prostatic carcinoma, 
composed of ill-defined glands with poorly formed glandular lumina and 
accompanied by gland fusion. 
Gleason 6 (3+3) is recommended as the lowest score on biopsy material (71) and 
is considered low risk. Gleason 7 (3+4 and 4+3) is considered moderate risk and 
Gleason 8-10 is considered high risk disease.  Gleason score has implications for 
both prognosis and treatment options and timing. 
1.3.2.6 T stage 
The TNM classification is used to stage prostate cancer (Table 1.1).  It combines 
the extent of the primary tumour (T stage), the absence or presence of spread 
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to lymph nodes (N stage) and the absence or presence of metastasis (M stage).  
Increased clinical stage is associated with increased disease specific mortality. 
Table 1.1 TNM staging for prostate cancer (72) 
Stage Sub-stage Definition 
 
Tumour  Primary tumour 
TX  Primary tumour cannot be assessed 
T0  No evidence of primary tumour 
T1 
 
Clinically inapparent tumour, neither palpable nor 
visible by imaging 
T1a 
Tumour incidental histological finding in <5% 
resected tissue 
T1b 
Tumour incidental histological finding in >5% 
resected tissue 
T1c Tumour identified by needle biopsy 
T2  Tumour confined within prostate 
T2a Tumour involves ≤50% of one lobe or less 
T2b Tumour involves >50% of one lobe, but not both lobes 
T2c Tumour involves both lobes 
T3  Tumour extends through the prostatic capsule 
T3a 
Extracapsular extension including microscopic 
bladder neck involvement 
T3b Tumour invades seminal vesicle(s) 
T4  
Tumour is fixed or invades adjacent structures 
other than seminal vesicles e.g. external sphincter, 
rectum, levator muscles, and/or pelvic wall 
 
Node  Regional lymph nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph nodes metastasis 
N1 Regional lymph node metastasis 
 
Metastasis  Distant metastasis 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Non-regional lymph node(s) 
M1b Bone(s) 
M1c Metastasis at other site(s) 
 
The factors above are combined in order to risk stratify patients at diagnosis as 
per the National Institute for Clinical Excellence (NICE) guidelines (Table 
1.2).(72)  This has implications for treatment decision making. 
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Table 1.2 Risk stratification for prostate cancer 
 Serum PSA  Gleason  Clinical Stage 
Low <10ng/ml and ≤6 and T1-2a 
Intermediate 10-20ng/ml or 7 or T2b 
High >20ng/ml or 8-10 or ≥T2c 
 
 
1.3.3 Management of prostate cancer 
The management of prostate cancer depends upon whether it is clinically 
localised, locally advanced or metastatic at diagnosis.  Other factors such as life 
expectancy and co-morbidities are taken into account when undertaking 
treatment decision making. 
1.3.3.1 Radical treatment options 
Radical treatment is available for all risk groups except patients with metastatic 
disease at diagnosis. 
Active surveillance 
Active surveillance for prostate cancer is a delayed treatment approach whereby 
low or intermediate risk patients suitable for radical therapy undergo 
intervention only when biochemical, histological or clinical progression is 
demonstrated.(72)  Active surveillance avoids the side effects of radical 
treatment such as urinary incontinence, erectile dysfunction and a small risk of 
death.  The recent stage and grade migration of prostate cancer secondary to 
serum PSA testing has led to the over diagnosis and over treatment of clinically 
insignificant disease. Active surveillance provides a potential solution to this 
problem and NICE recommend it as the preferred treatment option for low risk 
patients.(72)  Intermediate risk patients can also be considered for active 
surveillance if they do not wish to undergo immediate radical therapy. 
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Radical prostatectomy 
Radical prostatectomy is suitable for low and intermediate risk patients.  In 
cases of high risk prostate cancer radical prostatectomy may be offered if there 
is a realistic chance of long term disease control.  Surgery is performed in order 
to remove the prostate and seminal vesicles.  This can be done via an open, 
laparoscopic or robotically assisted laparoscopic approach dependent upon 
geographical service provision.  However, both laparoscopic and robotically 
assisted laparoscopic surgery have reduced length of patient stay in hospital and 
surgical blood loss.  Risks of radical prostatecomy include incontinence, erectile 
dysfunction and a small risk of mortality.  Radical prostatectomy is a major 
operation that is usually only offered to fit men without significant co-
morbidities. 
Radiotherapy 
Radical radiotherapy can take the form of external beam or by placement of 
radiation sources directly into the prostate gland (brachytherapy).  External 
beam radiotherapy is the most common treatment in the UK for men with 
localised prostate cancer.  It can be used for all risk groups and is usually 
performed in conjunction with neoadjuvant hormone treatment, and is given in 
daily fractions over 4–8 weeks as an outpatient.  Low and intermediate risk 
prostate cancer patients may be offered brachytherapy.  Brachytherapy involves 
the insertion of small radioactive pellets directly into the prostate gland.  These 
then deliver local radiotherapy over a period of weeks-months which minimises 
the damage to surrounding ‘normal’ tissue.  Intermediate and high risk patients 
may be offered brachytherapy in combination with external beam radiotherapy.  
Chapter 1 Introduction  45 
 
The side effects of both forms of radiotherapy treatment can include alteration 
in urinary and bowel function and erectile dysfunction. 
1.3.3.2 Non radical treatment options 
Non radical treatment options are suitable for all risk groups and in particular 
patients with metastatic disease at diagnosis.  These treatment options may be 
selected in preference to radical treatment in the context of significant 
comorbidities and reduced life expectancy. 
Watchful waiting 
Watchful waiting is a conservative approach without curative intent by which 
treatment is only initiated when symptoms develop.  If and when symptoms 
develop treatment is usually with hormonal therapy.  This approach is usually 
offered to older men or those with significant comorbidities, in whom prostate 
cancer is unlikely to be of clinical significance within their predicted lifetime. 
Hormonal treatment 
Hormonal treatment is the mainstay of treatment for metastatic prostate 
cancer. 
Androgen deprivation 
Androgen deprivation slows metastatic prostate cancer progression by 18 months 
on average.  Castration can be surgical (bilateral orchidectomy) or medical via 
luteinising hormone releasing hormone (LHRH) agonists which downregulate the 
hypothalamic-pituitary axis inhibiting androgen production. Side effects include 
hot flushes, headaches, erectile dysfunction, loss of libido, gynaecomastia and 
osteoporosis. 
Chapter 1 Introduction  46 
 
Androgen blockade 
Androgen action can be blocked peripherally by the use of anti androgens.  Anti 
androgens bind competitively to the AR.  Anti androgens can be used in place of 
or in combination with LHRH agonists.  They are often used during the initiation 
of LHRH agonist therapy in order to prevent tumour flare.  The use of both LHRH 
agonists and anti androgens is known as combined androgen blockade.  Anti 
androgens have a similar but less severe sexual side effect profile to LHRH 
agonists.  Men treated with anti androgens are more likely to develop 
gynaecomastia. 
Although initial response rates to hormonal therapy are high eventually all 
prostate cancers will relapse developing castrate resistant disease within 18-24 
months.  Castrate resistant prostate cancer (CRPC) is characterised by the re-
emergence of serum PSA expression following hormonal treatment.  Once 
established CRPC is an ultimately fatal disease with limited treatment options.  
Median survival of patients with CRPC without treatment is 9-22 months. 
Chemotherapy 
Chemotherapy using a combination of docetaxel and prednisolone is used in 
CRPC and can provide a modest increase in survival.  The side effects of this 
combination can be overwhelming and it may prohibit its use. 
Current treatment is not optimal due to a lack of understanding of the 
underlying molecular mechanisms associated with development and progression 
of prostate cancer. 
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1.3.4 Molecular mechanisms of prostate cancer development and 
progression. 
Dysregulation of many genes has been linked to the development and 
progression of prostate cancer. 
1.3.4.1 PTEN 
The phosphatase and tensin homolog (PTEN) is a tumour suppressor gene located 
on chromosome 10q23.  The PTEN gene encodes a phospholipid phosphatase 
which is active against both protein and lipid substrates negatively regulating 
the PI3K/Akt/mTOR signalling pathway which is essential for cell cycle 
progression and cell survival.  PTEN antagonises the action of PI3K by de-
phosphorylating PIP3 (a PI3K product) at the D3 position.  This removes the 
membrane-localisation factor from the Akt signalling pathway and thereby 
significantly inhibits the downstream activation of Akt. 
In prostate cancer the most common somatic PTEN mutation is via copy number 
loss rather than point mutation.(73)  PTEN loss is proposed as a late event in 
prostate carcinogenesis as loss of PTEN heterozygosity has been seen in up to 
60% of advanced prostate cancer tumours (74), however germline PTEN 
mutations have not previously been associated with prostate cancer.(75,76)  
Furthermore, commonly utilised prostate cancer cell lines cultured from 
metastatic deposits in lymph node (LNCaP) and brain (PC3) are known to have 
PTEN deletion and highly active PI3K/Akt signalling.(77,78)  Loss of PTEN has 
been associated with progression from hormone sensitive to CRPC in human 
tissue specimens.  In a cohort of 57 prostate cancer patients with matched 
hormone sensitive and CRPC prostatic tissue PTEN gene deletion, identified via 
fluorescent in situ hybridisation (FISH), significantly increased from 23% to 52% in 
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CRPC tumours.(79)  In addition loss of PTEN expression was an independent 
predictor of disease specific survival.(79) 
1.3.4.2 c-Myc 
c-Myc is a proto-oncogene of the helix–loop–helix leucine zipper protein family 
of transcription factors.  It is located on chromosome 8q24 and encodes the c-
Myc protein which dimerizes with its protein partner Max in order to 
transactivate gene expression which promotes cell proliferation and 
transformation.  c-Myc is believed to regulate up to 15% of all genes involved in 
almost every important cellular function.(80) 
The discovery that c-Myc is translocated to one of the immunoglobulin loci in 
virtually all Burkitt's lymphomas highlighted c-Myc as a human oncogene.(81)  It 
is now known that c-Myc is overexpressed in the majority of human cancers.  
The amplification and overexpression of c-Myc has been observed in 8% of 
primary prostate cancers and in approximately 30% of metastatic 
deposits.(82,83)  Over the past three decades c-Myc mRNA has been consistently 
shown to be overexpressed in the majority of prostate adenocarcinomas as 
compared to BPH and benign prostatic tissue.(84,85)  More recently c-Myc 
overexpression has been demonstrated at the protein level in prostatic 
intraepithelial neoplasia (PIN), localised and metastatic prostate cancer.(86)  A 
significant correlation with increasing Gleason grade and worsening prognosis has 
been described with c-Myc expression in advanced prostate cancer.(83)  The 
molecular mechanisms underlying c-Myc overexpression in prostate cancer 
remain largely unclear however, gene amplification and rearrangement and the 
influence of other signalling cascades have all been shown to contribute.(87) 
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1.3.4.3 TMPRSS2-ERG 
The transmembrane serine protease 2 (TMPRSS2) gene and members of the ETS 
transcription family (ETV1, ETV4, ETV5, ERG and FLI1) are responsible for 
genetic rearrangement and creation of the fusion gene TMPRSS2-ETS.(88)  The 
most common ETS family member to undergo fusion with TMPRSS2 is ERG.  Over 
50% of all prostate cancers are thought to harbour the TMPRSS2-ERG fusion gene, 
and as such it is the most common genomic alteration in prostate cancer.(89) 
TMPRSS2-ERG fusion results in the overexpression of the ERG oncogene.  The 
precise function of ERG in prostate cancer is unclear, and it is known that ERG 
overexpression alone is not sufficient for prostatic carcinogenesis.  ERG has been 
shown to cooperate with several different genes e.g. PTEN in the development 
of murine prostate cancer.(90)  It has been postulated to have a role in prostatic 
epithelial cell migration and invasion. 
TMPRSS2-ERG fusion has never been detected in BPH or the benign prostate.  
Therefore TMPRSS2-ERG fusion is a very specific prostate cancer biomarker.  ERG 
overexpression has been seen in PIN lesions and as such is generally considered 
an early event in prostate carcinogenesis.(91)  However, it remains to be 
established whether TMPRSS2-ERG fusion plays a role in PIN to cancer 
progression.  Of all the genes linked to prostate cancer AR is the most widely 
studied. 
1.4 Androgen receptor 
The AR is a type one nuclear receptor which is activated by androgens and acts 
as a ligand dependent transcription factor.  The gene for the AR is located on 
the X chromosome at Xq11-12 and the protein is comprised of 919 amino acids 
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with a molecular mass of approximately 110kDa.  In the normal prostate AR is 
essential for prostate development, cellular proliferation, survival, apoptosis 
and secretion. 
The AR is expressed in both stromal and epithelial prostatic cells (92) and is 
thought to mediate different effects within each cellular compartment.  For 
example functional AR in prostatic stroma is necessary during prostate 
development while prostatic epithelium has been shown to induce smooth 
muscle differentiation of a subset of the stroma.(93)  AR is required in both 
cellular compartments for the development of functional secretory prostatic 
epithelia.(93)  Furthermore, cell-specific AR is reported to have differing effects 
on proliferation, with stromal AR shown to promote proliferation (94) while 
epithelial AR inhibits epithelial cell proliferation.(95)  However these roles are 
complex with studies showing overexpression of epithelial AR increases epithelial 
proliferation.(96) 
1.4.1 AR Structure 
The AR is comprised of three major functional domains (Figure 1.6).  The N-
terminal domain is the largest and comprises over half of the receptor.  The N 
terminal exhibits an activation domain called activation function 1 (AF1).  AF1 is 
constitutively active in truncated receptors that do not contain the ligand 
binding domain (LBD).  The DNA binding domain (DBD) is an independently folded 
protein domain which contains two zinc fingers.  The first zinc finger contains a 
P-box and interacts with the half-site of the androgen-response element 
(ARE).(97-99)  The second zinc finger contains a D-box and facilitates 
dimerization of the receptor on AREs.  A short flexible peptide sequence known 
as the hinge region links the DBD and LBD.  It is responsible for the regulation of 
AR nuclear localisation, DNA binding, and coactivator recruitment.(100)  The LBD 
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contains the C terminal and the ligand dependent transcriptional activation 
function 2 (AF2).  In the case of most nuclear receptors AF2 is more potent and 
more important for ligand activation than AF1.  However, in AR transactivation 
AF2 appears to have less impact than AF1.  Interestingly, a ligand-dependent 
functional interaction between AF1 and AF2 suggests that the two regions work 
in synergy in order to maximise AR transactivation.(101) 
Figure 1.6 Structure of the androgen receptor 
 
The location of the activation function (AF) sites 1 and 2 are shown.  DBD = 
DNA binding domain. 
1.4.2 AR activation 
In the absence of androgens the AR is located in the cytoplasm in an inactive 
state bound to heat shock proteins (HSPs), which prevent it from entering the 
nucleus.  The activation of AR occurs via androgen binding as already stated.  
Testosterone is primarily produced by the Leydig cells of the testes and is 
converted to the more potent androgen, dihydrotestosterone (DHT) by the 
enzyme type II 5 alpha reductase.  DHT then binds to inactive AR in the 
cytoplasm which causes a conformational change and dissociation of HSPs, 
activation of AR cofactors, formation of homodimers and translocation of AR to 
the nucleus.  AR then binds to AREs which results in gene transcription (Figure 
1.7).  Coactivators, corepressors and chromatin remodelling complexes are 
recruited to the promoter in order to facilitate transcription of AR target genes.  
PSA is one of the best known genes regulated by AR, however AR also regulates 
many other genes that are involved in proliferation and apoptosis. 
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Figure 1.7 Androgen receptor activation in prostatic cells by androgens 
 
Testosterone (T) enters the prostatic cells and is converted to 
dihydrotestosterone (DHT) in the cytoplasm by 5-α-reductase enzyme.  DHT 
then binds to the androgen receptor (AR) which causes dissociation of heat 
shock proteins (HSP 70/90), and transactivation by dimerization and 
phosphorylation (p).  AR homodimers then translocate to the nucleus where, 
in the presence of co-activators, AR binds to androgen response elements 
resulting in gene transcription. 
1.4.2.1 AR splice variants 
In addition to classical activation of the AR via ligands it may also be activated 
when truncated.  Truncated versions of AR are known as AR splice variants and 
co-exist with full length AR in clinical specimens.  The expression levels of 
individual AR variants almost always comprise a small fraction of the expression 
level of full length AR.(102,103)  The most common AR splice variant is AR-
V7/AR3, this receptor lacks the LBD (Figure 1.8) and as a consequence is 
constitutively active.  However many different splice variants have been 
observed (Figure 1.8), most of which lack the LBD. 
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Figure 1.8 AR splice variants (104) 
 
Constitutive AR activation is commonly observed in CRPC, in particular AR-
V7/AR3 was detected at approximately 20x higher levels in CRPC than in 
hormone naïve clinical specimens, driving expression of androgen-responsive 
genes in an androgen independent manner.(102)  Overexpression of AR-V7/AR3 
in cell lines activated AR gene transcription in the presence and in the absence 
of full length AR.  However the transcriptional activity of other AR variants has 
been shown to be cell type specific.  AR-V1 and AR-V9 demonstrated 
transcriptional activity in LNCaP cells (full length AR positive) but not in PC3 
cells (full length AR negative).(105) 
Truncated forms of the AR result in variability of molecular weight of the 
receptor as detected by western blot.  This is readily observed in prostatic cell 
lines, including LNCaP, where molecular weight bands in the range of 70–90 kDa 
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are commonly observed by western blot in addition to bands at 110-112 kDa due 
to full length AR. 
1.4.3 Post translational serine phosphorylation of the AR 
Modulation of AR functional activity can be achieved by post translational 
modifications, which may include phosphorylation, acetylation, ubiquitination, 
sumoylation and methylation.  Post translational modification of AR at a total of 
23 sites can result in changes to transcriptional activity, protein stability, 
cellular localisation and protein structure. 
Phosphorylation of the AR influences receptor stability, DNA binding, subcellular 
localisation, transcription and interactions with coregulators.  It is by these 
methods that AR phosphorylation regulates the activity of the receptor.  
Therefore alterations in AR may be involved in the progression and development 
of prostatic disease. 
It has previously been shown that mutations of the AR have been linked to 
disease states.  For example germline missense mutations resulting in an amino 
acid substitution in the LBD or DBD results in abnormal receptor function and 
have been implicated in androgen insensitivity disorders.  Non-sense mutations 
and others resulting in premature splicing of AR mRNA have also been identified 
in relation to disorders of androgen insensitivity.(106)  Somatic mutations of the 
AR have been observed in prostate cancer specimens.  Increased frequency of 
mutations is observed in CRPC compared to early prostate cancer, implicating 
that they may have a role in tumour progression.(107)  As discussed above, 
truncated forms of the androgen receptor have been identified lacking the LBD.  
These variants have been shown to be constitutively active and highly expressed 
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in CRPC.(108)  Amplification of AR expression at the gene and protein level has 
been previously shown in CRPC, and is postulated as a mechanism for androgen 
escape.(109)  As it has influences on AR activation, AR phosphorylation status 
may play a role in prostatic disease. 
Phosphorylation of the AR was first reported in 1984 by Goueli and colleagues 
(110) and has been extensively studied since.  The AR is phosphorylated in 18 
serine, threonine and tyrosine residues and each of the major functional 
domains contains at least one phosphorylation site (Figure 1.9).  The NTD 
contains the majority of the phosphorylation sites whilst the DBD and hinge 
region harbour only one site each (Ser-578 and Ser-650 respectively).  The LBD 
contains two phosphorylation sites.  Each phosphorylation site is reported to 
have individual functional consequences by increasing or decreasing protein 
interactions that occur proximal to the phosphosite.(100) 
Figure 1.9 Location of androgen receptor phosphorylation sites (111) 
 
The location of serine (S), tyrosine (T) and threonine (Y) phosphorylation 
sites in relation to the major structural domains of the androgen receptor are 
shown.  DBD = DNA binding domain, AF = activating function. 
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The majority of the phosphorylation sites on the AR correspond to serine 
residues (Figure 1.9).  Dependent upon the phosphosite concerned the AR can be 
phosphorylated in the presence and/or absence of androgens.  Phosphorylation 
of AR at serine residues influences receptor stabilisation and proteasomal 
degradation.(112)  AR phosphorylation may also influence transactivation of the 
AR since AR transcriptional activity correlates strongly with phosphorylation of 
specific serine residues.(113)  Therefore AR serine phosphorylation may 
influence the development and progression of AR-dependent prostatic diseases 
such as prostate cancer and BPH. 
Serine site 81 is the most commonly phosphorylated site in response to 
androgens on the AR.(114)  It has been postulated to have a role in AR 
transactivation.  When LHS nontumorigenic immortalized human prostate 
epithelial cells were transfected with wild type and S81A mutant AR, cell growth 
rate was increased 15% in the wild type cells.(115)  The effect of Ser-81 
phosphorylation on AR transcriptional activity was studied in the same 
transfected LHS cells.  From 11 AR target genes TMPRSS2 and ORM1 showed 
reduced transcription in S81A mutants when compared to wild type AR 
cells.(115)  However, the remainder of the AR target genes either showed no 
change or increased expression in S81A mutants compared to wild type AR.  In 
support of this finding loss of Ser-81 phosphorylation led to a reduction in AR 
transactivation of PSA and TMPRSS2 in prostate cancer LNCaP cells using a ligand 
switch model.(116)  This data suggests that AR Ser-81 phosphorylation may 
regulate AR promoter selectivity.  In addition the reduction in growth of S81A 
mutants in comparison to the wild type AR LHS cells may be related to overall 
changes in the AR transcriptional program.  Multiple studies have also linked AR 
phosphorylation at Ser-81 to nuclear localisation of AR.(116-119) 
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Evidence suggests that Ser-94 is constitutively phosphorylated; Ser-94 
phosphorylation was present in Human Embryonic Kidney 293 cells (HEK 293) 
when the LBD truncated AR was expressed.(118)  Ser-94 phosphorylation has 
been shown to increase with cytoplasmic localisation.(120)  The function of Ser-
94 phosphorylation has not been previously investigated, however when both S81 
and S94 alanine mutants were employed in HEK 293FT cells AR transcriptional 
activity was not altered.(121,122) 
The functional consequences of AR Ser-213 phosphorylation are postulated to be 
dependent upon the activating kinase.  Interestingly Ser-213 phosphorylation by 
Akt has been shown to have differing effects on AR transcriptional activity in 
different prostate cancer cell lines corresponding to different stages of disease.  
When AR was transfected into the castrate resistant prostate cancer cell line 
DU145, AR transactivation was repressed by Akt treatment.(123)  However in 
androgen dependent prostate cancer LNCaP cells, Akt mediated AR 
phosphorylation increased AR transcriptional activity and promoted cell 
survival.(123,124)  Negative regulation of AR signalling has been demonstrated 
by the AR regulated gene hematological and neurological expressed 1 (HN1).  In 
LNCaP cells HN1 overexpression resulted in a reduction of AR Ser-213 
phosphorylation corresponding to an overall decrease in AR expression 
levels.(125)  The reverse was also observed in HN1 knockdown cells resulting in 
heightened Ser-213 phosphorylation and increased AR expression levels.(125)  
PIM-1 kinase mediated phosphorylation at Ser-213 has been shown to enhance AR 
interaction with Mdm2 and promote protein destabilisation and proteolysis.(126)  
Furthermore in AR knockdown LNCaP cells re-expression of S213A mutant 
increased cellular stability when compared to wild type AR.(123)  PIM-1L isoform 
has been shown to increase expression of AR target genes under low androgen 
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conditions via Ser-213 phosphorylation.(127)  Conversely PIM-1S mediated AR 
Ser-213 phosphorylation has been shown to decrease AR target gene expression 
under high androgen conditions.(128)  In 68 matched hormone sensitive and 
CRPC clinical specimens a significant increase in AR phosphorylation at Ser-213 
was seen with the development of CRPC.(129)  In addition high expression of 
Ser-213 phosphorylation in the CRPC cohort was associated with decreased 
survival from biochemical relapse and a three year reduction in disease specific 
survival.(129) 
Ser-515 phosphorylation is associated with AR transactivation as demonstrated 
by the S515A mutant which had reduced transcriptional activity in assays using a 
PSA reporter.(130,131)  In addition AR Ser-515 phosphorylation may regulate 
protein turnover as wild type AR was seen to recruit the E3 ligase Mdm2 to the 
PSA promotor whilst S515A mutants recruited the E3 ligase CHIP.  Both ligases 
result in ubiquitination, however Ser-515 phosphorylation status appears to 
direct which E3 ligase is utilised to regulate AR activity.(131) 
Previous mutagenesis studies investigated the effect on subcellular localization 
of AR in a fibroblast-like cell line derived from monkey kidney (COS cells).  This 
work demonstrated that in wild type cells AR is distributed between the nucleus 
and cytoplasm indicative of nuclear-cytoplasmic shuttling.(130)  However in 
S578A mutant cells AR expression was found exclusively in the nucleus and 
associated with Ku70/80 regulatory subunits of DNA-PK which may have 
implications for AR transactivation.(130) 
AR phosphorylation at Ser-515 and Ser-578 has been proposed to be linked.  The 
S578A and S515A mutants both reduced AR transactivation, with the greatest 
effect seen with S578A.(130)  The double S515/S578A mutant had almost no 
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transcriptional activity.(130)  It is therefore postulated that AR phosphorylation 
at Ser-578 is dominant to that at Ser-515. 
Ser-650 is located in the hinge region in close proximity to the nuclear export 
signal contained within the DBD.  Phosphorylation at Ser-650 has been shown to 
be required for nuclear export of the AR via mutant studies.(132,133)  Ser-650 
phosphorylation is therefore a negative regulator of AR gene transcription. 
As discussed above AR serine phosphorylation may have exciting implications for 
the development and progression of AR-dependent prostatic diseases.  Although 
extensively studied in cell lines the significance of AR serine phosphorylation in 
prostatic disease has not been previously investigated in clinical specimens 
relating to hormone naïve prostate cancer and BPH. 
1.5 Kinases associated with AR serine phosphorylation 
As discussed above AR serine phosphorylation is influenced by kinases in the 
presence/absence of androgens.  Kinases may be mutated or deregulated in 
disease resulting in alterations in phosphorylation status and downstream gene 
transcription.  The kinases driving AR serine phosphorylation are therefore of 
functional importance in both prostate cancer and BPH and may harbour 
opportunities for therapeutic intervention. 
Candidate kinases of AR serine phosphorylation include members of the cyclin 
dependent kinase (Cdk) family, extracellular signal-regulated kinases (ERK), 
protein kinase C (PKC) and Akt. 
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1.5.1 Cdk1 
There are 11 classical Cdks that regulate the cell cycle.  Cdk1-6 are involved in 
cell cycle progression and Cdk7-11 act as transcriptional regulators.  Cdk1 is 
essential for progression from G2 phase into the mitotic phase of the cell cycle.  
Cdk1 binds to cyclin B1 which activates the kinase forming a complex upon 
which progression into mitosis is critically dependent.  Further activation of the 
Cdk1/Cyclin B1 complex is via phosphorylation of Cdk1 threonine 161 site by the 
CDK activating kinase. 
Cdk1 has been linked with prostate cancer previously.(134,135)  Cdk1 has been 
shown to inhibit the tumour suppressor forkhead transcription factor FOXO1, 
promoting cellular proliferation and survival in prostate cancer LNCaP cells.(135)  
In addition Cdk1 has been shown to phosphorylate the AR at Ser-81.(136)  Co-
transfection of AR and Cdk1 into HEK 293T cells resulted in increased Ser-81 
phosphorylation of the AR and total AR protein expression levels.(136)  The use 
of the pan-Cdk inhibitor roscovitine blocked DHT-stimulated Ser-81 
phosphorylation and decreased AR expression in both LNCaP cells and AR 
transfected HeLa cells.(136)  Interestingly when HEK 293T cells were co-
transfected with wild type or S81A mutant AR alongside active or inactive Cdk1, 
Cdk1 enhanced AR expression in both wild type and S81A mutants.(136)  This 
suggests that Cdk1 can influence AR protein expression by a mechanism 
independent of Ser-81 phosphorylation.  Ser-81 phosphorylation has also shown 
to be influenced by Cdk5 and Cdk9.(115,117) 
Cdk1 has been shown to increase AR stability by phosphorylation at other serine 
sites.(136)  Ser-515 phosphorylation, although not previously linked with Cdk1 
has been associated with Cdk7.  Purified recombinant TFIIH (general 
Chapter 1 Introduction  61 
 
transcription factor), of which CDK7 is an essential component, phosphorylated 
the AR in vitro and phosphorylation was reduced when wild type AR was replaced 
with a S515A mutant.(131)  This suggests that CDK7 may play a role in 
phosphorylation of the AR on Ser-515. 
1.5.2 ERK1/2 
ERKs form part of the classical mitogen-activated protein kinases (MAPKs) group 
and are widely expressed protein kinase intracellular signalling molecules.  
Signalling generally follows a three-tiered kinase cascade, members of the Raf 
family are activated by the Ras family of GTPases.  These activated Raf 
members then translocate to the cell membrane where they further 
phosphorylate and activate MEK1/2.  MEK1/2 then continues to phosphorylate 
and activate ERK1/2.  Activation of ERK1/2 has been shown to increase the 
transcription of AR target genes via phosphorylation of AR or its cofactors.(137-
140) 
ERK1/2 has previously been shown to be associated with poor prognosis in 
prostate cancer patients.  A rise in total ERK1/2 expression in CRPC compared to 
hormone sensitive clinical specimens was associated with a decrease in survival 
from biochemical relapse and translated to an overall reduction in disease 
specific survival.(141)  In the same previous study ERK1/2 expression strongly 
correlated with pERK1/2 expression.(141)  With regards to AR phosphorylation, 
ERK1/2 has been shown previously to phosphorylate AR at Ser-515.(130)  
Following alanine/phenylalanine mutational study of candidate AR serine, 
threonine and tyrosine phosphorylation sites Ser-515 was identified as the site of 
AR phosphorylation in response to EGF treatment.(130)  Furthermore the 
treatment with a MEK1/2/5 inhibitor (U0126) was seen to reduce Ser-515 
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phosphorylation after treatment with EGF.(130)  Ser-650 phosphorylation has 
previously been observed in response to EGF treatment (114), suggesting that 
MAPKs may also be involved in regulating this phosphosite.  However, further 
investigation demonstrated that Ser-650 phosphorylation is likely primarily 
influenced by stress kinases; MKK4/JNK and MKK6/p38 and not the MEK/ERK 
pathway.(132)  Moreover, treatment of LNCaP cells with U0126 had no effect on 
Ser-650 phosphorylation.(132) 
1.5.3 PKC 
PKC isozymes are a family approximately 15 serine/threonine kinase enzymes.  
They are divided into 3 subgroups based on their structural and biochemical 
properties; conventional, novel and atypical.  Conventional PKCs require 
calcium, diacylglycerol and a phospholipid for activation.  Novel PKCs require 
diacylglycerol but do not require calcium and atypical PKCs require neither 
diacylglycerol nor calcium.  PKCs then undergo further activation by 
phosphorylation upon which PKC proteins are translocated to the plasma 
membrane by receptors for activated C kinase (RACK) proteins.  Following 
membrane translocation the opening of the isozyme allows binding of ATP and 
phosphorylation of various substrates.  PKCs have a central role in cellular 
signaling transduction involved in cell proliferation, differentiation, apoptosis 
and angiogenesis.  PKC isoforms have been detected in normal, BPH and 
neoplastic prostate tissue.(142-144)  PKC has been previously shown to promote 
the proliferation of human prostatic stromal cells, which may play a role in BPH 
development and/or progression.(145)  Deregulation of PKC signalling has been 
reported in many cancers including prostate and is a target of therapeutic 
intervention within the context of clinical trials.(146)  Expression of PKC, along 
with its transcriptional target c-Jun, has previously been associated with 
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decreased survival from biochemical relapse in CRPC clinical specimens.(144)  In 
the same cohort an increase in PKC expression between hormone sensitive and 
CRPC was associated with decreased survival from biochemical relapse.(144) 
PKC is the putative kinase for AR phosphorylation at Ser-578.  Site directed 
mutagenesis of Ser-578 in castrate resistant prostate cancer cell lines 
demonstrated that PKC-dependent AR phosphorylation was reduced on average 
by 50% when compared to wild type cells.(130)  In addition ligands such as 
epidermal growth factor have been shown to increase AR transcriptional activity 
and cell growth via PKC dependent Ser-578 phosphorylation.(130) 
1.5.4 Akt 
Akt comprises three family members (Akt 1, 2 and 3 ) and are activated by the 
PI3K cascade which recruits Akt to the plasma membrane inducing a 
conformational change which results in its activation.  Phosphorylation of Akt at 
threonine and serine residues increases its stability and level of activation.  
Activated Akt translocates to the cytoplasm and the nucleus where it acts as a 
critical mediator of downstream signal transduction cascades.  Akt has been 
previously shown to regulate cellular proliferation, survival, angiogenesis and 
invasion.  Akt1 dysregulation has been frequently implicated in prostate cancer 
via loss of PTEN and mutations in the catalytic subunit of PI3K, 
p110α.(79,147,148)  High expression levels of activated Akt (phosphorylated at 
serine 473) have previously been associated with low expression of PTEN in 
clinical prostate cancer specimens.(79)  Although not quite reaching significance 
(p=0.058), previous work has shown that an increase in activated Akt expression 
in primary prostate cancer tumour samples trended towards an association with 
shorter overall survival.(149)  In addition an increase in activated Akt expression 
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between matched hormone sensitive and CRPC clinical specimens was associated 
with a significant reduction in survival from biochemical relapse and disease 
specific survival.(129,149) 
Akt has been shown to phosphorylate the AR at Ser-213.  Transfection of wild 
type and S213A AR mutants into DU145 cells showed a significant increase of 
phosphorylation at Ser-213 in response to Akt treatment in the wild type cells 
compared to the mutants.(123)  In addition the use of immunocomplex kinase 
assays showed that phosphorylation of AR was significantly increased in response 
to Akt in wild type versus S213A mutants.(124)  Furthermore, co-
immunoprecipitation revealed that activated Akt specifically associated with 
endogenous AR in LNCaP cells.(123)  In human prostate cancer tissue 
immunohistochemical analysis of activated Akt was associated with poor 
prognosis (149) and AR phosphorylation at Ser-213 expression showed a strong 
correlation in expression levels in hormone refractory prostate cancer 
tissue.(129) 
The candidate kinases influencing AR serine phosphorylation have been 
previously identified and investigated in mutagenesis cell line studies, however 
this has not been translated into prostatic tissue specimens.  In addition the 
kinases mediating AR serine phosphorylation in BPH have not been previously 
studied.  The kinases driving clinically significant AR serine phosphorylation in 
prostatic disease therefore require further investigation within BPH and prostate 
cancer clinical specimens and may have implications for therapeutic 
intervention. 
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1.6 Statement of research aims 
The overarching aim of this thesis was to determine the prognostic and 
predictive significance of AR serine phosphorylation, and the candidate kinases 
driving such phosphorylation, in patients with BPH and prostate cancer.  It was 
hypothesised that AR phosphorylation by candidate kinases could prognosticate 
and predict response to treatment for these diseases.  Therefore to investigate 
this hypothesis we aimed to: 
1. Establish and verify the specificity of a panel of phosphospecific AR 
antibodies. 
2. Determine the clinical significance of AR serine phosphorylation sites, and 
the candidate kinases driving such phosphorylation, in a pilot cohort of 
hormone naïve prostate cancer. 
3. Further investigate clinically significant AR phosphorylation sites, and 
associated kinases, identified in the pilot prostate cancer cohort in a 
cohort of prostate cancer patients treated by active surveillance. 
4. Verify the results of the AR phosphorylation sites and candidate kinases in 
the first active surveillance cohort in a second prospectively collected 
cohort of prostate cancer patients treated by active surveillance. 
5. Determine the clinical significance of AR serine phosphorylation sites, and 
the candidate kinases driving such phosphorylation, in a cohort of benign 
prostatic hyperplasia patients. 
 
66 
 
2 Materials and Methods 
2.1 Patients 
Four patient cohorts were established as described below as part of this proof of 
concept study. 
2.1.1 Pilot prostate cancer cohort 
Ninety patients with hormone-naïve prostate cancer and tissue samples available 
for analysis were recruited from Glasgow Royal Infirmary between 1992 and 
2002.  Last date of follow up was 11/01/2012.  Paper and electronic medical 
records were reviewed for each patient and an anonymised database was 
created comprising of clinical, biochemical and pathological information. 
Patients gave written consent for the use of their clinical information and tissue 
and West of Scotland Research Ethics Committee approved the study (reference: 
05/S0704/94). 
2.1.2 Clinical outcome measures pilot prostate cancer cohort 
The clinical outcome measures and rational for the pilot prostate cancer cohort 
were: 
1. Time to biochemical relapse 
This was measured from the time of diagnosis to the time of biochemical 
relapse as evidenced by rising serum PSA level dependent on treatment; 
radical prostatectomy serum PSA >0.2ng/ml, radical radiotherapy serum 
PSA of 2.0ng/ml above the post treatment nadir level, hormone 
treatment 2-3 consecutive rises in serum PSA levels above the nadir 
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obtained at intervals of >2 weeks.(150,151)  This end point is equivalent 
to progression/disease free survival.  This is important in prostate cancer 
for two reasons; 1. for the majority of patients who have undergone 
primary treatment with the aim of cure this is the point at which their 
disease becomes incurable, 2. in patients who have undergone hormone 
treatment this is the point at which their disease becomes castrate 
resistant, with a mean life expectancy of 18-24 months.  Therefore 
patients who experience biochemical relapse are more likely to die from 
prostate cancer and therefore may harbour more aggressive disease at 
diagnosis. 
2. Disease specific survival. 
This was measured from the time of diagnosis to the time of death where 
“prostate cancer” was recorded as a primary or secondary cause of death 
on the official death certificate.  This is an important end point as it is a 
major goal of cancer treatment and is of direct benefit to patients.  If 
patients can be identified at diagnosis as being high risk for death from 
prostate cancer any delay in potentially curative treatment, e.g. via 
active surveillance, can be avoided. 
2.1.3 Retrospective active surveillance prostate cancer cohort 
One hundred and twelve consecutive active surveillance patients were identified 
from the Greater Glasgow and Clyde urology multidisciplinary team (MDT) 
records between May 2005 and March 2010.  Ninety patients had clinical 
information available and of these 51 had diagnostic tissue available and were 
thus eligible for inclusion in the study.  Paper and electronic medical records 
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were reviewed for each patient and an anonymised database was created 
comprising of clinical, biochemical and pathological information.   
West of Scotland Research Ethics Committee approved the study (reference: 
12/WS/0087). 
2.1.4 Prospective active surveillance prostate cancer cohort 
One hundred and four consecutive active surveillance patients were recruited 
prospectively, following tissue diagnosis, in NHS Ayrshire and Arran between 
13/11/1998 and 17/03/2011.  All patients had clinical information available and 
84 had diagnostic tissue available and were thus eligible for inclusion in the 
study.  Paper and electronic medical records were reviewed for each patient and 
an anonymised database was created comprising of clinical, biochemical and 
pathological information.   
West of Scotland Research Ethics Committee approved the study (reference: 
12/WS/0087). 
2.1.5 Clinical outcome measures active surveillance cohorts 
The clinical outcome measures and rational for the retrospective and 
prospective active surveillance cohorts were: 
1. Time to treatment intervention 
This was measured from the time of diagnosis to the time of treatment 
intervention.  This end point is deemed important in active surveillance 
prostate cancer patients as it likely represents disease progression 
(biochemical, clinical, radiological). 
Chapter 2 Materials and methods  69 
 
2. Time to development of metastases. 
This was measured from the time of diagnosis to the time of detection of 
local or distant metastases usually via radiological imaging.  This end 
point relies on clinical follow up and detection, therefore accuracy in 
relation to precise timing is lost.  However this end point is deemed 
important in prostate cancer patients treated by active surveillance as it 
is a marker of disease progression and occult aggressive disease.  If these 
patients with occult aggressive disease can be identified at diagnosis they 
can undergo immediate radical treatment and avoid delay via active 
surveillance. 
2.1.6 Benign prostatic hyperplasia cohort 
Six hundred and seventy eight consecutive patients with histological evidence of 
BPH diagnosed on transurethral resection (TUR) of prostate specimens between 
01/01/1996 and 31/12/2005 were identified from the north Glasgow pathology 
archives.  Of these patients 336 had clinical information and diagnostic tissue 
available and were thus eligible for inclusion in the study.  Paper and electronic 
medical records were reviewed for each patient and an anonymised database 
was created comprising of clinical, biochemical and pathological information.  
West of Scotland Research Ethics Committee approved the study (reference: 
11/AL/0214). 
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2.1.7 Clinical outcome measures benign prostatic hyperplasia 
cohort 
The clinical outcome measures and rational for the benign prostatic hyperplasia 
cohorts were: 
1. Time to postoperative acute urinary retention (AUR) >30 days post TUR 
This was measured from 31 days post TUR of prostate operation to time of 
AUR.  AUR was defined as a sudden and painful inability to void requiring 
a urinary catheter to be inserted.  This was an important end point as if 
high risk patients were identified immediately following TUR then 
prophylactic medical treatment could be instituted and emergency 
hospital attendances could be avoided as well as the risks to patients and 
costs to the health service. 
2. Time to failure of surgical management 
This was measured from the time of TUR of prostate operation to the time 
of prescription of an alpha blocker and/or 5-alpha reductase inhibitor 
postoperatively.  This was also deemed an important end point as if AR 
serine phosphorylation was found to be significant it could provide a 
rational for undertaking a prostate biopsy at first assessment in all BPH 
patients in order to identify those who would most benefit from operative 
management.  It would allow better patient selection for TUR and avoid 
the anaesthetic and surgical risks in those patients who are unlikely to 
benefit symptomatically from such a procedure. 
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3. Time to reoperation. 
This was measured from the time of original TUR operation to the time of 
second TUR operation if it occurred.  This was deemed important because 
those patients at risk of reoperation may have prophylactic medical 
therapy instituted immediately postoperatively.  In addition if a 
diagnostic prostate biopsy was undertaken then it may inform the surgical 
technique, e.g. more tissue may be resected than in a patient who was 
not high risk for reoperation, or a total prostatectomy may be performed. 
2.2 Prostatic tissue preparation 
Areas of prostate cancer or BPH were identified and marked by a consultant 
uropathologist on haematoxylin and eosin (H&E) stained sections of the 
diagnostic prostatic tissue specimens for all 4 cohorts. 
2.2.1 Tissue micro array construction 
Tissue micro arrays (TMAs) were constructed for the pilot prostate cancer cohort 
and the BPH cohort.  TMAs allow rapid tissue processing of large numbers of 
samples under standardised conditions.  Following marking of the H&E stained 
sections the corresponding paraffin embedded tissue blocks were retrieved from 
the pathology archives.  Three 0.6mm2 cores of tissue were then removed from 
the areas of interest identified (marked by a uropathologist) in each block.  
Recipient array blocks were constructed in triplicate in order to account for 
heterogeneity of the prostatic tissue.  Three micrometer thick sections were 
then cut from the TMA blocks using a Leica RM 2135 microtome.  The sections 
were then floated in a water bath heated to 45oC in order to allow the tissue to 
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flatten out.  The sections were then applied to Superfrost Plus microscope slides 
(Fischer Scientific, Loughborough, UK).  After drying in an oven overnight at 56oC 
the slides were stored at 4oC. 
2.2.2 Tissue section preparation 
The diagnostic tissue for the active surveillance cohorts was obtained via TUR of 
prostate operations and trans rectal ultrasound (TRUS) guided prostate biopsies.  
The tissue obtained from TRUS biopsy has an average diameter of 0.866mm and 
therefore was insufficient for TMA construction.  Following marking of the H&E 
stained sections the corresponding paraffin embedded tissue blocks were 
retrieved from the pathology archives.  Three micrometer thick sections were 
cut from each block and prepared as per section 2.2.1.  The marked H&E section 
was retained for reference in order to perform the analysis. 
2.3 Inflammatory scoring systems 
Assessment of the local and systemic inflammatory response was undertaken on 
original H&E stained tissue sections.  The sections were reviewed by a 
pathologist and the best representative areas of BPH were marked. Two 
independent observers graded the local inflammatory response and extent of 
tissue necrosis and any differences in results were settled by discussion. 
2.3.1 Systemic inflammatory response 
The modified Glasgow prognostic score (mGPS) is an assessment of the 
preoperative systemic inflammatory response.  The mGPS comprises a 
combination of serum albumin and C-reactive protein (CRP).(152)  Routine 
laboratory measurements of albumin and CRP were recorded preoperatively.  
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Patients with both a raised CRP level (more than 10 mg/l) and 
hypoalbuminaemia (below 35g/l) were allocated a score of 2.  Those in whom 
neither of these abnormalities was present were allocated a score of 0.  Patients 
with a raised level of CRP alone were scored 1, whereas those with 
hypoalbuminaemia alone were scored 0. 
2.3.2 Local inflammatory response 
The Klintrup-Makinen criteria is a well-established measure of the inflammatory 
cell infiltrate at a local level.(153)  The Klintrup-Makinen criteria involved the 
margin of each marked area of BPH being scored on a four point scale.  A score 
of 0 indicated absence of inflammatory cells; score 1 denoted a mild or patchy 
presence of inflammatory cells, score 2 a prominent inflammatory reaction, and 
score 3 a florid ‘cup-like’ inflammatory infiltrate. 
2.3.3 Tissue necrosis 
The extent of tissue necrosis was graded with 0 when no necrosis was present; a 
score of 1 when there was <25% necrosis, a score of 2 when necrosis was 25–50%, 
and 3 for necrosis of >50%.  Necrosis related to haemorrhage and foci of 
hyalinization were not considered. 
2.4 Identification of candidate kinases mediating AR 
phosphorylation 
Scansite 2.0 (http://scansite.mit.edu/) was utilised to identify the candidate 
kinases mediating AR phosphorylation.(154)  Scansite searches for motifs within 
proteins that are likely to be phosphorylated by specific protein kinases.  
Optimal phosphorylation sites for each individual kinase are predicted using the 
matrix of selectivity values for amino acids at each position relative to the 
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phosphorylation site as determined from the orientated peptide library 
technique.(155,156)  The search was conducted using the protein ID 
“ANDR_HUMAN” (Accession number: P10275). 
2.5 In-vitro studies 
An androgen sensitive human prostate adenocarcinoma cell line was utilised 
(LNCaP).  LNCaP cells were originally derived from the left supraclavicular lymph 
node metastasis from a 50-year-old caucasian male in 1977.(157)  They are the 
most clinically relevant prostate cancer cell line consisting of adherent 
epithelial cells which grown both in aggregates and as single cells.  LNCaP cells 
are also known to express AR and respond to androgen stimulation.(157)  This 
was key to their selection for use within this study. 
2.5.1 Culturing prostate cancer cells 
LNCaP cells (ATCC) were routinely maintained in RPMI 1640 (Invitrogen) 
containing phenol red and supplemented with 10% foetal calf serum (Invitrogen, 
UK) and 2mM L-glutamine.  LNCaP cells were grown in T-75 flasks in an incubator 
with conditions set to 5% CO2 and 37
oC.  The medium was changed twice per 
week and the flasks were split when the cells reached 70-80% confluence. 
2.5.2 Trypsinisation of cells 
LNCaP cells were routinely spilt 1:6 by trypsinisation when around 70-80% 
confluent.  This was in order to maintain the monolayer growth pattern and 
prevent formation of cell towers due to overcrowding.  The medium was 
removed from the flasks and the cells were washed twice in warmed PBS 
(Invitrogen) in order to remove all traces of medium.  The cells were then 
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incubated in 3ml of trypsin (Invitrogen) for 5min in 5% CO2 at 37
oC.  Once the 
cells had detached from the flask a further 3ml of RPMI was added in order to 
neutralise the trypsin.  The cells were disaggregated from their clusters by 
gentle pipetting and then reseeded 1:6 into new flasks containing 10ml of RPMI.  
Cells were then incubated in 5% CO2 at 37
oC without disruption for up to 48h in 
order to allow reattachment to the bottom of the flask. 
2.5.3 Cell treatments 
The response of protein phosphorylation status in LNCaP cells to extracellular 
stimuli and inhibitors was measured. 
2.5.3.1 Dihydrotestosterone 
Dihydrotestosterone (DHT) is a potent androgen which binds to the androgen 
receptor resulting in post translational modifications, including phosphorylation, 
ultimately leading to gene transcription.  Cells were treated with 10nM DHT 
diluted in dimethyl sulphoxide (DMSO) for 5, 10, 15 and 30min. 
2.5.3.2 Roscovitine 
Roscovitine (Cell Signaling) is a selective inhibitor of Cdks (Cdk1, 2 and 5).  Cells 
were treated with 20μM Roscovitine diluted in PBS for 24h. 
2.5.4 Time course stimulation and inhibitor treatments of LNCaP 
cells 
Following trypsinisation cells were seeded at 4x105 cells/ml/well in 6 well 
plates.  Each well was made up to a total volume of 2ml with RPMI.  After 72 
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hours the cells were incubated in serum free RPMI overnight.  The appropriate 
treatments were added to each well along with a vehicle (containing diluent 
only) and an untreated control well.  The treatments were applied for the 
appropriate times in 5% CO2 and at 37
oC as documented above.  All treatments 
were applied identically and in triplicate in three different passages of the cell 
line.  All plates were put on ice and the cells were removed using a cell scraper.  
Care was taken to ensure the cell scraper was washed well between wells to 
avoid contamination.  The cells were transferred to labelled 15ml tubes, kept on 
ice, using disposable pastettes.  Each well was then washed in 1-2ml of ice cold 
PBS and the wash was transferred to the appropriate 15ml tube.  The 15ml tubes 
were then centrifuged at 1400rpm for 10min until a pellet was formed.  The 
supernatant was carefully removed and the pellet was resuspended in 1ml ice 
cold PBS and then vortexed thoroughly in order to wash the cells.  The cell 
suspension was then transferred to a labelled eppendorf.  The eppendorfs were 
centrifuged at 1600rpm for 10min until a pellet was formed.  The supernatant 
was carefully removed and the cells were lysed in 150μl of Radio Immuno 
Precipitation Assay (RIPA) lysis buffer.  The RIPA lysis buffer contained: 
150 mM sodium chloride 
1.0% NP-40 
0.5% sodium deoxycholate 
0.1% SDS (sodium dodecyl sulphate) 
50 mM Tris, pH 8.0 
1:100 protease inhibitor 
The cells were mechanically sheared by passing them repeatedly through a 
needle syinge tip.  The lysates were then stored short term at -20oC and long 
term at -80oC. 
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2.5.5 Time course treatments of LNCaP cells cell pellet formation 
Cell lines were grown in T-75 flasks until 70-80% confluent, the medium was 
removed and the cells washed in warmed PBS.  The cells were then incubated in 
serum free RPMI overnight.  The following day, medium was removed and the 
cells washed in warmed PBS in preparation for the appropriate drug treatment.  
LNCaP cells were treated with Roscovitine (20μM) for 24h or DHT (10nM) for 3h.  
A vector flask (diluent only) and an untreated control were included in each 
experiment.  Each flask was treated with 3mls inhibitor, stimulator or control, 
ensuring that all cells were completely covered, and incubated at 37°C in 5% 
CO2 for the required time.  The cells were trypsinised and collected by 
centrifugation at 1200rpm.  The supernatant was discarded and pellets were 
washed in HBSS.  Cells were fixed in 4% formalin, briefly vortexed and rested at 
room temperature for 15 min.  The cells were then centrifuged at 2500rpm for 
3min, the supernatant discarded and then washed in HBSS.  The cells were set in 
1% agarose at 4oC for 1h.  Cell pellets were dehydrated through graded alcohol 
and xylene and embedded into paraffin blocks.  Immunohistochemistry was 
performed as described (antigen retrieval reduced to 2.5 min) for protein 
expression. 
2.6 Antibody Validation 
Cross-reactivity of phospho-specific antibodies is a known issue.  Therefore 
validation of the specificity of these antibodies is required by more than one 
method.  In addition to the manufacturer’s validation techniques, western 
blotting and peptide competition assays were performed on each phospho-
specific antibody. 
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2.6.1 Western blotting 
Western blotting was performed to confirm antibody specificity before their 
usage in immunohistochemical staining of the TMAs and tissue sections.  Western 
or immunoblotting is a method by which a specific protein can be detected and 
quantified in tissue or cells.  In brief this technique includes extracting protein 
samples from cultivated tissue or cells, separating the denaturated proteins by 
gel electrophoresis and transferring them to a PVDF membrane.  The membrane 
is then exposed to a primary antibody specific to the protein of interest, 
followed by a secondary antibody recognising the antibody-antigen complex.  To 
detect the proteins chemi-luminescent and chemi-fluorescent method is used.  
Western blotting was used to verify the specificity of all antibodies and to 
measure the quantity of protein in samples from time course and inhibitor 
studies. 
2.6.1.1 Preparation of protein samples 
Determination of concentration of protein samples 
In order to maintain consistency the same amount of protein from each sample 
tested must be used.  Therefore the protein concentration of each sample must 
be known before undertaking western blotting.  The method utilised to achieve 
this is the Bio-Rad protein assay, based on the Bradford dye-binding 
procedure.(158)  A colorimetric assay is used to measure the total protein 
concentration. 
The protein samples were prepared as a low-concentration assay in disposable 
cuvettes (Gibo).  A standard solution (200μl of Bio-Rad Reagent and 795μl dH2O) 
was pipette into one cuvette, followed by 5μl of protein sample.  The solution 
was mixed thoroughly with a pipette in order to ensure an accurate 
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concentration reading.  Protein standards were prepared using Bovine Serum 
Albumin (BSA).  Stock BSA (2mg/ml) was diluted with dH2O to 1mg/ml.  One 
reference sample (dH20 only and Bio-Rad Dye) and seven protein standards 
(serial dilutions from 1-50μg/ml) were prepared in disposable cuvettes.  The 
reference sample and protein standards were used to calibrate the 
spectrophotometer (Bio-Rad) applying the Protein 595 Assay program.  
Optical density for the reference and the protein standards were measured at 
595 nm. Optical density at 595 nm (O.D. 595) was then read for all other protein 
samples.  The spectrophotometer calculated at that time the amount of protein 
(μg/ml) present in the sample, plotting a graph of absorbance at 595 nm against 
the protein concentration of the standard samples.  This is the standard curve 
used to determine the protein concentration of the measured sample from its 
O.D. 595 value. 
 
The initial protein concentration (μl/ml) was calculated from a diluted protein 
sample (1:200).  The final protein concentration in mg/ml was calculated using 
the formula ‘Protein reading (μl/ml) x 0.2 = Final protein concentration 
(mg/ml)’. 
Proteins were aliquoted and stored at -80oC until required.  A standard 50μg of 
protein was used for western blotting, the volume of each sample required (μl) 
was calculated from the final concentration. 
Protein denaturisation 
Proteins were denatured to unfold them in order to allow the antibody access to 
the epitope.  Denaturisation also improves the efficiency at which the proteins 
run through the gels.  Having determined the protein concentration in each 
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sample an appropriate volume was removed from each sample and placed on ice 
in a new Eppendorf tube.  2x Laemmli’s buffer at a ratio of 1:1 was added to 
each protein sample.  2x Laemmli’s buffer contains: 
4% SDS 
10% 2-mercaptoethanol 
20% glycerol 
0.004% bromophenol blue 
0.125 M Tris HCl. 
The ingredients in 2x Laemmli’s buffer each have a specific purpose.  SDS 
denatures proteins by ‘wrapping round’ the polypeptide backbone.  SDS then 
provides a negative charge to the proteins by their attachment to SDS anions.  
SDS attaches to proteins at a mass ratio of 1.4:1.  The unfolded proteins 
therefore become negatively charged rods with a charge consistently 
proportional to its length.  The samples were then boiled at 100oC on a 
preheated hotplate for 5min.  2-mercaptoethanol reduces disulphide bridges in 
proteins and helps to maintain the protein in its denatured state.  Glycerol 
increases the density of the sample in order to maintain the loaded sample at 
the bottom of the well and prevent well overflowing and uneven gel loading.  
Bromophenol blue is a small ionic dye which migrates to the front of the protein 
mixture to be separated.  It allows visualisation of the separation process.  After 
mixing with Laemmli’s buffer the samples were boiled for 5min at 100oC on a 
preheated hotplate.  This heat treatment contributes to the protein 
denaturisation process.  The molecular weight marker (Biotinylated Protein 
Ladder –Cell Signaling Technology) that was used to determine the size of the 
detected protein was also boiled at 100°C for 5min.  Following heating all 
samples were vortexed well and then immediately stored back on ice. 
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2.6.1.2 Preparation of SDS-PAGE Gels 
The separation of proteins according to their molecular weight is routinely done 
by Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis (SDS-PAGE).  
Polyacrylamide gels are formed from the polymerization acrylamide and N,N-
methylenebis-acrylamide (Bis).  Bis is a cross-linking agent for the gels.  The 
separation of molecules within a gel is determined by the relative size of the 
pores formed within the gel.  The pore size of a gel is determined by the total 
amount of acrylamide (%T) and the amount of cross-linker (%C) present.  As the 
total amount of acrylamide increases, the pore size decreases.  In general a 
higher percentage of resolving gels are used for smaller proteins, and lower 
percentage gels are more effective for separating larger proteins.  The 
percentage of the gel utilised must be carefully selected as this determines the 
rate of migration and degree of separation between proteins. 
Throughout this study 1.0mm 4-12% Bis-Tris gels from NuPAGE® (Invitrogen) were 
utilised to maintain consistency. 
2.6.1.3 Electrophoresis 
As previously described SDS confers a negative charge onto the proteins.  This 
negative charge allows the proteins to move through the gel as they are 
attracted to the positive anode.  Proteins are separated by gel electrophoresis 
by their molecular weight.  Small proteins travel much quicker through the 
acrylamide pores than large proteins.  Therefore small proteins can be found 
much further down the gel than larger ones. 
Gels were placed in the electrode assembly in a mini buffer tank and combs 
were removed.  The tank was then filled with running buffer (Novamix 10x 
running buffer (Invitrogen, Life Technologies Ltd, Paisley, UK) diluted to 1x with 
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dH20) until the whole gel complex was completely submerged.  Denatured 
protein samples (50μg) and the molecular weight marker (10μl) were then 
carefully loaded into the wells using special gel loading tips.  Tubulin (MW 
55kDa) was used as a loading control to check that each lane was equally loaded 
with sample in each gel.  Care was taken not to poke the well bottom with the 
tip as this can create a distorted band.  In addition it was paramount that the 
wells were not overfilled as this could lead to spillage into adjacent wells and 
inaccurate data.  Once all samples were loaded the gel was run at approximately 
140V for approximately 90min. 
2.6.1.4 Protein transfer 
The proteins require to be transferred from the polyacrylamide gel to a PVDF 
(polyvinylidene difluoride) membrane.  This process uses the same principle of 
electrical charge in order to induce the proteins to travel via an electrical field 
from a gel to a membrane that ‘blots’ the proteins from the gel.  Due to the 
larger size of the proteins of interest (110-112kDa) wet transfer method was 
used in this study.  PVDF membranes are soaked for 5min in 100% methanol prior 
to transfer.  The gel was carefully separated from its plastic cover and the wells 
were cut away.  The gel was equilibrated in transfer buffer in order to prevent 
shrinkage during the transfer process.  The gel, membrane, sponges and 3M 
Whatmann paper (VWR) are then soaked in transfer buffer and assembled as a 
‘transfer sandwich’; sponge/ paper/ gel/ membrane/ paper/ sponge.  All air 
bubbles were eradicated as they can prevent adequate transfer of protein to the 
membrane.  Once this was complete the sandwich was clamped tightly together 
and locked in a cassette which was placed in the electrode assembly and 
positioned into the Mini-Trans Blot Cell tank (Bio-Rad Laboratories) which was 
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prefilled with transfer buffer.  A Bio-Ice pack was added to the tank in order to 
keep the temperature down during transfer.  A magnetic stirrer also maintained 
an even temperature and ion distribution within the tanks.  An electrical charge 
was applied to transfer the proteins from gel (negative/cathode) to membrane 
(positive/anode) over 90min at 240mAmp. 
2.6.1.5 Blocking membranes 
Blocking the membrane is necessary in order to prevent non-specific background 
binding of the primary and/or secondary antibodies to the membrane.  The 
membrane has a high capacity for binding proteins and therefore the same is 
true for antibodies.  This was achieved by incubating the membrane in 5% non-
fat dry milk (Marvel) for 1 hour on an orbital shaker.  The orbital shaker was 
utilised for all future steps. 
2.6.1.6 Incubation with primary antibody 
The membrane was incubated with the primary antibodies diluted in 5% non-fat 
dry milk (Marvel) in order to reduce further non-specific binding.  Membranes 
were incubated with 20ml antibody overnight at 4oC in 50ml universal containers 
on a roller.  The membrane was then washed thoroughly (6x 15min) in TBST 
(0.001% Tween-20 in TBS) at room temperature to remove residual primary 
antibody. 
2.6.1.7 Incubation with secondary antibody 
The membrane was incubated with the secondary antibody diluted in the 
appropriate blocking agent.  Detection of the protein of interest required a 
secondary antibody bound to either biotin or an enzyme conjugate, such as 
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horseradish peroxidase (HRP), which was species-specific to the primary 
antibody. The secondary antibodies used were therefore HRP-linked anti-mouse 
IgG or anti-rabbit IgG (both Cell Signaling Technology).  Each was diluted 
1:10,000 in the appropriate blocking agent and incubated with the membrane on 
an orbital shaker for 90min at room temperature.  The membrane was then 
washed thoroughly (6x 15min) in TBST (0.001% Tween-20 in TBS) at room 
temperature to remove residual secondary antibody. 
2.6.1.8 Visualisation 
Chemiluminescent detection methods depend on incubation of the western blot 
with a substrate that will luminesce when exposed to the reporter on the 
secondary antibody. The light is then detected by photographic film.  Horse-
radish peroxidase catalyzes oxidation of luminol, a chemiluminescent substrate, 
in alkaline conditions. Oxidation results in the luminol being in an excited state 
which then decays to ground state via a light emitting pathway.  In order to 
perform this method ECL plus (Amersham, GE Healthcare Life Sciences, Little 
Chalfont, UK) was used.  The following steps were performed in a dark room as 
ECL reagents are photo sensitive.  The reagents, stored at 4oC, were first 
warmed to room temperature.  ECL reagent A was then mixed with reagent B at 
1:1 ratio to a final minimum volume of 0.1ml/cm2 of membrane.  The mixed 
detection reagent was then pipetted onto the membrane (protein side up) and 
incubated for 5min at room temperature.  Excess detection reagent was blotted 
from the membrane and they were transferred to a fresh piece of Saran wrap, 
which it was then enveloped in.  Finally the membrane was transferred to a film 
cassette where it was exposed to autoradiography film for various times.  
Generally the incubation times were 30 seconds and 1, 5, 15 minutes.  The film 
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was developed using a Kodak X-OMAT x-ray processor and both the marker and 
protein bands visualised. 
2.6.1.9 Stripping membranes 
In order to confirm equal sample loading, the primary antibody was removed 
from probed membranes using Re-Blot Stripping buffer (Chemicon).  The 
membrane was then washed in TBST (3x 15min) to remove excess antibody.  
Membranes were incubated in 20mls of stripping buffer (diluted 1:10 in dH2O) at 
room temperature for 20min.  The membranes were then blocked again in 5% 
Non-Fat Dry Milk/TTBS and re-probed with anti-αTubulin HRP linked antibody 
(1:1000 AbCam) to confirm equal protein loading. 
2.6.2 Peptide competition assays 
Peptide competition assays were performed to confirm antibody specificity for 
each AR serine phosphorylation site.  pARS213 (Protein sequence 
GRAREA(pS)GAPTSSKD raised in rabbit by EZbiolab Inc., Carmel, IN, USA) peptide 
was incubated at a ratio 1:1 for 1h with each antibody.  pARS81 (Protein 
sequence QQQQQQET(pS)PRQQ raised in rabbit by EZbiolab Inc., Carmel, IN, 
USA), pARS94 (Protein sequence QQQQQGEDG(pS)PQAH raised in rabbit by 
EZbiolab Inc.), pARS515 (Protein sequence MVSRVPYP-S(pS)-PTCV raised in rabbit 
by Eurogentec Ltd.), pARS578 (Protein sequence ALTCG-S(pS)-CKVFFKR raised in 
rabbit by Eurogentec Ltd., Seraing, Belgium) and pARS650 (Protein sequence 
EEGEASSTT(pS)PTEE raised in rabbit by EZbiolab Inc.) peptides were incubated 
at ratios of 1:1, 2:1, 500:1, 200:1 and 100:1, respectively, with each antibody 
overnight at 4oC.  Immunohistochemistry was then performed as described in 
section 2.7. 
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2.7 Immunohistochemistry 
Immunohistochemistry is a method by which a particular antigen within cells 
and/or tissue can be detected using a specific antibody.  In general there are 
two methods by which immunohistochemistry can be conducted; direct and 
indirect.  The direct method is the more simplistic, ‘one step’ staining method 
by which a marker attaches directly onto the antigen of interest.  Indirect 
immunohistochemistry uses a secondary antibody which binds to the primary 
antibody which, in turn, is bound to the antigen of interest.  Indirect 
immunohistochemistry is more sensitive than the direct method as it generates 
signal amplification through several secondary antibody reactions with different 
antigenic sites on the primary antibody.  The method used in this study was the 
DAKO Envision+ dual link system-HRP.  This is a two step staining procedure 
based on dextran polymer technology.  Primary rabbit or mouse antibodies 
recognise and bind to the antigens of interest.  The DAKO Envision detection 
reagent is a peroxidase-conjugated polymer which also carries antibodies to 
mouse and rabbit immunoglobulins.  Following incubation with the Envision 
detection reagent 3,3, diaminobenzidine (DAB) is applied.  The peroxidase 
molecules then react with the DAB which produces an insoluble brown 
precipitate which can be readily viewed via light microscopy. 
2.7.1 Tissue preparation 
Immunohistochemistry was conducted on 3μm sections taken from formalin 
fixed, paraffin embedded prostatic tissue blocks as described in sections 2.2.1 
and 2.2.2.  Sections were baked at 56oC for 1h prior to use.  Sections were then 
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placed in a slide rack and dewaxed in xylene (2 x 3min) and rehydrated through 
graded alcohol solutions; 100% (2 x 2min), 90% (1 x 2min) and 70% (1x 2min). 
2.7.2 Antigen retrieval 
Antigen retrieval is a necessary step in immunohistochemistry in order to unmask 
epitopes and allow antibody binding.  Masking of epitopes often occurs during 
tissue fixation and can be caused by crosslinking of amino acids within the 
epitope, crosslinking of peptides near the epitope resulting in conformational 
change at the epitope or a change in the electrostatic charge of the antigen.  
Antigen retrieval is any method which reverses the masking process. 
Two heat-based methods of antigen retrieval were utilised in this study.  The 
first involved preheating 1l of buffer solution tris-EDTA pH8 (1mM EDTA (Sigma) 
and 5mM Tris (VWR)) or sodium citrate pH6 (10mM tri-sodium citrate and 2mM 
anhydrous citric acid), for 13.5min to 96oC in a microwave.  The tissue sections 
were then added to the preheated solution and cooked under pressure for 5min 
before being cooled for 20min.  The second method involved incubating the 
tissue sections in approximately 50ml of DAKO high pH target retrieval solution 
(1:10 dilution) or tris-EDTA pH9 (0.25mM EDTA (Sigma) and 10mM Tris (VWR)) for 
20min at 96oC in a waterbath (Table 2.1). 
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Table 2.1 Antibody information 
Protein Antibody 
Antibody 
Dilution 
Antibody 
Incubation 
Conditions 
Retrieval 
Method 
Blocking 
Agent 
Cdk1 
Mouse 
Abcam 
ab18 
1:400 
1h 
room 
temperature 
EDTA pH 8 
5min under 
pressure 
5% Horse 
Serum 
pCdk1161 
Rabbit 
Abcam 
ab47329 
1:500 
Overnight 
4oC 
EDTA pH 8 
5min under 
pressure 
5% Horse 
Serum 
pERK1/2 
Rabbit 
Cell 
Signaling 
#9101L 
1:8000 
Overnight 
4oC 
EDTA pH 9 
20min at 96oC 
10% Casein 
PKC 
Rabbit 
Abcam 
ab59363 
1:500 
Overnight 
4oC 
Citrate pH 6 
5min under 
pressure 
5% Horse 
Serum 
Ki67 
Mouse 
Dako 
F0788 
1:150 
1h 
room 
temperature 
Citrate pH 6 
5min under 
pressure 
5% Horse 
Serum 
AR 
Mouse 
Dako 
AR441 
1:100 
Overnight 
4oC 
High pH antigen 
retrieval 
solution 
20min at 96oC 
5% Horse 
Serum 
pARS81 
Rabbit 
Millipore 
# 07-1375 
1:4000 
Overnight 
4oC 
EDTA pH 8 
5min under 
pressure 
5% Horse 
Serum 
pARS94 
Rabbit 
Abcam 
ab62205 
1:200 
Overnight 
4oC 
EDTA pH 8 
5min under 
pressure 
5% Horse 
Serum 
pARS213 
Mouse 
Imgenex 
IMG-561 
1:100 
1h 
room 
temperature 
EDTA pH 8 
5min under 
pressure 
5% Horse 
Serum 
pARS515 
Rabbit 
Eurogentec 
1:500 
1h 
room 
temperature 
EDTA pH 8 
5min under 
pressure 
5% Horse 
Serum 
pARS578 
Rabbit 
Eurogentec 
1:1000 
Overnight 
4oC 
EDTA pH 8 
5min under 
pressure 
5% Horse 
Serum 
pARS650 
Rabbit 
Abcam 
ab47563 
1:200 
Overnight 
4oC 
EDTA pH 8 
5min under 
pressure 
5% Horse 
Serum 
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2.7.3 Blocking of non-specific staining 
Peroxidase interacts with 3,3, diaminobenzidine and is therefore a potential 
source of background staining.  Background staining was prevented by quenching 
endogenous peroxidase activity using 3% hydrogen peroxide for 10min followed 
by a wash in water.  The formation of hydrophobic bonds between tissue 
proteins and immunoglobulins can result in non-specific binding of the 
primary/secondary antibody to the tissue.  This also has the potential to result 
in background staining, so in order to counteract this the sections were 
incubated with 5% horse serum (vector) in TBS buffer (0.1M Tris/HCl, 1.5M NaCl, 
pH 7.5) or 10% casein in TBS buffer as per Table 2.1. 
2.7.4 Incubation with primary antibody 
Antibodies for the following proteins were used; Cdk1, pCdk1161, pERK1/2, PKC, 
Ki67 (proliferation index), AR and AR phosphorylated at serine 81, 94, 213, 515, 
578 and 650.  The quality of staining produced was first optimised by serial 
alterations to antigen retrieval methods, blocking agents, antibody dilutions and 
incubation times and temperatures.  The antibodies were diluted to the optimal 
concentrations in DAKO Antibody Diluent and incubated as shown in Table 2.1.  A 
positive and negative isotype matched control was included in each 
immunohistochemistry run in order to ensure no false positive staining.  The 
positive control confirmed that the antibody and method was working whilst the 
negative control checked for any non-specific antibody binding. 
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2.7.5 Incubation with secondary antibody 
Following completion of incubation with the primary antibody the sections were 
washed in TBS buffer (2x 5min) and then incubated with the secondary antibody; 
DAKO Envision+ detection system.  As previously described this uses a secondary 
antibody raised in goat attached to a dextran backbone upon which peroxidase 
molecules are also attached.  The tissue was incubated with the secondary 
antibody for 30min at room temperature.  Following this the sections were 
thoroughly washed in TBS (2x 5min). 
2.7.6 Detection 
The substrate chromogen used to detect the secondary antibody is DAB (Vector).  
A combination of 4 drops DAB, 2 drops hydrogen peroxide and 2 drops pH buffer 
were added to 5ml distilled water.  The slides were then incubated for 10min at 
room temperature with the DAB solution until a brown coloured appeared, 
before being thoroughly washed in running water for a further 10min. 
2.7.7 Counterstaining 
The slides were counterstained with haematoxylin and Scott’s tap water 
substitute.  The slides were submerged in haematoxylin for approximately 30s 
before being dipped in acid alcohol in order to remove excess staining.  The 
slides were then immersed for 30s in Scott’s tap water substitute in order to 
produce a blue counter stain.  The slides were then rinsed for 1min in running 
water. 
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2.7.8 Dehydration and mounting 
The slides were then dehydrated through graded alcohol solutions; 70% (1x 
1min), 90% (1x 1min) and 100% (2x 1min).  Finally the slides were submerged in 
xylene (2x 1min) and mounted using DPX and glass coverslips. 
2.8 TUNEL Assay 
Apoptosis is a form of cell death which eliminates compromised or superfluous 
cells.  Overall, apoptosis results in a well characterised process of change in 
cellular morphology including; shrinkage, chromatin margination, membrane 
blebbing, nuclear condensation, segmentation and then division into apoptotic 
bodies which may be phagocytosed.  These characteristic apoptotic bodies are 
short-lived and minute, and can resemble other cellular constituents when 
viewed under the light microscope.  In addition, DNA fragmentation in apoptotic 
cells is followed by cell death and removal from the tissue, usually within 
several hours.  A rate of tissue regression of 25% per day can result from 
apparent apoptosis in only 2-3% of the cells at any one time.  Therefore, the 
quantitative measurement of an apoptotic index by morphology alone can be 
difficult.  DNA fragmentation is usually associated with ultrastructural changes in 
cellular morphology in apoptosis.  The Terminal deoxynucleotidyl transferase 
dUTP Nick End Labeling (TUNEL) assay is a method by which to examine DNA 
fragmentation during apoptosis.  The ApopTag® In Situ Apoptosis Detection Kit 
(Millipore) was used to detect DNA strand breaks by enzymatically labeling the 
free 3'-OH termini with modified nucleotides.  These new DNA ends that are 
generated upon DNA fragmentation are typically localized in morphologically 
identifiable nuclei and apoptotic bodies.  In contrast, normal or proliferative 
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nuclei, which have relatively insignificant numbers of DNA 3'-OH ends, usually do 
not stain with the kit.  Apoptosis is distinct from accidental cell death (necrosis).  
The ApopTag® kit distinguishes apoptosis from necrosis by specifically detecting 
DNA cleavage and chromatin condensation associated with apoptosis.  However, 
it is accepted that there may be some instances where cells exhibiting necrotic 
morphology may stain lightly or, rarely, DNA fragmentation can be absent or 
incomplete in induced apoptosis. 
2.8.1 Rehydration of tissue 
Briefly, tissue sections were dewaxed in xylene (2x 3min) and rehydrated in 
graded alcohol solutons; 100% (2x 2min), 90% (1x 2min) and 70% (1x 2min).  The 
tissue sections were then washed in tap water for 2min. 
2.8.2 Pre-treatment of tissue 
Proteinase K solution was prepared to a concentration of 20µg/ml in PBS.  The 
solution was then incubated with slides for 25min at room temperature.  Slides 
were then washed twice in dH2O for 2min. 
2.8.3 Quenching of endogenous peroxidase activity 
Endogenous peroxidase activity was quenched with 3% H2O2 5min at room 
temperature.  The slides were then washed twice in dH2O for 5min. 
2.8.4 Application of equilibriation buffer 
Excess liquid was tapped off and the slides were blotted dry.  The slides were 
then incubated with equilibration buffer at 25oC for 1h. 
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2.8.5 Application of terminal deoxynucleotidyl transferase 
enzyme 
Terminal deoxynucleotidyl transferase (TdT) enzyme was diluted to working 
strength in reaction buffer (70% reaction buffer: 30% TdT) and mixed well by 
vortexing.  The slides were incubated in a humidified chamber at 37oC for 1h. 
2.8.6 Application of stop/wash buffer 
Working strength stop/wash buffer was prepared by diluting the stop/wash 
buffer 1:35 with dH2O.  Slides were then washed with working strength 
stop/wash buffer for 10min at room temperature.  Slides were then washed in 
TBS (3x 1min) at room temperature. 
2.8.7 Application of anti-digoxigenin conjugate 
An aliquot of anti-digoxigenin conjugate was removed from the stock vial and 
brought to room temperature.  Excess liquid was tapped and then blotted from 
the slides before incubating with antidigoxigenin conjugate for 30min at 25oC in 
a humidified chamber.  Slides were washed in PBS at room temperature (4x 
2min). 
2.8.8 Detection 
The substrate chromogen used is DAB (Vector).  A combination of 4 drops DAB, 2 
drops hydrogen peroxide and 2 drops pH buffer were added to 5ml distilled 
water.  The slides were then incubated for 10min at room temperature with the 
DAB solution until a brown coloured appeared, before being thoroughly washed 
in running water for a further 10min. 
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2.8.9 Counterstaining 
The slides were counterstained with haematoxylin and Scott’s tap water 
substitute.  The slides were submerged in haematoxylin for approximately 30s 
before being dipped in acid alcohol in order to remove excess staining.  The 
slides were then immersed for 30s in Scott’s tap water substitute in order to 
produce a blue counter stain.  The slides were then rinsed for 1min in running 
water. 
2.8.10 Dehydration and mounting 
The slides were then dehydrated through graded alcohol solutions; 70% (1x 
1min), 90% (1x 1min) and 100% (2x 1min).  Finally the slides were submerged in 
xylene (2x 1min) and mounted using DPX and glass coverslips. 
2.9 Analysis of protein expression 
Following immunohistochemical staining of prostatic tissue it was necessary to 
analyse the staining level using a semi-quantitive scoring method. 
2.9.1 Digitalisation of slides 
Slides stained by immunohistochemistry were scanned using a Hamamatsu 
NanoZoomer (Hertfordshire, UK).  Visualisation of slides on a computer monitor 
was carried out using the Slidepath Tissue IA system version 3.0 (SlidePath's 
Tissue IA system, Dublin, Ireland). 
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2.9.2 Histoscoring 
Tissue staining intensity was scored visually on a computer monitor by two 
blinded independent observers using a semi-quantitative weighted histo-score 
(H-score) method.(159,160)  Staining in the nucleus and cytoplasm of epithelial 
cells was evaluated.  In the stromal compartment nuclear staining of smooth 
muscle cells and stroma (fibroblastic) cells was evaluated.  The intensity of 
staining was assessed and graded as negative (0), weak (1), moderate (2) and 
strong (3) staining.  The percentage of tumour/BPH cells within each category 
was then estimated and a histoscore was calculated using the following formula: 
0x (% negative tumour cells) + 1x (% of cells staining weakly positive) + 2x (% of 
cells staining moderately positive) + 3x (% of cells staining strongly positive).  
Therefore the histoscore ranged from zero (minimum) to 300 (maximum).  
Results were considered discordant if scores differed by more than 50 between 
observers.  These cases were re-evaluated by both observers and settled by 
discussion.  In addition both intra-(variation in individual scoring) and inter-
(variation between two observers) class correlation coefficients were calculated.  
Agreement between observers was considered excellent if the ICCC value was 
≥0.80 (an ICCC of 1 indicates identical scoring).  Bland Altman plots were 
constructed to ensure there was no bias between scorers.  The mean histoscore 
from staining conducted in triplicate was used for analysis.  Protein expression 
levels were subsequently divided into low (≤median) and high expression 
(>median) for further statistical analysis. 
2.9.3 Automated Ki67 and TUNEL Scoring 
The Ki-67 antigen is a nuclear protein which, during interphase, can be 
exclusively detected within the nucleus, whereas in mitosis most of the protein 
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is relocated to the surface of the chromosomes.(161)  The Ki-67 protein is 
expressed in all proliferating cells during late G1, S, M and G2 phases of the cell 
cycle while cells in the G0 (non-cycling cells) phase consistently lack the Ki-67 
antigen.  In diagnostic histopathology and cell biology numerous studies have 
shown the use of measuring the Ki-67 labelling index or growth fraction in 
various solid tumours and proliferative disorders using 
immunohistochemistry.(161) 
Digitised slides were accessed via the Slidepath Image Analysis system and 
further evaluated for Ki67 and TUNEL cell counts using the program's nuclear 
scoring algorithm.  This quantifies nuclear staining within individual cores and 
derives a counting score for each target area.  Nuclei stained brown with DAB 
and/or blue with haematoxylin are identified.  These nuclei are then separated 
by a thresholding and segmentation algorithm.  Using the Slidepath software, 
specific cell populations within a heterogeneous sample can be selected for 
analysis according to an operator adjusted cell nuclear area.  Staining intensity 
thresholds (positive/negative) can also be specified by the observer.  Thresholds 
for staining intensity and nuclear area were chosen based on a sample of 
prostate tissue and once set they were used for analysis over all patient cohorts 
without adjustment.  This method has been validated within our laboratory 
previously.(162)  In order to ensure consistency 10% of each patient cohort was 
also scored visually on a computer monitor.  The percentage of Ki-67 and TUNEL 
positive prostatic cells was evaluated at x400 magnification by scoring a minimum of 
1000 prostatic cells of each core of the tissue microarray/tissue section.  The 
number of positive cells was then divided by 1000 and multiplied by 100 in order to 
gain a percentage score.  ICCC scores were undertaken in order to establish 
concurrence of scoring. 
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2.10 Statistics 
Statistical analysis was performed using IBM SPSS Statistics version 19.0 for 
Windows.  Inter-class correlation coefficients (ICCCs) confirmed histo-scoring 
consistency between observers.  Pearson’s rank correlation coefficients (c.c.) 
assessed associations between protein expression.  Chi-squared test assessed 
relationships between protein expression and clinico-pathologic characteristics.  
Kaplan-Meier methods, using the log-rank test compared clinical outcome 
measures between patients according to clinico-pathologic parameters and 
high/low protein expression.  Significant univariate results were included in a 
cox-regression model to determine independence from current clinical 
parameters.  A <0.05 significance level was utilised.  The Bonferroni correction 
was applied when >10 variables were being studied.  It is acknowledged that if a 
lower global significance level was used then some of the results would become 
insignificant.
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3 Antibody Validation Results 
One of the major challenges in the investigation of protein phosphorylation is 
the acquisition of antibodies of high specificity and sensitivity.  Cross reactivity 
of phospho specific antibodies is a recognised problem.  This is complicated by 
the transient nature of phosphorylation and the potential of degradation during 
the tissue fixation process and over time, leading to issues with archival stored 
specimens.  For this reason it was essential to further validate the specificity of 
the antibodies utilised in this study in addition to the manufacturer’s own 
specificity checks. 
3.1 Peptide competition assays 
Peptide competition assays were performed for each AR serine phosphorylation 
site studied Figures 3.1-3.6. 
Figure 3.1 pAR
S81
 peptide competition assay 
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Each phospho-AR antibody is pre-incubated with pARS81 peptide at a 1:1 
ratio and subsequent immunohistochemical staining is displayed on the 
bottom row.  The top row represents the positive control for each phospho-
AR antibody.  Immunohistochemical staining is absent when pARS81 
antibody is combined with its corresponding peptide (highlighted in red), 
however staining is maintained across the other phosphorylation sites.  
Therefore pARS81 antibody is specific. 
 
Figure 3.2 pAR
S94
 peptide competition assay 
 
Each phospho-AR antibody is pre-incubated with pARS94 peptide at a 1:2 
ratio and subsequent immunohistochemical staining is displayed on the 
bottom row.  The top row represents the positive control for each phospho-
AR antibody.  Immunohistochemical staining is absent when pARS94 
antibody is combined with its corresponding peptide (highlighted in red), 
however staining is maintained across the other phosphorylation sites.  
Therefore pARS94 antibody is specific. 
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Figure 3.3 pAR
S213
 peptide competition assay 
 
Each phospho-AR antibody is pre-incubated with pARS213 peptide at a 1:1 
ratio and subsequent immunohistochemical staining is displayed on the 
bottom row.  The top row represents the positive control for each phospho-
AR antibody.  Immunohistochemical staining is absent when pARS213 
antibody is combined with its corresponding peptide (highlighted in red), 
however staining is maintained across the other phosphorylation sites.  
Therefore pARS213 antibody is specific. 
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Figure 3.4 pAR
S515
 peptide competition assay 
 
Each phospho-AR antibody is pre-incubated with pARS515 peptide at a 1:500 
ratio and subsequent immunohistochemical staining is displayed on the 
bottom row.  The top row represents the positive control for each phospho-
AR antibody.  Immunohistochemical staining is absent when pARS515 
antibody is combined with its corresponding peptide (highlighted in red), 
however staining is maintained across the other phosphorylation sites.  
Therefore pARS515 antibody is specific. 
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Figure 3.5 pAR
S578
 peptide competition assay 
 
Each phospho-AR antibody is pre-incubated with pARS578 peptide at a 1:200 
ratio and subsequent immunohistochemical staining is displayed on the 
bottom row.  The top row represents the positive control for each phospho-
AR antibody.  Immunohistochemical staining is absent when pARS578 
antibody is combined with its corresponding peptide (highlighted in red), 
however staining is maintained across the other phosphorylation sites.  
Therefore pARS578 antibody is specific. 
 
Chapter 3 Antibody validation results  103 
 
Figure 3.6 pAR
S650
 peptide competition assay 
 
Each phospho-AR antibody is pre-incubated with pARS650 peptide at a 1:100 
ratio and subsequent immunohistochemical staining is displayed on the 
bottom row.  The top row represents the positive control for each phospho-
AR antibody.  Immunohistochemical staining is absent when pARS650 
antibody is combined with its corresponding peptide (highlighted in red), 
however staining is maintained across the other phosphorylation sites.  
Therefore pARS650 antibody is specific. 
 
3.2 Western blotting 
Western blots were performed to support antibody specificity experiments and 
were successful for each AR serine phosphorylation site studied with the 
exception of Ser-578, unfortunately this antibody was not suitable for use in 
western blots.  In all experiments the dominant band observed was for full 
length AR at 112 kDa (Figure 3.7), known splice variants for the AR were also 
observed at 45 kDa and between 70-90 kDa for antibodies to AR Ser-213, 515 and 
650, these are sizes associated with truncation of the ligand binding domain.  No 
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bands at 90 kDa were observed for AR Ser-81 or 94, this is believed to be due to 
truncation in the NTD region, this splice variant is known as AR-A and is 
truncated from amino acid 1 to 188 (Figure 3.8). 
The western blots achieved are shown in relation to treatment with DHT (10nM) 
(Figure 3.7) 
Figure 3.7 Western blot AR and AR phosphorylated at serine sites following DHT treatment 
 
Western blot was performed on 50ug of extracts from LNCaP cells treated 
with 10nM DHT for various lengths of time as indicated. 
 
Figure 3.8 Splice variant of the androgen receptor (AR-A) 
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Illustration of splice variant AR-A of the androgen receptor.  The N-terminal 
is truncated from amino acid 1-188.  Abbreviations: NTD = N-terminal 
domain; DBD = DNA binding domain, LBD = ligand binding domain. 
3.3 Discussion 
Phosphorylation is a key post translational modification which effects a 
conformational change altering the activity, binding properties and subcellular 
localisation of proteins.  Phosphorylation is both rapid and reversible occurring 
on serine, tyrosine and threonine residues.  Generally only a small fraction of 
the available target protein undergoes phosphorylation and following signal 
activation this process is then quickly arrested via phosphatases or degradation 
resulting in de-phosphorylation.  This transient nature of phosphorylation 
presents the biggest challenge for its investigation, which is the production of 
antibodies of high enough specificity and sensitivity in order to capture an 
intracellular event of low frequency and abundance.(163) 
Phosphospecific antibodies are the most commonly used method for 
investigating protein phosphorylation status.  Phosphosite specific antibodies not 
only recognise the phosphorylation site (serine/ tyrosine/ threonine) but also the 
amino acid sequence surrounding the phosphorylation site and therefore a 
particular target site within a particular protein can be identified.  However, 
target sites can be conserved or similar between several proteins which is a 
potential confounder.  To strike a balance between the identification of the 
phosphosite within a particular protein and restriction of antibodies to the non-
phosphorylated portions of said protein, during antibody synthesis the 
phosphorylated amino acid is placed in the centre of a 10-14 amino acid long 
peptide. 
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Verification of antibody specificity is imperative to ensure that none of the other 
phosphorylation sites within the same protein are recognised by the same 
antibody.  This is of particular importance on a protein such as AR with multiple 
phosphorylation sites.  It is generally recommended that a variety of methods 
are used for verification and these may include ELISA, western blotting, siRNA 
and knockout mice, phosphatase and competition assays, kinases and 
phosphatase inhibitors, cell transfectants and site specific mutagenesis, 
immunohistochemistry and flow cytometry.(164) 
The accepted initial step for antibody validation is via western blot in order to 
demonstrate that it detects a single band (or multiple bands if family members 
share the same motifs) of appropriate molecular weight.  However, validation of 
the specificity of an antibody is partly dependent on the type of immunogen e.g. 
synthetic peptide or purified protein.  In the case of synthetic peptides the 
amino acid sequence to which the antibody binds is known, however, the 3-D 
structure of the native protein is often not taken into account.(165)  Therefore 
antibodies generated against a synthetic peptide may produce suboptimal results 
when a protein is in its native form and may not be useful in techniques such as 
immunohistochemistry where this is the case.  However such antibodies may 
work well in western blot following protein denaturisation.  Similarly antibodies 
raised against the purified protein may work well in immunohistochemistry when 
the protein is in its native form, however may not work well on denaturised 
proteins in western blot.  This has been shown in the current study with some of 
the phosphospecific antibodies displaying higher quality results in western blot 
than others.  In addition pARS578 antibody did not produce any results in western 
blot.  Therefore western blot cannot be considered the standard for verification 
of antibody specificity and other methods such as immunohistochemistry must 
be employed.  This is of particular relevance if, as in the current study, the aim 
Chapter 3 Antibody validation results  107 
 
is to use the antibody for another application.  The antibody must be 
demonstrated to specifically recognise its target in the application concerned, in 
this case immunohistochemistry.  Although pARS578 antibody demonstrated good 
results in the peptide competition assay experiment, the results should be 
interpreted with caution and further validation work is required. 
In addition to western blot, peptide competition experiments were utilised to 
evaluate antibody specificity in immunohistochemistry.(166)  As demonstrated 
above the peptide sequences used to generate the antibodies are pre-incubated 
with the antibody.  Immunohistochemistry is then performed on the tissue of 
interest with the antibody alone and the antibody pre-incubated with the 
peptide.  Specificity is determined if the addition of the peptide results in loss 
of staining on the tissue, as seen for each phosphospecific antibody in the 
current study.  Peptide competition experiments demonstrate antibody 
specificity for the peptide from which it was generated.  However, as in the case 
of G protein –coupled receptor antibodies (167), it does not demonstrate 
selectivity, as pre-incubation with the peptide will also inhibit off-target binding 
activity of the antibody.  Future work would include the immunohistochemical 
staining of cell pellets corresponding to the cell lines and treatments utilised for 
western blot.  In addition target expression can be quantified both in western 
blot and in immunohistochemistry via the use of software programs such as 
Image J, AQUA and Slidepath.(168-170)  The expression levels of the target 
proteins between the two methods should correlate to demonstrate antibody 
specificity.  Unfortunately there was insufficient laboratory time to undertake 
this analysis within the scope of the present project and the work will be carried 
out by future lab members. 
Reproducibility of antibodies over time using different lots on different days is 
another criterion for validation.  Over the course of the current study the 
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reproducibility of the antibodies concerned was consistently demonstrated.  
Each new lot was considered as a new antibody and validation was undertaken 
using the methods described above before proceeding with the 
immunohistochemical staining of experimental tissue. 
Further issues regarding the use of phosphospecific antibodies in human tissue 
are largely related to tissue collection and fixation.  The method of tissue 
collection and the speed of fixation is therefore critical to the attainment of 
accurate results upon further analysis.  Some of the tissue utilised in this study 
was obtained by diathermy resection and it is acknowledged that this may affect 
tissue phosphorylation status.  Heat treatment of tissues is known to induce a 
number of biological processes including gene activation, cell cycle arrest and 
apoptosis.  Following heat treatment in prostate cancer cells via high-intensity 
focused ultrasound the expression level of phosphorylated human checkpoint 
kinase2 was increased.(171)  Diathermy resection of tissues, as performed during 
TUR of prostate surgery, may also alter tissue phosphorylation status.  Tissue 
ischaemia times can vary hugely in clinical practise from a few minutes to 
several hours.  Tissue ischaemia time can affect the phosphorylation status of a 
surgical specimen.  The opening of tissues can alone result in rapid phosphatase 
activation and resultant de-phosphorylation.  Recent studies have demonstrated 
a significant influence of tissue ischaemia time on immunohistochemical staining 
of breast, colorectal and lung tumour tissue specimens with phosphospecific 
antibodies.(172,173)  The prostatic tissue utilised in the current study is 
generally fixed in the operating theatre within minutes following extraction.  
However this process is not standardised and the potential confounding effect of 
tissue ischaemia cannot be ignored. 
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The type of fixative used has been related to the quality of 
immunohistochemical staining.  A recent study found that standard formalin 
fixation was best for immunohistochemical detectability for a range of proteins 
including phosphorylated HER2 when compared to five other fixation 
methods.(174)  In particular, when using alcohol fixation HER2 protein was 
detected however the phosphorylated form of the receptor was not.(174)  This 
reinforces the importance on the type of fixative used especially in the 
investigation of phosphorylated proteins in human tissue.  All the samples in the 
current study were fixed in standard formalin. 
Fixative penetration has been acknowledged as a potential issue regarding the 
interpretation of protein phosphorylation status in human tissue specimens.  All 
prostatic tissue specimens utilised in the current study were fixed in formalin 
and embedded in paraffin.  Fixative penetrates tissue at an approximate rate of 
1mm/hour in formalin.  Therefore the innermost areas of larger pathological 
specimens may suffer from progressive ischaemia until the fixative has fully 
penetrated and crosslinked the cellular structures within the specimen.  
However in small tissue specimens of 1mm diameter phosphorylated protein 
expression has been shown to be conserved between formalin fixed paraffin 
embedded and fresh frozen samples from the same patient.(172)  Prostatic 
biopsies and TUR chips are both small and submerged in fixative minutes 
following extraction from the patient so the effect of tissue ischaemia is 
minimised.  However, this process is not standardised and this limitation is 
acknowledged. 
The inherent limitations surrounding the investigation of phosphorylated proteins 
in human tissue specimens have been described.  However, the study of 
phosphorylated target proteins may well be more precise in evaluating 
deregulated intracellular signalling in disease states, as presence of 
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phosphorylation suggests an actively signalling pathway.  With regards to the 
current study, the further investigation of AR serine phosphorylation status is 
deemed necessary in order to provide the preliminary assessment of its clinical 
relevance, and potential as a therapeutic target, in prostatic disease.  This study 
is certainly not conclusive but will provide a foundation for future work. 
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4 Pilot Prostate Cancer Cohort Results 
4.1 Cohort demographics 
Analysis was based on 90 hormone-naïve prostate cancer patients.  Patient 
characteristics are shown in Table 4.1.  Patients were treated by surgery (18), 
radiotherapy (21) and hormones (37).  Treatment information was missing for 14 
patients.  Twenty three patients had metastases; local lymph nodes (3), bone 
(13) and at both sites (7). 
Forty seven patients had biochemical relapse (median time to biochemical 
relapse 2.7y, (interquartile range (IQR) 1.5–3.8).  Twenty four patients were 
alive at time of analysis, median follow-up 11.7y (IQR 9.9–14.0).  Forty six died 
of their disease (median time to death 4y, IQR 1.9–7.2) and 20 deaths were 
attributed to intercurrent disease (median time to death of 4.1y, IQR 0.9–5.5). 
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Table 4.1 Pilot prostate cancer cohort demographics 
 
 
 
Clinical Parameter 
Percentage of 
patients (%) 
Number of 
patients 
Age 
<70yr 37.8 34 
≥70 yr 62.2 56 
Gleason 
<7 31.2 28 
=7 32.5 29 
>7 36.4 33 
PSA at 
diagnosis 
<10ng/ml 27.5 25 
10-20ng/ml 20.3 18 
>20ng/ml 52.2 47 
Lymphovascular 
Invasion 
absence 93.3 84 
presence 6.7 6 
Recurrence PSA 
<10ng/ml 
77.6 70 
10-20ng/ml 
2.0 2 
>20ng/ml 
20.4 18 
 
4.2 Clinicopathological factors related to outcome 
measures 
Table 4.2 shows associations with clinical parameters (grouped data) and 
outcome measures using Kaplan-Meier methods. 
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Table 4.2 Pilot prostate cancer cohort clinicopathological factors related to outcome 
 
 
Time to 
biochemical 
relapse 
Disease 
Specific 
Survival 
Age 
(<70 vs ≥70 yrs) 
0.260 0.020 
Gleason 
(<7 vs =7 vs >7) 
0.013 
0.007 
Diagnosis PSA 
(<10 vs 10-20 vs >20ng/ml) 
0.002 
0.001 
Recurrence PSA 
(<10 vs 10-20 vs >20ng/ml) 
 
<0.001 
Lymphovascular Invasion 
(presence vs absence) 
0.001 
0.114 
Presence of metastases 
(presence vs absence) 
0.001 <0.001 
Proliferation Index (Ki67) 
(low vs high) 
0.730 
0.033 
 
Well known features of aggressive disease were associated with shorter time to 
biochemical relapse; higher Gleason score, higher PSA level at diagnosis, 
presence of lymphovascular invasion and presence of metastases.  Interestingly 
older patients had shorter disease specific survival than younger patients.  
Clinicopathological factors associated with aggressive disease were associated 
with shorter disease specific survival as expected; higher Gleason score, 
diagnostic PSA ≥20ng/ml, relapse PSA ≥10ng/ml, presence of metastases and 
higher proliferation index. 
4.3 Androgen receptor expression 
Expression of all proteins was observed at varying levels in the cytoplasm and 
nucleus of both stromal and epithelial cells (Figure 4.1).  Protein expression was 
found to be heterogeneous throughout and less intense in the stromal cells.  
There was presence of PIN and benign tissue, adjacent to the neoplastic tissue, 
Chapter 4 Pilot prostate cancer cohort results  114 
 
in some of the TMA cores.  Expression of proteins in the interspersed PIN and 
benign tissue and the normal prostate control core was heterogeneous and less 
intense than the neoplastic tissue.  Only protein expression observed in the 
tumour cells was scored.  ICCCs were performed to verify consistency between 
scorers and all values were >0.80.  Scatter plots for each antibody were used to 
display this data and to confirm there was no bias between scorers Bland Altman 
plots were constructed.  Protein expression levels were subdivided into low 
(≤median) and high expression (>median) for analysis.  Median AR and pAR 
histoscore expression levels are shown in Table 4.3.  Median cell counts for Ki67 
protein was 1.0% IQR 0.0-3.0%. 
Figure 4.1 Example high/low AR and pAR immunohistochemical staining 
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Table 4.3 Protein expression levels for AR and pAR sites 
Protein 
Subcellular 
Location 
Median Histoscore 
(Histoscore units) 
Interquartile Range 
(Histoscore units) 
AR 
Cytoplasm 62.5 50.0-80.5 
Nucleus 67.7 43.8-82.9 
pARS81 
Cytoplasm 50.0 20.0-100.0 
Nucleus 140.0 73.8-206.3 
pARS94 
Cytoplasm 30.0 10.0-51.3 
Nucleus 60.0 33.8-105.0 
pARS213 
Cytoplasm 5.0 2.5-11.7 
Nucleus 70.0 50.0-113.3 
pARS515 
Cytoplasm 5.0 1.3-10.0 
Nucleus 130.0 82.5-165.0 
pARS578 
Cytoplasm 50.0 31.3-100.0 
Nucleus 169.2 130.0-206.3 
pARS650 
Cytoplasm 52.5 20.0-100.0 
Nucleus 120.0 68.3-187.5 
 
 
4.4 Phosphorylated androgen receptor related to 
clinicopathological factors 
AR and phosphorylated AR is related to clinicopathological factors as shown in 
Table 4.4.  High expression of pARS81 (cytoplasmic), pARS515 (nuclear and total) 
and pARS650 (cytoplasmic, nuclear and total) were associated with increased age.  
High expression of cytoplasmic pARS213 and pARS578 was associated with increased 
Gleason score.  High expression of nuclear pARS578 was associated with increased 
PSA level at diagnosis.  Presence of LVI was associated with high AR (nuclear, 
cytoplasmic and total), pARS213 (nuclear) and pARS515 (cytoplasmic) expression.  
Presence of metastases was associated with high AR (total) and high pARS515 
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(cytoplasmic) expression.  High expression of pARS81 (nuclear and total) and low 
expression of pARS94 (cytoplasmic) were associated with high Ki67 score. 
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Table 4.4 Clinicopathological factors as related to high/low AR and pAR expression
 
Proteins 
Clinical Variables 
Age 
(<70 
vs 
≥70yrs) 
Gleason 
(<7 vs 
=7 vs 
>7) 
Diagnosis PSA 
(<10 vs 
10-20 vs 
>20ng/ml) 
Recurrence PSA 
(<10 vs 
10-20 vs 
>20ng/ml) 
Lymphovascular 
Invasion 
(presence 
vs 
absence) 
Presence of 
metastases 
(presence 
vs 
absence) 
Ki67 
(≤median 
vs 
>median) 
AR 
Cytoplasm 0.909 0.841 0.979 0.496 0.028 0.061 0.230 
Nucleus 0.284 0.450 0.301 0.380 0.006 0.107 0.154 
Total 0.422 0.464 0.493 0.800 0.002 0.027 0.627 
pARS81 
Cytoplasm 0.035 0.811 0.269 0.566 0.175 0.660 0.498 
Nucleus 0.651 0.401 0.462 0.601 0.666 0.229 0.039 
Total 0.220 0.425 0.389 0.632 0.290 0.195 0.041 
pARS94 
Cytoplasm 0.447 0.714 0.437 0.820 0.234 0.165 0.040 
Nucleus 0.651 0.069 0.726 0.386 0.234 0.892 0.361 
Total 0.754 0.417 0.964 0.496 0.864 0.554 0.191 
pARS213 
Cytoplasm 0.189 0.011 0.306 0.860 0.100 0.277 0.145 
Nucleus 0.546 0.062 0.282 0.167 0.019 0.407 0.919 
Total 0.543 0.087 0.160 0.167 0.115 0.277 0.676 
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Table 4.4 continued Clinicopathological factors as related to high/low AR and pAR expression 
Proteins 
Clinical Variables 
Age 
(<70 
vs 
≥70yrs) 
Gleason 
(<7 vs 
=7 vs 
>7) 
Diagnosis PSA 
(<10 vs 
10-20 vs 
>20ng/ml) 
Recurrence PSA 
(<10 vs 
10-20 vs 
>20ng/ml) 
Lymphovascular 
Invasion 
(presence 
vs 
absence) 
Presence of 
metastases 
(presence 
vs 
absence) 
Ki67 
(≤median 
vs 
>median) 
pARS515 
Cytoplasm 0.221 0.109 0.181 0.273 0.018 0.040 0.233 
Nucleus 0.042 0.336 0.052 0.116 0.673 0.948 0.156 
Total 0.048 0.120 0.287 0.120 0.463 0.528 0.229 
pARS578 
Cytoplasm 0.094 0.008 0.096 0.071 0.305 0.682 0.312 
Nucleus 0.296 0.324 0.015 0.394 1.000 0.236 0.920 
Total 0.117 0.341 0.061 0.296 1.000 0.923 0.762 
pARS650 
Cytoplasm 0.046 0.446 0.976 0.761 0.773 0.750 0.260 
Nucleus 0.018 0.531 0.169 0.935 0.279 0.216 0.756 
Total 0.020 0.465 0.216 0.827 0.516 0.447 0.504 
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4.5 Phosphorylated androgen receptor related to 
outcomes 
Univariate analysis of AR and pAR protein expression was carried out using 
Kaplan Meier methods with reference to the clinical outcome measures.  The 
results are shown in Table 4.5. 
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Table 4.5 Univariate analysis of phosphorylated AR expression and clinical outcome 
measures 
Protein 
Time to 
biochemical 
relapse 
Disease specific 
survival 
AR 
Cytoplasm 0.466 0.517 
Nucleus 0.001 0.233 
Total <0.001 0.580 
pARS81 
Cytoplasm 0.166 0.057 
Nucleus 0.594 0.031 
Total 0.925 0.039 
pARS94 
Cytoplasm 0.927 0.864 
Nucleus 0.375 0.991 
Total 0.178 0.884 
pARS213 
Cytoplasm 0.987 0.308 
Nucleus 0.548 0.069 
Total 0.596 0.026 
pARS515 
Cytoplasm 0.020 <0.001 
Nucleus 0.877 0.072 
Total 0.708 0.034 
pARS578 
Cytoplasm 0.034 <0.001 
Nucleus 0.461 0.036 
Total 0.496 0.004 
pARS650 
Cytoplasm 0.977 0.113 
Nucleus 0.909 0.177 
Total 0.530 0.059 
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4.5.1  Biochemical Relapse 
As shown in Table 4.5 several proteins were associated with time to biochemical 
relapse. Specifically high nuclear AR was associated with shorter time to 
biochemical relapse (proportion of patients relapsed at 5y 79.2% vs 46.9%) HR 
2.8 (95% CI 1.5–5.3).  High total AR was associated with shorter time to 
biochemical relapse (proportion of patients relapsed at 5yr 85.1% vs 40.2%) HR 
3.03 (95%CI 1.6-5.6).  High cytoplasmic pARS515 was also associated with shorter 
time to biochemical relapse (proportion of patients relapsed at 5y 78.6% vs 56%) 
HR 2.2 (95% CI 1.1–4.2).  High cytoplasmic pARS578 was also associated with time 
to biochemical relapse (proportion of patients relapsed at 5y 82.6% vs 51.9%) HR 
2.1 (95% CI 1.0-4.2). 
4.5.2 Disease specific survival 
Several proteins were found to have a significant relationship with disease 
specific survival. High nuclear pARS81 was associated with reduced disease-
specific survival (10y survival 24.4% vs 54.5%), HR 2.1 (95% CI 1.1–4.2).  High 
total pARS81 was associated with reduced disease-specific survival (10yr survival 
25.6% vs 56.5%) HR 2.0 (95%CI 1.0-4.1).  High total pARS213 was associated with 
shorter disease specific survival (10y survival 33.7% vs 64.3%) HR 2.7 (95% CI 1.1-
4.7).  High cytoplasmic pARS515 was associated with disease-specific survival (10y 
survival 14.4% vs 65.2%) HR 4.4 (95% CI 2.1–9.1).  High total pARS515 was 
associated with reduced disease-specific survival (10yr survival 35.8% vs 57.5%) 
HR 2.1 (95%CI 1.0-4.2).  High cytoplasmic and total pARS578 was also associated 
with disease specific survival (10y survival 17.7% vs 71.1%) HR 4.5 (95% CI 2.0-
10.4) and (10y survival 26.1% vs 66.9%) HR 3.0 (95% CI 1.4-6.7) respectively.  
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High nuclear pARS578 was associated with disease specific survival (10y survival 
30.2% vs 63.9%) HR 2.2 (95% CI 1.0-4.9). 
4.6 Kinase protein expression 
Scansite 2.0 predicted Cdk1 as a strong candidate mediating phosphorylation of 
Ser-81 and Ser-515.  ERK1/2 was a strong candidate mediating Ser-515 
phosphorylation.  Similarly PKC was a strong candidate mediating Ser-578 
phosphorylation. 
Expression of all proteins was observed at varying levels in the cytoplasm and 
nucleus of both stromal and epithelial cells (Figure 4.2).  Protein expression was 
found to be heterogeneous throughout and less intense in the stromal cells.  
There was presence of PIN and benign tissue, adjacent to the neoplastic tissue, 
in some of the TMA cores.  Expression of proteins in the interspersed PIN and 
benign tissue and the normal prostate control core was heterogeneous and less 
intense than the neoplastic tissue.  Only protein expression observed in the 
tumour cells was scored.  ICCCs were performed to verify consistency between 
scorers and all values were >0.80.  Scatter plots for each antibody were used to 
display this data and to confirm there was no bias between scorers Bland-Altman 
plots were constructed.  Protein expression levels were subdivided into low 
(≤median) and high expression (>median) for analysis.  Median kinase histoscore 
expression levels are shown in Table 4.6. 
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Figure 4.2 Example high/low immunohistochemical staining of candidate kinases 
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Table 4.6 Protein expression levels for kinases
Protein 
Subcellular 
Location 
Median Histoscore 
(Histoscore units) 
Interquartile Range 
(Histoscore units) 
Cdk1 
Cytoplasm 40.0 20.0-76.3 
Nucleus 46.3 17.5-80.0 
pCdk1161 
Cytoplasm 30.0 17.5-43.8 
Nucleus 82.5 42.5-128.8 
pERK1/2 
Cytoplasm 150.0 129.2-183.8 
Nucleus 10.0 0.0-57.1 
PKC 
Cytoplasm 138.3 100.0-162.5 
Nucleus 205.0 174.4-222.5 
 
 
4.7 Kinases related to clinicopathological factors 
Candidate kinase expression as related to clinicopathological factors is shown in 
Table 4.7. High total pCdk1161 and high nuclear, cytoplasmic and total PKC 
protein expression were associated with increased age.  High nuclear and total 
pCdk1161 and nuclear PKC expression were associated with increased PSA level at 
diagnosis.  High nuclear pCdk1161 expression was also associated with increased 
PSA level at biochemical relapse.
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Table 4.7 Clinicopathological factors as related to high/low candidate kinase expression 
Proteins 
Clinical Variables 
Age 
(<70 
vs 
≥70yrs) 
Gleason 
(<7 vs 
=7 vs 
>7) 
Diagnosis 
PSA 
(<10 vs 
10-20 vs 
>20ng/ml) 
Recurrence PSA 
(<10 vs 
10-20 vs 
>20ng/ml) 
LVI 
(presence 
vs 
absence) 
Presence of 
metastases 
(presence 
vs 
absence) 
Ki67 
(≤median 
vs 
>median) 
Cdk1 
Cytoplasm 0.902 0.687 0.774 0.268 0.327 0.760 0.534 
Nucleus 0.815 0.431 0.133 0.227 0.398 1.000 0.957 
Total 0.187 0.831 0.277 0.130 0.583 0.432 0.879 
pCdk1161 
Cytoplasm 0.928 0.271 0.148 0.120 0.262 0.281 1.000 
Nucleus 0.069 0.985 0.028 0.011 0.643 0.648 0.743 
Total 0.044 0.263 0.108 0.017 0.621 0.204 0.918 
pERK1/2 
Cytoplasm 0.481 0.630 0.903 0.304 0.463 0.365 0.175 
Nucleus 0.920 0.591 0.903 0.069 0.417 0.691 0.131 
Total 0.315 0.555 0.936 0.569 0.160 0.428 0.280 
PKC 
Cytoplasm 0.018 0.630 0.478 0.910 0.643 0.141 0.539 
Nucleus 0.032 0.431 0.009 0.683 0.701 0.625 0.539 
Total 0.003 0.621 0.135 0.683 0.217 0.414 0.296 
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4.8 Kinases related to outcomes 
Univariate analysis of kinase protein expression was carried out using Kaplan 
Meier methods with reference to the clinical outcome measures.  The results are 
shown in Table 4.8. 
Table 4.8 Univariate analysis of candidate kinase expression and clinical outcome measures
 
Protein 
Time to 
biochemical 
relapse 
Disease 
specific 
survival 
Cdk1 
Cytoplasm 0.988 0.007 
Nucleus 0.791 0.434 
Total 0.827 0.134 
pCdk1161 
Cytoplasm 0.396 0.013 
Nucleus 0.889 0.001 
Total 0.166 0.007 
pERK1/2 
Cytoplasm 0.353 0.668 
Nucleus 0.384 0.509 
Total 0.525 0.973 
PKC 
Cytoplasm 0.938 0.267 
Nucleus 0.712 0.203 
Total 0.691 0.055 
 
4.8.1 Biochemical relapse 
As shown in Table 4.8 high none of the candidate kinases were associated with 
time to biochemical relapse. 
4.8.2 Disease specific survival 
As shown in Table 4.8 several proteins were associated with disease specific 
survival. Specifically high cytoplasmic Cdk1 was associated with reduced disease 
specific survival (10y survival 26.8% vs 57.2%) HR 2.4 (95% CI 1.2–4.5). High 
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cytoplasmic, nuclear and total pCdk1161 were also associated with reduced 
disease specific survival; 10y survival 29.8% vs 58.3%, HR 2.5 (95% CI 1.2-5.4), 
10y survival 27.8% vs 67.9%, HR 3.7 (95% CI 1.6-8.5) and 10yr survival 30.6% vs 
64.4%, HR 2.9 (95%CI 1.3-6.4) respectively. 
4.9 Association of candidate kinases to phosphorylated 
AR sites 
Once the clinical significance of the candidate kinases had been analysed, their 
association with AR phosphorylation was then investigated in order to establish 
whether the predicted kinase was observed to correlate with AR phosphorylation 
in the clinical samples (Table 4.9). 
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Table 4.9 Associations between candidate kinases and clinically relevant androgen receptor phosphorylation sites in pilot prostate cancer cohort 
 
 Candidate Kinases 
AR 
phosphorylation 
sites 
 
Cdk1 pCdk1161 pERK1/2 PKC 
Cytoplasmic Nuclear Total Cytoplasmic Nuclear Total Cytoplasmic Nuclear Total Cytoplasmic Nuclear Total 
Ser-81 
Cytoplasmic 
C.C. 0.545 0.208 0.509 0.446 0.211 0.346 -0.068 -0.158 0.218 0.321 0.361 0.443 
p value <0.001 0.099 <0.001 0.001 0.134 0.012 0.61 0.231 0.113 0.020 0.008 0.001 
Nuclear 
C.C. 0.057 0.569 0.439 0.185 0.278 0.305 0.019 0.003 0.014 0.101 0.533 0.406 
p value 0.657 <0.001 <0.001 0.190 0.046 0.028 0.886 0.979 0.918 0.476 <0.001 0.003 
Total 
C.C. 0.300 0.500 0.552 0.345 0.297 0.382 -0.019 -0.072 0.218 0.224 0.559 0.504 
p value 0.016 <0.001 <0.001 0.012 0.032 0.005 0.888 0.586 0.113 0.110 <0.001 <0.001 
Ser-515 
Cytoplasmic 
C.C. 0.273 -0.025 0.167 0.455 0.008 0.172 0.051 0.061 0.074 0.293 -0.033 0.189 
p value 0.025 0.843 0.178 <0.001 0.954 0.210 0.706 0.649 0.583 0.031 0.814 0.172 
Nuclear 
C.C. 0.181 0.532 0.507 0.105 0.558 0.531 -0.098 0.038 
-
0.029 
-0.037 0.543 0.337 
p value 0.143 <0.001 <0.001 0.444 <0.001 <0.001 0.464 0.780 0.831 0.793 <0.001 0.013 
Total 
C.C. 0.275 0.457 0.167 0.297 0.500 0.549 -0.061 0.060 0.009 0.106 0.472 0.392 
p value 0.024 <0.001 <0.001 0.028 <0.001 <0.001 0.648 0.656 0.949 0.447 <0.001 0.003 
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Table 4.9 continued Associations between candidate kinases and clinically relevant androgen receptor phosphorylation sites in pilot prostate cancer 
cohort 
 Candidate Kinases 
AR 
phosphorylation 
sites 
 
Cdk1 pCdk1161 pERK1/2 PKC 
Cytoplasmic Nuclear Total Cytoplasmic Nuclear Total Cytoplasmic Nuclear Total Cytoplasmic Nuclear Total 
Ser-578 
Cytoplasmic 
C.C. 0.262 0.375 0.445 0.163 0.430 0.434 0.070 -0.081 -0.02 0.019 0.426 0.284 
p value 0.043 0.003 <0.001 0.257 0.002 0.002 0.614 0.559 0.887 0.894 0.002 0.044 
Nuclear 
C.C. 0.137 0.540 0.485 0.364 0.604 0.663 0.030 -0.035 
-
0.009 
0.284 0.469 0.498 
p value 0.298 <0.001 <0.001 0.009 <0.001 <0.001 0.831 0.804 0.951 0.044 0.001 <0.001 
Total 
C.C. 0.231 0.526 0.538 0.304 0.600 0.635 0.058 -0.067 
-
0.016 
0.172 0.518 0.450 
p value 0.075 <0.001 <0.001 0.032 <0.001 <0.001 0.678 0.629 0.906 0.227 <0.001 0.001 
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As shown in Table 4.9 pERK1/2 expression was not significantly associated with 
any of the clinically relevant AR phosphorylation sites, however Cdk1 and/or 
pCdk1161 were significantly associated with pARS81 and pARS515 as predicted by 
Scansite 2.0.  Similarly, nuclear PKC expression was significantly associated with 
pARS578 expression both in the cytoplasm and the nucleus.  Interestingly nuclear 
pARS81 and pARS515 were both associated with nuclear PKC expression.  Nuclear 
Cdk1 expression was significantly correlated with nuclear pARS578 expression.  
Nuclear pCdk1161 expression was associated with both cytoplasmic and nuclear 
pARS578 expression (Table 4.9).  This suggests that there is cross talk between 
these kinases and AR serine phosphorylation sites. 
In view of the correlation with Scansite 2.0 predictions further investigations 
were undertaken separating the phospho-AR sites by their kinases, i.e: 
 PKC  pARS578 
 Cdk1/pCdk1161  pARS81 and pARS515 
4.10 Multivariate analysis 
Significant univariate results were included in a backwards conditional cox-
regression model to determine independence from current clinical parameters. 
4.10.1 PKC predicted AR phosphorylation sites 
AR and pARS578 expression were combined with significant clinicopathological 
variables in a multivariate analysis for each of the three clinical outcome 
measures.  Neither AR nor nuclear or cytoplasmic pARS578 were deemed 
independent from current clinical parameters with regards to time to 
biochemical relapse or disease specific survival.  Therefore further analysis of 
these parameters was not pursued  
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4.10.2 Cdk1/pCdk1161 predicted AR phosphorylation sites 
AR and pARS515 expression were combined with Gleason score, PSA at diagnosis, 
LVI and presence of metastases in a multivariate cox regression analysis.  
Cytoplasmic pARS515 expression (p=0.038, HR 4.5 (95% CI 1.1–20.6)) and PSA at 
diagnosis (p=0.003, HR 7.3 (95% CI 2.0–27.5)) were independently associated 
with time to biochemical relapse.  As these variables were deemed independent 
it was investigated whether pARS515 expression could inform on patients with PSA 
≤20ng/ml at diagnosis.  These patients, within each individual clinical context, 
are generally considered suitable for immediate or delayed radical treatment 
(via active surveillance).  Many of these patients will have indolent disease that 
may never reach clinical consequence and therefore are at risk of 
overtreatment.  In contrast, a subset have occult aggressive tumours that will 
progress if treatment is delayed.  Therefore biomarkers to aid treatment 
decision-making in this group of patients would have important clinical 
implications.  When patients with PSA at diagnosis ≤20ng/ml, were stratified by 
cytoplasmic pARS515 expression, those tumours with high expression had 
significantly shorter time to biochemical relapse than those patients with low 
expression (p=0.005) (Figure 4.3). This translated into significantly shorter 
disease-specific survival (p<0.001, 10y survival 38.1% vs 100%) (Figure 4.4). 
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Figure 4.3 Kaplan Meier Graph illustrating pAR
S515
 cytoplasmic expression as related to time 
to biochemical relapse 
 
Kaplan Meier survival plot showing time to biochemical relapse in patients 
with PSA ≤20ng/ml at diagnosis (n=28) stratified according to low and high  
cytoplasmic pARS515 expression.  Patients received a variety of treatments 
(surgery, radiotherapy and hormones) and, due to small numbers, it was not 
possible to unpick these groups. 
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Figure 4.4 Kaplan Meier Graph illustrating pAR
S515
 cytoplasmic expression as related to 
disease specific survival 
 
Kaplan-Meier survival plot showing disease-specific survival in patients with 
PSA ≤20ng/ml at diagnosis (n=28) stratified according to low and high 
cytoplasmic pARS515 expression. 
High/low pARS81 nuclear expression was combined with age, Gleason score, PSA 
at diagnosis, PSA at biochemical relapse, presence of metastases and 
proliferation index in a multivariate cox regression analysis.  pARS81 nuclear 
expression (p=0.030, HR 0.033 95% CI 0.002-0.721), proliferation index (p=0.019, 
HR 47.20 95% CI 1.88-1184.95), PSA at diagnosis (p=0.029, HR 105.00 95% CI 
1.63-6778.60) and Gleason score (p=0.049, HR 4.74 95% CI 1.01-22.24) were 
independently associated with disease specific survival.  As these variables were 
deemed independent it was investigated whether pARS81 nuclear expression could 
inform on patients with PSA ≤20ng/ml at diagnosis.  When patients with PSA at 
diagnosis ≤20ng/ml, were stratified by nuclear pARS81 expression, those tumours 
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with high expression had significantly shorter time to cancer specific death than 
those patients with low expression (p=0.014, 10y survival 50% vs 93.3%) (Figure 
4.5). 
Figure 4.5 Disease specific survival by pAR
S81
 expression in patients with PSA ≤20ng/ml 
 
Kaplan-Meier survival plot showing disease specific survival in patients with 
PSA ≤20ng/ml at diagnosis (n=24) stratified according to low and high 
cytoplasmic pARS81 expression. 
These results therefore warranted further investigation in cell line studies. 
4.11 Cell stimulation / inhibition studies 
4.11.1 AR agonists stimulate Cdk1 and AR phosphorylation 
In the clinical specimens pARS81 and pARS515 were demonstrated to correlate with 
pCdk1161 (Table 4.9).  In vitro, it was observed by western blot analysis that the 
androgen DHT could induce phosphorylation of Cdk1161, ARS81 and ARS515, with AR 
and Cdk1 expression levels remaining constant (Figure 4.6).  Analysis of paraffin-
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embedded cell pellets confirmed the observation that treatment with DHT 
stimulates phosphorylation at Cdk1161, ARS81 and ARS515 (Figure 4.7).  As shown in 
Figure 4.7 it was demonstrated that DHT stimulated cellular proliferation, as 
assessed by Ki67.  In addition, treatment with a Cdk inhibitor, roscovitine, 
markedly decreased basal expression of pCdk1161, pARS81, pARS515 and cell 
proliferation (Figure 4.7). 
Figure 4.6 DHT inducing protein phosphorylation on western blot 
 
Western blot was performed on 50ug of extracts from LNCaP cells treated 
with 10nM dihydrotestosterone (DHT) for various lengths of time as shown.  
Cdk1 is known to have an isomer called CDC2deltaT that lacks 171 
nucleotides corresponding to 57 amino acids, which compose most of the T-
loop.(175)  CDC2deltaT has been identified in breast cancer tissue, and 
currently there is no evidence for this in prostate cancer but it may account 
for the duplex band seen in Cdk1 and pCdk1161. 
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Figure 4.7 Treated cell pellets stained for protein expression 
 
LNCaP cells were grown in full media and treated with either 10nM 
dihydrotestosterone (DHT) (3hr) or 20uM Roscovitine (24hr).  Pellets were 
stained by immunohistochemistry for expression of pCdk1161, pARS81, pARS515 
and the nuclear marker of proliferation; Ki67.  Weighted histoscores for 
cytoplasmic and nuclear expression are shown below each image for 
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pCdk1161, pARS81 and pARS515.  Percentage of positive cells counted is shown 
below the images for Ki67. 
4.12 Discussion 
Previous work relating to total AR expression has demonstrated widely 
conflicting results with regards to its use as a prognostic marker.(176-179)  
These conflicting findings may depend on several factors such as tissue 
heterogeneity, timing of specimen dissection and methods to detect AR 
expression including the use of different antibodies.  In addition, the simple 
expression of AR does not reflect its function or its activity, and therefore may 
account for the variations reported with regards to prognostic significance.  AR 
phosphorylation, which is known to provide molecular stability, may therefore 
be a marker of activation.  The current study lends support to this argument as 
it has demonstrated, for the first time in vivo, that those patients who have a 
high level of pARS578 have reduced overall survival when compared to AR 
expression alone.  This result should, however, be interpreted with caution as a 
single band western blot was not achieved for this antibody.  Ser-81 is the most 
frequently phosphorylated site on AR in response to androgen binding.(136)  
However, pARS515 was found to be independent of current clinical parameters 
ahead of pARS81.  This is in line with previous work which demonstrated that 
abolishment of pARS81 in cell lines did not alter androgen-dependent AR 
transcriptional activity, rapidly-induced AR-regulated genes or AR stabilization 
mediated by Cdk1.(136)  In contrast, similar removal of pARS515 resulted in 
reduction of AR transcriptional activity in response to androgens.(130)  The 
current study provides additional evidence to support the hypothesis that site-
specific AR phosphorylation is of clinical importance in prostate cancer. 
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It was interesting to observe that phosphorylated AR expression in the cytoplasm 
was a stronger prognostic factor than nuclear expression.  However, presence of 
cytoplasmic AR is expected as the AR localizes to the cytoplasm in the absence 
of ligand-binding due to a ligand-regulated nuclear export signal.(124,180)  It is 
suggested that immunohistochemical detection of cytoplasmic AR is an adverse 
prognostic feature as it may indicate high levels of nuclear receptor, as was the 
case with glucocorticoid receptors.(160)  This is not the first study to observe 
that cytoplasmic AR expression is a stronger prognostic factor than nuclear 
expression, cytoplasmic AR expression in patients with negative surgical margins 
after radical prostatectomy was associated with worse prognosis.(181)  
Furthermore, the expression of cytoplasmic AR increased with the progression of 
prostate intraepithelial neoplasia to prostate cancer and from hormone-naïve to 
castrate-resistant cancer.(181)  In addition the subcellular location and activity 
of AR is likely to be directly influenced by its phosphorylation status.  Previous 
mutagenesis studies investigated the effect on subcellular localization of AR in 
COS cells.  This work demonstrated that in wild type pARS578 cells AR is 
distributed between the nucleus and cytoplasm indicative of nuclear-cytoplasmic 
shuttling.(130)  However, in cells where the pARS578 site was mutated, AR 
expression was found exclusively in the nucleus.(130)  The current study is in 
agreement with this work and provides further evidence for the involvement of 
phosphorylated AR in nuclear-cytoplasmic shuttling in neoplastic prostate tissue. 
With reference to the clinical outcome measures, total (nuclear + cytoplasmic) 
protein expression was observed to be of significance only when expression in at 
least one subcellular location (nucleus or cytoplasm) was significant.  This 
highlights the importance of analysing protein expression within each subcellular 
compartment and also within each cell type.  For this reason total protein 
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expression was not analysed in the remaining patient cohorts within the 
following chapters. 
Contrary to previous reports, pERK1/2 did not correlate with any of the AR 
phosphorylation sites predicted by Scansite.(182)  In addition, pERK1/2 was not 
associated with any clinical outcome measures.  Work performed in the host 
laboratory has previously reported that ERK1/2 is a negative prognostic marker 
in castrate resistant prostate cancer, therefore activation of the ERK1/2 
pathway may be a late event and not associated with hormone-naïve 
disease.(141)  In support of this hypothesis it was previously reported that 
ERK1/2 expression was low or undetectable in the majority of prostate cancer 
specimens at diagnosis, however increased with stage, Gleason grade and 
progression to castrate resistant disease.(132)  In the pilot prostate cancer 
cohort phosphorylated ERK1/2 was not associated with Gleason grade and it is 
postulated that disease progression may occur via other indirect mechanisms 
such as phosphorylation of the AR coactivator steroid receptor cofactor 1, and 
increasing cellular proliferation through AP-1, c-MYC, and NF-κB (139,183-185). 
The results suggest that Cdk1 and PKC may phosphorylate serine sites on the AR 
and demonstrate that they are of clinical significance in prostate cancer.  In 
broad agreement with predictions by Scansite (154), phosphorylation of all 
putative Ser-Pro target sites on the AR correlated significantly with the 
expression of Cdk1 or PKC, but not ERK1/2, in at least one cellular location.  Not 
only did phosphorylation of the AR at serine sites correlate with the predicted 
kinases, both Cdk1 and pCdk1161 were also strongly associated with clinical 
outcome measures.  The association of Cdk1 expression in radical prostatectomy 
specimens with prostate cancer recurrence has been reported previously.(186)  
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Our study has added to this by observing that high expression of Cdk1, pCdk1161 
and phosphorylation of the putative Cdk1-consensus sites pARS81 and pARS515 were 
associated reduced disease-specific survival.  These results suggest that 
phosphorylation of the AR by Cdk1 may be of functional importance. 
In agreement with previous reports PKC expression correlated strongly with 
pARS578 expression.  Previous site directed mutagenesis work in castrate resistant 
cell lines has demonstrated that PKC induced phosphorylation is reduced in 
pARS578 knock down cells.(130)  The current study adds to this by suggesting that 
the link between PKC and AR phosphorylation is also present in hormone naïve 
prostate cancer tissue and therefore may have important implications in both 
early and late stages of the disease.  Similar site directed mutagenesis studies 
are necessary in early prostate cancer cell lines in order to confirm this finding. 
Through inhibitor studies, it was observed that pARS81 and pARS515 expression is 
mediated, at least in part, by Cdk1.  Previous work has suggested that increased 
Cdk1 activity is a mechanism for increasing AR expression, stability and cellular 
proliferation.(136)  In the current study although an increase in Cdk1 
phosphorylation was observed, AR expression remains stable, however change in 
expression might take place over a longer time frame than investigated in the 
current study.  Another role of Cdk1, out-with cell cycle progression, may be AR 
phosphorylation (in particular at serine 515).  Thus, Cdk1 may provide a 
mechanism for accelerating disease progression in hormone-naïve prostate 
cancer and a novel point for therapeutic intervention.   
The phosphorylated AR antibodies were stringently validated using western blot 
and peptide competition assays.  The possibility of cross-reactivity in the usage 
of phosphospecific antibodies is acknowledged, particularly on a protein such as 
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AR with multiple phosphorylation sites.  Future work would include additional 
antibody validation via site-directed mutagenesis followed by 
immunohistochemistry of cell pellets to establish with absolute certainty that 
the results observed are due to the individual phosphorylation sites. 
An obvious limitation of this study is the small sample size and as such the 
results should be interpreted with caution and future work should include 
validation in a large independent cohort.  However, even with low patient 
numbers, it has been demonstrated that site specific AR phosphorylation by Cdk1 
is of independent prognostic significance.  These results are striking in particular 
when considered that this was a hormone-naïve cohort of patients who 
subsequently received a variety of treatments (surgery, radiotherapy and 
hormones) and that, due to small numbers, it was not possible to unpick these 
groups. 
In combination with current diagnostic tools, site specific AR serine 
phosphorylation may provide a desperately needed prognostic marker to aid 
treatment decision-making in hormone-naïve prostate cancer patients.  This 
finding has the potential to reduce over-treatment of clinically insignificant 
disease and prevent delay in treatment of occult aggressive disease.  To this end 
this study was extended to ascertain the clinical significance of site specific AR 
phosphorylation in prostate cancer patients treated by active surveillance.  
These patients have low risk disease which is suitable for delayed radical 
treatment if clinical, biochemical or pathological progression is demonstrated.  
As previously stated there are potential complications associated with the use of 
phosphorylated antibodies. It has previously been demonstrated that use of 
phosphorylated antibodies is unreliable when comparing the expression levels of 
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phosphorylated proteins in tumour core biopsies and tumour excision tissue.  The 
limitations associated with phosphorylated antibodies are manageable in the 
research environment; however; this is not feasible in the routine diagnostic 
laboratory setting. Therefore it is appropriate to undertake further validation of 
AR phosphorylation as a maker in active surveillance prostate cancer patients as 
discussed in the following chapter.  However if validated, the host laboratory 
plan to undertake a study that will enable the barrier of the use of 
phosphorylated antibodies to be overcome by identifying surrogate markers of 
pAR to ensure that findings from experimental studies remain suitable for 
translation into clinically useful biomarkers and drug targets.  However this is 
out with the scope of the current study and funding will be applied for in order 
for the work to be performed by future team members. 
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5 Active surveillance prostate cancer cohort 
results of clinical audit and clinical relevance of 
clinicopathological variables 
Active surveillance for prostate cancer is a deferred treatment approach 
whereby low risk patients suitable for radical therapy undergo intervention only 
when biochemical, histological or clinical progression is demonstrated.(72)  The 
aim of active surveillance is to identify and cure those patients with progressive 
disease and to avoid the complications of radical treatment, such as urinary 
incontinence, erectile dysfunction and a small risk of death, in those who have 
clinically insignificant prostate cancer.  The recent stage and grade migration of 
prostate cancer secondary to serum PSA testing has led to the over-diagnosis and 
over-treatment of clinically insignificant disease.  Active surveillance provides a 
potential solution to this problem and the National Institute for Clinical 
Excellence (NICE) recommend it as the preferred treatment option for low risk 
patients in whom radical treatment is suitable.(72)  An investigation into the 
adherence to these guidelines was undertaken in the form of a clinical audit. 
5.1 Clinical Audit 
A snapshot clinical audit was undertaken in order to evaluate adherence to 
clinical guidelines regarding the selection and management of active 
surveillance patients.  NICE published clinical guidelines entitled “Prostate 
Cancer: diagnosis and treatment” in February 2008 and these were used for 
reference.  The selection of patients was examined with regards to the NICE 
‘low risk’ criteria illustrated in Figure 5.1.  The subsequent management of 
active surveillance patients was examined with regards to the phase III 
randomised study of ‘active surveillance versus radical treatment in patients 
with favourable-risk prostate cancer’ (proSTART) protocol as recommended by 
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NICE; PSA every 3 months until 2 years from diagnosis and 6 monthly thereafter, 
TRUS guided biopsy years 1, 4, 7 and 10 following diagnosis and then every 5 
years. 
Figure 5.1 Selection Criteria for Active Surveillance 
NICE LOW RISK CRITERIA FOR PROSTATE CANCER (NICE 2008) 
1. Pathological stage T1c 
2. ≥10 biopsy cores taken at diagnosis 
3. Cancer in less than 50% of the total number of biopsy cores 
4. Gleason score 3+3 
5. PSA <10 ng/ml 
6. PSA density <0.15ng/ml/ml 
 
 
5.1.1 Selection of active surveillance patients 
One hundred and twelve patients with non metastatic organ confined prostate 
adenocarcinoma at diagnosis, initially treated by AS, were identified.  Data was 
available for all patients, unless otherwise stated.  Table 5.1 shows the overall 
adherence to the NICE selection criteria.  Overall just 10% of patients fulfilled 
all NICE selection criteria. 
Table 5.1 Adherence to NICE selection criteria for patients treated by active surveillance 
Criteria Adherence (%) 
Pathological Stage T1c 89.3 
Number of biopsy cores taken at TRUS ≥10 27.7 
Percentage of cancer in biopsy cores <50% 64.9 
Gleason 3+3 77.7 
PSA <10ng/ml 71.4 
 
83.9% were pathological stage T1c.  Of the remainder 12.5% were T1a and 3.6% 
were T1b with no follow up diagnostic TRUS performed. Of those who had a 
diagnostic TRUS, 44.6% had <10 biopsy cores taken, 27.7% had ≥10 cores taken 
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and 27.7% had an undefined number of cores taken.  64.9% had cancer in <50% 
biopsy cores, 17% not documented, 18.1% had cancer in ≥50% biopsy cores.  
77.7% of patients were Gleason 3+3, 17.9% were Gleason 3+4, 3.6% were 4+3 and 
0.9% had a Gleason score of 4+4 at diagnosis.  71.4% had serum PSA <10ng/ml at 
diagnosis, 24.1% had PSA between 10-20ng/ml and in 4.5% of patients PSA was 
>20ng/ml.  PSA density was unavailable for all patients. 
5.1.2 Management of active surveillance patients 
5.1.2.1 PSA checks 
Data was missing for 1 patient.  100% of patients had PSA follow up after 
diagnosis.  49.5% had 3 monthly PSA checks in the first 2 years following 
diagnosis.  87.2% of those eligible (n=86) had 6 monthly PSA checks after 2 years. 
5.1.2.2 Rebiopsy schedule 
Overall 63.4% had a rebiopsy at any time following diagnosis.  Two patients were 
offered but declined rebiopsy at 1 and 4 years respectively, these patients were 
excluded from the analysis.  10.8% had a rebiopsy at 1 year +/- 30 days after 
diagnosis.  Median time till first rebiopsy was 18 months (IQR 12.4-26.9).  Of 
those eligible (n=32), 3.1% had a rebiopsy at 4 years +/- 30days.  Median time till 
second rebiopsy was 34.3 months (IQR 20.5-50.5). 
5.2 Clinical investigation of active surveillance patients 
Given the poor adherence to the NICE guidelines regarding the selection and 
management of active surveillance patients further investigation was conducted 
in the active surveillance cohort.  The effect of clinical and pathological 
variables on clinical outcome measures was assessed. 
Chapter 5 Active surveillance clinical results  146 
 
5.2.1 Cohort demographics 
Median age at diagnosis was 67y (range 48-78).  Median follow up was 40.5 
months (IQR 30.3–53.8).  Median PSA at diagnosis was 7.4ng/ml (IQR 5.1–10.6).  
10 (8.9%) patients were type 2 diabetic.  35 (31.3%) were on regular aspirin, 42 
(37.5%) were ex-smokers and 15 (13.4%) were current smokers. 
Eighteen (16.1%) patients had a trans-urethral resection (TUR) of prostate at 
diagnosis, the remainder had a trans-rectal ultrasound (TRUS) guided biopsy of 
prostate.  Twenty one (18.8%) patients had evidence of high grade prostate 
intraepithelial neoplasia (HG PIN) in their diagnostic specimen.  Eleven (9.8%) 
patients had perineural invasion (PNI).  Breakdown of Gleason scores is shown in 
Table 5.2. 
Twenty nine (25.9%) patients received or were offered intervention for clinical, 
biochemical or histological progression, one (0.9%) of whom declined treatment.  
Six (5.4%) patients were transferred to watchful waiting due to advancing age 
and/or change in performance status.  Median time to intervention was 23.6 
months (IQR 15.5–34.4). 
Three (10.7%) patients who received treatment intervention experienced 
biochemical relapse. 
Six (6.8%) patients developed metastases; 5 (5.7%) to lymph node and 1 (1.1%) to 
bone.  Median time to development of metastases was 31.5 months (IQR 2.2–
38.2). 
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Table 5.2 Patient Breakdown by Gleason Sum 
Gleason 
Sum 
Gleason 
Grade 
No of patients 
(%) 
6 3+3 87 (77.7) 
7 
3+4 20 (17.9) 
4+3 4 (3.6) 
8 4+4 1 (0.9) 
 
 
5.2.2 Clinicopathological variables related to outcome measures 
Table 5.3 details the clinicopathological variables as related to clinical outcome 
measures. 
Table 5.3 Univariate analysis of clinicopathological variables related to clinical outcome 
measures in first active surveillance cohort 
Host/Tumour Variable Time to 
Intervention 
Time to 
development of 
Metastases 
Age <70 0.177 0.959 
Diabetes 0.881 0.312 
Aspirin 0.417 0.046 
Smoking Status 0.389 0.359 
PSA <10ng/ml 0.014 0.326 
Gleason >6 0.029 0.392 
PIN 0.622 0.244 
PNI 0.005 0.753 
% of cores positive for cancer 0.017 0.708 
 
 
5.2.2.1 Intervention 
Serum PSA level <10ng/ml was associated with increased time to treatment 
intervention (60 month intervention free survival 71.4% vs 45.5% p=0.014) 
(Figure 5.2).  Gleason >6 was associated with decreased time to treatment 
intervention (60 month intervention free survival 54.6% vs 66.1% p=0.029) 
(Figure 5.3). 
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Figure 5.2 Kaplan Meier plot illustrating PSA at diagnosis and time to treatment intervention 
 
Figure 5.3 Kaplan Meier plot illustrating Gleason sum and time to treatment intervention 
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As shown in Figure 5.4 absence of PNI was associated with increased time to 
treatment intervention (60 month intervention free survival 67.4% vs 36.8% 
p=0.005). 
Figure 5.4 Kaplan Meier plot illustrating PNI and time to treatment intervention 
 
<50% total number of biopsy cores positive for cancer was associated with 
increased time to treatment intervention (60 month intervention free survival 
66.5% vs 35.3% p=0.017) (Figure 5.5). 
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Figure 5.5 Kaplan Meier plot illustrating percentage of total number of biopsy cores positive 
for cancer and time to treatment intervention 
 
 
5.2.2.2 Development of Metastases 
Aspirin usage was associated with increased time to development of metastases, 
in fact all patients who developed metastases were not on aspirin (60 month 
metastases free survival 100% vs 81.6% p=0.046) (Figure 5.6). 
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Figure 5.6 Kaplan Meier plot illustrating aspirin usage and time to development of 
metastases 
 
5.3 Discussion 
The clinical audit revealed that although 100% of patients had PSA follow up, 
only 63.4% of patients had a rebiopsy at any time following diagnosis.  Rebiopsy 
has been repeatedly demonstrated to be a strong prognostic indicator of disease 
progression.(58)  Prostate biopsy remains one of the most objective measures of 
prostate cancer progression.  Tumour grade and stage, as determined by 
prostate biopsy, direct the timing and type of treatment patients with prostate 
cancer receive.  A study of 104 men with low risk prostate cancer treated by AS, 
who underwent repeat biopsy within 3 months of diagnosis showed 27% were 
upgraded or up staged.  Those up graded/upstaged cases that subsequently 
underwent radical prostatectomy were significantly more likely to show higher 
final pathological stage and grade.(58)  In addition a study of 186 patients on 
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active surveillance where 92 underwent at least 1 repeat prostate biopsy, 5-year 
progression-free probability was 82% for patients with a negative first repeat 
biopsy compared with 50% for patients with a positive first rebiopsy.(187)  
Although there is consensus on the importance of rebiopsy for patients on AS, 
the timing and frequency of such is highly debated and a recent systematic 
review failed to find sufficient evidence to support any one follow up 
regime.(188) 
Poor adherence to the NICE low risk entry criteria for active surveillance was 
found.  Established clinical parameters such as Gleason score were associated 
with time to treatment intervention.  In addition higher volume disease, as 
represented by ≥50% of the total number biopsy cores containing tumour, was 
associated with shorter time to disease progression. PSA <10ng/ml at diagnosis 
was also found to be associated with longer time to treatment intervention.  PSA 
has repeatedly been proven to have poor specificity for prostate cancer with 
15.2% of men with a “normal” level (<4.0ng/ml) demonstrating cancer on 
biopsy.(67)  This is further illustrated by the recent abandonment of the PSA 
screening programme in North America.  The study cohort was from an 
unscreened population and comprised of patients with a high clinical suspicion 
for prostate cancer which may account for the findings of the importance of PSA 
in relation to clinical outcome. 
Rate of treatment intervention was 25.9% this is similar to other recent larger 
studies.(189,190)  The relatively high rate of biochemical recurrence and 
development of metastases may be accounted for by the inclusion of patients 
who did not conform to the NICE low risk criteria.  In addition two of the 
patients who developed metastases did so less than 3 months post diagnosis.  It 
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is therefore likely that the disease had already micro-metastasised at 
presentation.  However the remainder of patients all underwent delayed 
treatment following a period of surveillance, thereby creating an opportunity for 
disease progression and spread.  This is clearly the major problem with active 
surveillance and at present there are no consistently reliable diagnostic tools to 
differentiate aggressive cancers from those which are slow growing and clinically 
insignificant. 
The host-tumour interaction is becoming recognised as one of the key influences 
on tumour progression and spread.(191)  PNI is the invasion of nervous structures 
by tumour cells.  It can be seen as one of the main “highways” by which the 
tumour-host interface is connected and thereby a recognised mechanism by 
which cancer cells spread beyond the prostate.(192)  The prognostic significance 
of PNI in prostate cancer has been widely studied and debated.(193)  The 
majority of these studies involve the use of PNI at diagnosis to predict outcome 
in the final pathological specimen at radical prostatectomy.(194-196)  The 
current study presents a unique “real life” cohort of prostate cancer patients 
that have been undergone a MDT assessment and active surveillance has been 
selected as the initial treatment strategy.  Time to treatment intervention has 
been used as a surrogate of disease progression.   In addition development of 
metastases was utilised as a clinical end point and the results presented are 
similar to others.(197)  The pathological specimens of those patients who 
underwent radical prostatectomy were not available for review.  However, they 
are few in number and the overarching aim of this study was solely to assess the 
prognostic significance of the features of the diagnostic tumour specimen.  An 
obvious limitation of the current patient cohort is the small size and relatively 
short follow up time in the context of the long natural history of prostate 
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cancer.  However despite this short follow up length one quarter of patients 
underwent treatment intervention for disease progression and this is in 
agreement with previous work.(197) 
Interestingly, no patients who took regular aspirin developed metastases.  This 
correlates with current thinking that controlling the host’s inflammatory 
response (e.g. via aspirin) can modulate the host-tumour interface likely via 
inhibition of cyclo-oxygenase (COX) enzymes in order to prevent tumour growth, 
angiogenesis and subsequent spread.(198) 
Of course there are inherent difficulties with the usage of PNI as a prognostic 
marker.  Firstly there is the problem of intra-observer variability between 
reviewing pathologists.(199)  This can be reduced via the central review of all 
tissue specimens and the addition of immunohistochemical staining in order to 
enhance nerve fibres.(199)  Secondly the small amount of tissue involved in 
TRUS guided prostate biopsies limits the amount of nerve tissue that is included.  
However the counterargument for this is that if there is sufficient volume of PNI 
invasion to be apparent on TRUS then it must be of clinical significance. 
A recent study by Al-Hussain retrospectively analysed 313 biopsy specimens of 
prostate cancer patients who subsequently underwent radical prostatectomy but 
who would have met the criteria for AS on biopsy.(194)  They found no 
difference in outcome at radical prostatectomy in patients with PNI on biopsy.  
The current study provides a clearer picture of how PNI can be utilised in a 
modern day real active surveillance cohort.  Treatment intervention and 
development of metastases were utilised as clinical end points, both are clear 
markers of disease progression.  The Al-Hussain study examined only 
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pathological markers at radical prostatectomy as end points (194) and as such 
the current study is deemed to be more clinically relevant and patient centred. 
Clinical staging is crucial in order to select the most appropriate management 
strategy for patients with prostate cancer.  This is particularly pertinent to those 
patients who are thought to have low risk curable disease in whom treatment is 
delayed during a period of active surveillance until evidence of progression is 
demonstrated.  This strategy works well for most patients, avoiding the risks and 
side effects of radical therapy, however some patients experience progression 
from curable to incurable disease.  The current clinical staging and risk 
stratification tools are therefore inadequate and the investigation into the use of 
additional host and/or tumour factors could yield rapid patient benefits. 
Further work is necessary in order to consider how PNI can be optimally utilised 
in established prognostic algorithms for prostate cancer patients on active 
surveillance. 
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6 Active surveillance prostate cancer cohort 
clinical significance of protein expression 
The aim of active surveillance is to identify and cure those patients with 
progressive disease and to avoid the risks of over treatment in those who have 
clinically insignificant prostate cancer.  Active surveillance therefore provides a 
potential solution to the problem of over diagnosis and over treatment.  
However, although these patients are carefully selected at diagnosis and 
subjected to intense follow up consisting of regular repeat biopsies and serum 
PSA tests, some patients experience disease progression and require treatment 
intervention.  The delay in treatment during the period of surveillance may 
result in disease progression after which the disease is no longer curable. 
As described in the previous chapter patients are selected for active surveillance 
via strict criteria including host and tumour factors.(72)  Despite this careful 
selection, currently there is no accurate way to differentiate indolent from 
occult aggressive disease at diagnosis.  In the pilot prostate cancer cohort pARS81 
and pARS515, driven by Cdk1/pCdk1161, were independent predictors of outcome 
in patients with PSA ≤20ng/ml at diagnosis.  The aim of the current study was to 
determine the prognostic significance of AR, AR phosphorylated at serine 81 and 
515 and Cdk1/pCdk1161 expression for disease progression in a cohort of prostate 
cancer patients whom, following discussion at a multidisciplinary team meeting, 
were initially treated by active surveillance.  Study outcome measures were 
treatment intervention (a surrogate for disease progression) and development of 
metastases. 
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6.1 Protein expression 
AR, AR phosphorylated at Ser-81 and Ser-515, Cdk1 and pCdk1161 protein 
expression was analysed in the AS cohort.  Tissue was available for 51 patients.  
Expression of all proteins was observed at varying levels in the cytoplasm and 
nucleus of epithelial cells (Figure 6.1) in both cancer and non-cancer areas. 
Figure 6.1 Example high/low protein immunohistochemical staining in first active 
surveillance cohort 
 
Protein expression was found to be heterogeneous throughout.  Only protein 
expression observed in the tumour cells was scored.  ICCCs were performed to 
verify consistency between scorers and all values were >0.80 and are shown in 
Table 6.1.  Scatter plots for each antibody were used to display this data and to 
confirm there was no bias between scorers Bland Altman plots were constructed. 
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Table 6.1 ICCC scores for protein expression analysis in first active surveillance cohort 
Protein Nucleus Cytoplasm 
Cdk1 0.977 0.983 
pCdk1161 0.953 0.937 
Ki67 0.998 - 
AR 0.821 0.946 
pARS81 0.951 0.882 
pARS515 0.923 0.986 
 
Protein expression levels were subdivided into low (≤median) and high 
expression (>median) for analysis.  Median protein histoscore expression levels 
are shown in Table 6.2.  Median cell counts for Ki67 protein were 0% range 0-
0.5%. 
Table 6.2 Protein expression levels in first active surveillance cohort 
Protein 
Subcellular 
Location 
Median Histoscore 
(Histoscore units) 
Interquartile Range 
(Histoscore units) 
AR 
Nucleus 150 117.5-201.3 
Cytoplasm 100 70-132.5 
pARS81 
Nucleus 180 135-218.3 
Cytoplasm 120 80.7-180 
pARS515 
Nucleus 200 155-217.5 
Cytoplasm 65 40-100 
Cdk1 
Nucleus 102.5 37.5-130 
Cytoplasm 120 85-140 
pCdk1161 
Nucleus 143.8 83.8-183.8 
Cytoplasm 97.5 48.3-122.5 
 
 
6.2 Protein expression related to clinicopathological 
factors 
Table 6.3 displays protein expression as related to clinicopathological factors as 
assessed by the chi square test.  High Cdk1 nuclear expression was associated 
with older age at diagnosis, p=0.004.  High cytoplasmic Cdk1 expression was 
associated with a positive smoking history, p=0.021.  High Ki67 expression was 
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associated with higher PSA at diagnosis and higher percentage of cores positive 
for cancer (p=0.033 and 0.019 respectively).  High nuclear Cdk1 expression was 
associated with a greater volume of cores positive for cancer, p=0.017. 
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Table 6.3 Chi squared analysis of high/low protein expression as related to clinicopathological variables in first active surveillance cohort 
 
Proteins 
Clinicopathological Variables 
Age 
(<70 
v 
≥70yrs) 
DM2 
(presence 
v 
absence) 
Aspirin 
Usage 
(yes 
v 
no) 
Smoking 
History 
(non- v 
ex- v 
smoker) 
PSA at 
Diagnosis 
(<10 
v 
≥10ng/ml) 
Gleason 
(≤6 
v 
>6) 
PIN 
(yes 
v 
no) 
PNI 
(yes 
v 
no) 
%Cores 
Positive 
for Cancer 
(<50 v 
≥50%) 
AR 
Nuclear 0.222 0.564 0.199 0.081 0.593 0.767 0.570 0.851 0.760 
Cytoplasmic 0.367 0.880 0.136 0.417 0.462 0.745 0.617 0.836 0.631 
pARS81 
Nuclear 0.980 0.564 0.590 0.820 0.792 0.980 0.570 0.870 0.888 
Cytoplasmic 0.689 0.716 0.237 0.514 0.632 0.689 0.304 0.666 0.574 
pARS515 
Nuclear 0.980 0.192 0.917 0.824 0.746 0.522 0.830 0.570 0.531 
Cytoplasmic 0.689 0.639 0.917 0.236 0.487 0.408 0.439 0.245 0.835 
Cdk1 
Nuclear 0.004 0.917 0.916 0.347 0.304 0.677 0.401 0.658 0.017 
Cytoplasmic 0.210 0.348 0.429 0.021 0.968 0.531 0.328 0.555 0.878 
pCdk1161 
Nuclear 0.120 0.519 0.936 0.690 0.763 0.351 0.422 0.713 0.481 
Cytoplasmic 0.120 0.519 0.936 0.690 0.365 0.120 1.000 0.13 0.958 
Ki67 Nuclear 0.488 0.452 0.142 0.052 0.033 0.601 0.152 0.284 0.019 
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6.3 Protein expression related to clinical outcome 
measures 
Table 6.4 displays the univariate analysis using Kaplan meier curve and log rank 
test with regards to protein expression as related to the clinical outcome 
measures. 
Table 6.4 Univariate analysis of protein expression as related to clinical outcome measures 
in first active surveillance cohort 
Protein 
Time to 
intervention 
Time to 
development 
of 
metastases 
AR 
Nucleus 0.506 0.480 
Cytoplasm 0.021 0.480 
pAR
S81
 
Nucleus 0.490 0.808 
Cytoplasm 0.488 0.092 
pAR
S515
 
Nucleus 0.384 0.225 
Cytoplasm 0.806 0.225 
Cdk1 
Nucleus 0.872 0.808 
Cytoplasm 0.851 0.225 
pCdk1
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Nucleus 0.925 0.317 
Cytoplasm 0.490 0.317 
Ki67 Nucleus 0.043 - 
 
High total AR expression in the cytoplasm was associated with shorter time to 
treatment intervention, p=0.021 (Figure 6.2).  In addition high proliferation 
index, represented by high Ki67 expression, was also associated with shorter 
time to treatment intervention, p=0.043 (Figure 6.3) 
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Figure 6.2 Kaplan Meier plot illustrating total AR cytoplasmic expression and time to 
treatment intervention in first active surveillance cohort 
 
Figure 6.3 Kaplan Meier plot illustrating Ki67 expression and time to treatment intervention 
in first active surveillance cohort 
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6.4 Association of candidate kinases to phosphorylated 
AR sites 
Once the clinical significance of protein expression had been analysed, the 
association between candidate kinases and AR phosphorylation was then 
investigated in order to establish whether the predicted kinase was observed to 
correlate with AR phosphorylation in the clinical samples (Table 6.5). 
Table 6.5 Associations between candidate kinases and androgen receptor phosphorylation 
sites in active surveillance cohort 
 
 Candidate Kinases 
AR 
phosphorylation 
sites 
 
Cdk1 pCdk1161 
Nuclear Cytoplasmic Nuclear Cytoplasmic 
Ser-81 
Nuclear 
C.C. 0.192 -0.101 0.256 0.100 
p value 0.656 0.656 0.262 0.666 
Cytoplasmic 
C.C. 0.371 0.643 0.429 0.662 
p value 0.090 0.001 0.052 0.001 
Ser-515 
Nuclear 
C.C. 0.261 -0.030 0.100 0.061 
p value 0.229 0.892 0.659 0.786 
Cytoplasmic 
C.C. -0.032 -0.016 0.181 0.275 
p value 0.884 0.941 0.419 0.215 
 
High cytoplasmic Cdk1 and pCdk1161 were associated with high expression of 
pARS81.  High nuclear pCdk1161 expression trended towards an association with 
pARS81 cytoplasmic expression.  Neither Cdk1 or pCdk1161 were associated with 
pARS515 expression in either the cytoplasm or the nucleus. 
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6.5 Multivariate analysis 
Significant univariate results were included in a backwards conditional cox-
regression model to determine which, if any, factors were independently 
significant with regards to time to treatment intervention.  Both PNI (p=0.003, 
HR 8.6 (95% CI 2.1-35.7)) and total cytoplasmic AR expression (p=0.021, HR 4.6 
(95% CI 1.3-16.8)) were independently associated with time to treatment 
intervention.  As these variables were deemed independent it was investigated 
whether total AR expression in the cytoplasm could further inform on patients 
with or without PNI noted on diagnostic pathological specimen.  In patients with 
presence of PNI total AR expression was not significant in predicting time to 
treatment intervention (p=0.494).  However in patients without PNI high total 
cytoplasmic AR expression in the diagnostic specimen conferred a shorter time 
to treatment intervention than those with low expression (p=0.002, HR 5.4 (95% 
CI 1.6-17.9)) 60 month progression free survival 38.6% vs 65.3%) (Figure 6.4). 
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Figure 6.4 Kaplan Meier plot illustrating total AR cytoplasmic expression in patients without 
perineural invasion and time to treatment intervention in first active surveillance cohort 
 
6.6 Verification of results in a second cohort 
A second cohort of active surveillance patients was established prospectively in 
order to verify the results seen in the first retrospective active surveillance 
cohort.  The second cohort was demographically comparable to the first; median 
age at diagnosis 68y (IQR 63-72), median PSA at diagnosis 7.0ng/ml (IQR 4.5-
10.2).  Median length of follow up was 30.0 months (IQR 19.1-49.6).  25.7% 
(n=27) patients underwent treatment intervention.  Median time to treatment 
intervention was 21.9 months (IQR 18.7-35.8).  Median expression levels for 
proteins of interest in the second cohort were also comparable to the first and 
are shown in Table 6.6. All ICCCs were >0.80. 
Chapter 6 Active surveillance protein expression results 166 
 
Table 6.6 Median histoscores of protein expression in second active surveillance cohort 
Protein 
Subcellular 
Location 
Median Histoscore 
(Histoscore units) 
Interquartile Range 
(Histoscore units) 
AR 
Nucleus 120 92.5-165 
Cytoplasm 80 50-100 
pARS81 
Nucleus 185 138.8-205 
Cytoplasm 100 80-126.2 
pARS515 
Nucleus 220 200-250 
Cytoplasm 100 80-120 
Cdk1 
Nucleus 120 90-170 
Cytoplasm 145 120-175 
pCdk1161 
Nucleus 180 150-215 
Cytoplasm 120 100-150 
Ki67 Nuclear 1 1-2 
 
 
6.6.1 Univariate analysis of clinical variables in second active 
surveillance cohort 
The univariate analysis of clinical variables in the second active surveillance 
cohort, with regards to treatment intervention, is shown in Table 6.7. 
Table 6.7 Univariate analysis of clinicopathological variables and time to intervention in 
second active surveillance cohort 
Clinicopathological 
Variable 
Time to 
intervention 
Age <70 0.823 
PSA <10ng/ml 0.015 
Gleason >6 0.100 
PIN 0.361 
PNI 0.443 
% of cores positive for cancer <0.001 
 
As demonstrated in the first active surveillance cohort PSA ≥10ng/ml at diagnosis 
was associated with shorter time to treatment intervention HR 2.7 (95% CI 1.2-
6.3), p=0.015 (Figure 6.5) in the second cohort.  In addition, ≥50% of cores 
positive for cancer was associated with shorter time to treatment intervention in 
the second cohort as previously demonstrated in the first HR 17.5 (95% CI 2.0-
157.0), p<0.001 (Figure 6.6). 
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Figure 6.5 Kaplan Meier plot illustrating PSA at diagnosis and time to treatment intervention 
in second active surveillance cohort 
 
Figure 6.6 Kaplan Meier plot illustrating percentage of cores positive for cancer and time to 
treatment intervention in second active surveillance cohort 
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The results from univariate analysis of protein expression in the second active 
surveillance cohort are shown in Table 6.8. 
Table 6.8 Univariate analysis of protein expression and time to intervention in second active 
surveillance cohort 
Protein 
Time to 
Intervention 
AR 
Nuclear 0.170 
Cytoplasm 0.654 
pAR
S81
 
Nuclear 0.748 
Cytoplasm 0.032 
pAR
S515
 
Nuclear 0.510 
Cytoplasm 0.079 
Cdk1 
Nuclear 0.443 
Cytoplasm 0.409 
pCdk1
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Nuclear 0.074 
Cytoplasm 0.178 
Ki67 Nuclear 0.757 
 
The relationships between high total cytoplasmic AR and high Ki67 expression 
and shorter time to treatment intervention were not replicated in this cohort.  
However, high cytoplasmic pARS81 expression was associated with shorter time to 
treatment intervention, HR 2.8 (95% CI 1.1-7.3) (Figure 6.7). 
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Figure 6.7 Kaplan Meier plot illustrating total AR cytoplasmic expression and time to 
treatment intervention in second active surveillance cohort 
 
Similar to results seen in the pilot prostate cancer cohort high cytoplasmic 
pARS515 expression and high pCdk1161 expression in the nucleus both trended 
towards an association with shorter time to treatment intervention but did not 
reach clinical significance (p=0.079 and p=0.074 respectively). 
Multivariate analysis of significant protein and clinicopathological variables did 
not yield any independently significant variables with regards to time to 
treatment intervention in the second active surveillance cohort. 
The significant relationship of cytoplasmic total AR expression in patients 
without PNI in the first cohort was also reanalysed in the second.  Unfortunately 
the relationship was not significant in the second active surveillance cohort for 
either cytoplasmic AR (p=0.552) or pARS81 expression (p=0.378). 
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6.6.2 Kinases related to AR phosphorylation in the second active 
surveillance cohort 
Table 6.9 displays the correlation between protein expression of pAR sites and 
candidate kinases.  As in the first active surveillance cohort cytoplasmic pCdk1161 
expression was associated with pARS81 expression in the cytoplasm and nuclear 
pCdk1161 trended towards an association.  In contrast to the first active 
surveillance cohort, but in line with the pilot prostate cancer cohort, 
cytoplasmic Cdk1 expression was associated with cytoplasmic pARS515 expression 
and trended towards an association with nuclear pARS515.  In addition pCdk1161 
trended towards an association with both nuclear and cytoplasmic pARS515 
expression.  These results are interesting and may reflect the larger size of the 
second active surveillance cohort, which is in line with the pilot prostate cancer 
cohort, enabling the relationships to be uncovered. 
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Table 6.9 Pearson's correlation coefficients between pAR sites and candidate kinases in the second active surveillance cohort 
 
 Candidate Kinases 
AR 
phosphorylation 
sites 
 
Cdk1 pCdk1161 
Nuclear Cytoplasmic Nuclear Cytoplasmic 
Ser-81 
Nuclear 
C.C. 0.285 0.058 0.215 0.118 
p value 0.012 0.617 0.062 0.310 
Cytoplasmic 
C.C. 0.149 0.241 0.309 0.451 
p value 0.197 0.035 0.007 <0.001 
Ser-515 
Nuclear 
C.C. 0.172 0.314 0.318 0.343 
p value 0.131 0.005 0.005 0.002 
Cytoplasmic 
C.C. 0.185 0.418 0.301 0.397 
p value 0.103 <0.001 0.008 <0.001 
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6.7 Discussion 
The results presented have highlighted the clinical significance of AR and AR 
serine phosphorylation in prostate cancer patients treated by active 
surveillance. 
Firstly the median expression levels of the proteins analysed are similar in both 
the first and second cohort.  This adds weight to the comparability of the two 
cohorts and the quality and consistency of the immunohistochemical staining.  
Interestingly the expression levels of almost all proteins are higher than those in 
the pilot prostate cancer cohort and the BPH cohort.  The single exception is 
Cdk1 staining in the first active surveillance cohort is slightly less intense than 
that observed in the BPH cohort, although still comparable.  The differences in 
staining between the pilot prostate cancer cohort and the active surveillance 
cohorts confirms the hypothesis that these groups are quite separate with a 
molecularly different profile and therefore should be managed as such in the 
clinical setting. 
In the first cohort high Cdk1 nuclear expression was associated with older age at 
diagnosis.  This is similar to Cdk1 stromal expression in the BPH cohort.  The 
reasons for this relationship are unclear and there is no previous work regarding 
chronological variation in Cdk1 expression levels.  It may be that the inverse 
relationship with Cdk inhibitor p27(Kip1) and age in BPH (200) also crosses over to 
early prostate cancer patients which would explain this finding in active 
surveillance patients but not in the pilot prostate cancer cohort. 
High cytoplasmic Cdk1 expression was associated with a positive smoking history.  
A recent study observed a greater risk of prostate cancer in smokers with 
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homozygote variant genotype and heterozygous mutant genotype of the Cdk 
inhibitor p21.(201)  This suggests that Cdk inhibitor genotype may have an 
impact on cell cycle control induced by DNA damage caused by carcinogens in 
tobacco smoke.(201)  This may translate into deregulation of Cdk driven cell 
cycle progression and may explain the findings in the current study. 
As expected high proliferation index was associated with higher PSA at diagnosis 
and higher percentage of cores positive for cancer.  Cell cycle deregulation is 
common in human cancer and as a key regulator of cell cycle progression it was 
unsurprising to observe that high nuclear Cdk1 expression was associated with a 
greater volume of cores positive for cancer. 
The Ki-67 protein is well known and widely used to assess the tumour 
proliferation rate.  In fact in breast cancer Ki67 tumour labelling is 
recommended when choosing the appropriate treatment.(202)  In the current 
study highly proliferating tumours were found to have a shorter time to disease 
progression in the first cohort.  Ki67 has been previously demonstrated to be an 
independent predictor of response to surgical treatment of prostate 
cancer.(203,204)  In particular Zellweger and colleagues analysed 279 pre-
teatment prostate biopsies in which high Ki67 labelling index was an 
independently predictive factor of biochemical relapse in low-risk disease.(205)  
High Ki67 expression has also been shown to be a predictor of biochemical 
recurrence, development of metastases and disease specific survival in prostate 
cancer patients treated with radical radiotherapy.(206-209)  With immediate 
relevance to the current study in 2009 Berney and colleagues (210) analysed the 
prognostic significance of 693 cases of conservatively managed localised prostate 
cancer diagnosed by TUR.  They found Ki67 to be an independent prognostic 
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factor of disease specific and overall survival.(210)  However when patients 
were grouped by Gleason score (<7 vs ≥7), the independent prognostic 
significance of Ki67 was not maintained for disease specific survival in those 
patients with Gleason <7.(210)  When the same research group analysed similar 
cases diagnosed by needle biopsy in 2013 they found once again that Ki67 was an 
independent prognostic factor of disease specific survival, although assessment 
in low risk patients was not undertaken.(211)  The current study utilised the 
diagnostic prostate specimen of which 89.3% were TRUS biopsies.  This 
represents a contemporary prostate cancer cohort and may account for the 
differences seen in low risk patients in Berney’s 2009 study.(210)  In addition the 
current study includes patients only treated by active surveillance, however 
Berney’s studies include localised prostate cancers some of which may be high 
risk and treated with watchful waiting.  To add weight to this argument a 
previous study conducted in needle biopsies of 60 active surveillance patients 
observed that high Ki67 expression was an independent determinant of shorter 
time to treatment intervention.(212)  These results were confirmed in the first 
active surveillance cohort.  However, the significant results related to Ki67 seen 
in the first cohort were not replicated in the second.  Differences in pre-
analytical factors may explain these results as the two active surveillance 
cohorts were from two separate health boards utilising different pathology 
laboratories.  Several studies have found that certain pre-analytical factors can 
decrease Ki67 expression; significant (overnight) delay in time to fixation, 
freezing of the specimen for frozen section analysis before fixation, any fixative 
other than neutral buffered formalin and prolonged storage of tissue on glass 
slides (rather than paraffin embedded blocks).(213-216)  Regardless, further 
work is required in a large prospectively collected cohort in order to clarify the 
relationship between Ki67 expression and time to treatment intervention. 
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Both PNI and total AR expression in the cytoplasm were independent variables 
for time to treatment intervention.  AR expression has been assessed previously 
with regards to treatment outcome in prostate cancer patients.  In contrast to 
the current study work involving 62 hormone sensitive prostate cancer patients 
who underwent radical prostatectomy low cytoplasmic total AR expression was 
associated with increased risk of biochemical relapse.(181)  However, in those 
patients with negative surgical margins high cytoplasmic total AR expression was 
associated with decreased recurrence free survival.(181)  Similarly in 211 radical 
prostatectomy specimens low AR expression was associated with a worse 
prognosis for relapse free survival.(217)  However, high AR nuclear expression in 
551 prostate cancer patients treated by radical prostatectomy was an 
independent predictor of shorter time to biochemical relapse.(218)  Similarly 
high nuclear AR expression was associated with decreased disease specific 
survival in 104 patients with castrate resistant disease.(219)  The reasons for 
these varying results are unclear however it may relate to disease stage and 
treatment type.  There are no previous studies examining expression levels of AR 
in active surveillance patients.  As discussed in the previous chapter presence of 
PNI was associated with shorter time to treatment intervention.  In patients 
without PNI total AR expression was found to be clinically significant in 
predicting time to treatment intervention.  However these results were not 
replicated in the second active surveillance cohort.  Verification in a large 
prospective clinical trial is required and if successful these results may be 
translated into clinical practice directing the early radical treatment of patients 
initially considered suitable for active surveillance. 
In the second active surveillance cohort high cytoplasmic pARS81 expression was 
associated with shorter time to treatment intervention.  In the pilot prostate 
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cancer cohort cytoplasmic expression trended towards a relationship with 
disease specific survival.  Ser-81 is the most frequently phosphorylated site on 
the AR in response to androgen binding.(136)  Phosphorylation of AR at Ser 81 is 
thought to play important roles in AR transactivation, cellular localization and 
stability as well as cell proliferation.(117,136)  Interestingly these results were 
not verified in the first active surveillance cohort and may reflect the larger 
number of cases in which tissue was available in the second cohort and/or the 
prospective nature of the second cohort.  pCdk1161 expression was correlated 
with pARS81 expression in the cytoplasm in both cohorts.  This is consistent with 
both the pilot prostate cancer cohort and previous work which has shown that 
activation of Cdk1 by cyclin B increases AR phosphorylation.(136) 
Interestingly, in the second active surveillance cohort high cytoplasmic pARS515 
expression trended towards significance with regards to shorter time to 
treatment intervention.  This was not seen in the first active surveillance cohort.  
The relevance of this is unclear and further work is required in order to establish 
the clinical application of the significant results seen in the pilot prostate cancer 
cohort in active surveillance patients. 
Similarly the relationship between Cdk1/pCdk1161 and AR phosphorylation at Ser-
515 remains unclear.  The positive results in the second cohort were not 
replicated in the first.  A prospectively collected large cohort would unpick 
these results in combination with further mechanistic cell line work. 
This work clearly demonstrates that AR and phosphorylation of AR at serine 
residues by Cdk1/pCdk1161 has some clinical relevance in prostate cancer 
patients treated by active surveillance, however these results require validation 
as there are discrepancies between both cohorts, therefore a study performed 
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on a large multi centre prospective cohort would conclusively demonstrate if 
these biomarkers are worth pursuing for clinical practice. 
Chapter 7 BPH and clinicopathological factors  178 
 
7 Benign prostate hyperplasia and 
clinicopathological factors 
Benign prostatic hyperplasia (BPH) is one of the most common diseases in elderly 
men.  Autopsy studies have demonstrated a prevalence of 50% in men aged 50-60 
years and 90% over 80 years.(1)  BPH can result in significant patient morbidity 
in the form of lower urinary tract symptoms (LUTS) and complications such as 
acute urinary retention (AUR).  Medical therapy for BPH often fails and surgical 
intervention is required.  A subset of men have ongoing symptoms despite 
surgical intervention and require further treatment with medication or repeat 
transurethral resection (TUR) of prostate operation.  Currently there is no way 
to predict the best time to offer surgical intervention or identify which patients 
will benefit from such a procedure. 
BPH has repeatedly been linked with clinicopathological factors such as type 2 
diabetes (DM2), cardiovascular disease (CVD), obesity and inflammation.  
However the significance of these relationships is highly debated and the 
influence on clinical outcome or response to treatment has not been previously 
investigated.  The aim of this study was to assess, in a cohort of patients with 
histologically proven BPH, the prognostic use of classical clinicopathological 
factors and both (novel) systemic and pathological factors not currently 
employed clinically in BPH, but demonstrated to have diagnostic utility in other 
diseases. 
7.1.1 Cohort demographics 
Six hundred and seventy eight patients were identified of which 336 had clinical 
data and pathological tissue available for analysis.  Cohort demographics for the 
336 patients are shown in Table 7.1.  Median length of follow up for these 
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patients was 8.2y (IQR 6.2–11.9).    Median time to failure of surgical 
management following primary TUR of prostate operation was 7.2y (IQR 5.4-
10.1), experienced by 37.1% of patients.  Median time to postoperative AUR 
occurring beyond 30 days following primary TUR was 7.8y (IQR 6.1-11.8), 
experienced by 10.2% of patients.  Reoperation rate was almost a quarter 
(24.4%) and median time to reoperation was 7.3y (IQR 5.7-10.3).  
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Table 7.1 Demographic information BPH cohort 
Classical clinicopathological variables 
Patients 
(%) 
Patients 
(n) 
Age 
<70 years 53.3 179 
≥70 years 46.7 157 
CVD 
Yes 49.1 165 
No 50.9 171 
DM2 
Yes 16.9 57 
No 83.1 279 
BMI 
Normal 32.1 108 
Overweight 44.4 149 
Obese 23.5 79 
Aspirin usage 
Yes 53.5 179 
No 46.5 157 
Smoking history 
Non smoker 43.5 146 
Ex smoker 41.6 140 
Smoker 14.9 50 
PSA at diagnosis 
<4ng/ml 61.3 206 
≥4ng/ml 38.7 130 
Weight of chips resected at 
TUR 
<11g 50.1 168 
≥11g 49.9 168 
Urinary catheter in-situ 
preoperatively 
Yes 31.5 106 
No 68.5 230 
Novel systemic and pathological factors   
Systemic inflammatory 
response 
(mGPS) 
Low 70.2 236 
Medium 27.5 93 
High 2.2 7 
Local inflammatory 
infliltrate 
(Klintrup-Makinen) 
None (0) 0.3 1 
Mild/patchy (1) 93.5 314 
Prominent (2) 5.9 20 
Chapter 7 BPH and clinicopathological factors  181 
 
Florid (3) 0.3 1 
Tissue necrosis 
None 97.7 328 
<25% 2.3 8 
25-50% 0 0 
>50% 0 0 
Proliferation Index 
(Ki67) 
Low 61.6 207 
High 38.4 129 
Apoptotic Index 
(TUNEL) 
Low 50.9 171 
High 49.1 165 
 
7.1.2 Clinicopathological factors related to outcome measures 
Table 7.2 shows associations with clinical parameters (grouped data) and 
outcome measures using Kaplan-Meier methods. 
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Table 7.2 Univariate analysis of clinicopathological factors in the BPH cohort 
Classical 
clinicopathological 
Variables 
Postoperative 
AUR 
Failure of 
surgical 
management 
Reoperation 
Age 
(<70 v ≥70 years) 
0.002 0.849 0.810 
BMI 
(normal v overweight v 
obese) 
0.508 0.008 0.204 
CVD 
(presence v absence) 
0.036 0.584 0.326 
DM2 
(presence v absence) 
0.414 0.331 0.933 
Aspirin Usage 
(presence v absence) 
0.577 0.211 0.232 
Smoking History 
(Non-smoker v ex-smoker 
v smoker) 
0.586 0.299 0.631 
PSA at diagnosis 
(<4 v ≥4ng/ml) 
0.693 0.010 0.435 
Weight of chips 
(≤11 v >11g) 
0.761 0.616 0.043 
Preoperative 
urinary catheter in 
situ 
(presence v presence) 
0.024 0.455 0.798 
Novel 
systemic and 
pathological factors 
   
Local inflammation 
(Klintrup-Makinen) 
(none v mild v prominent 
v florid) 
0.340 0.682 0.914 
Tissue Necrosis 
(0 v <25 v 25-50 v >50%) 
0.633 0.752 0.708 
Systemic 
inflammation 
(mGPS) 
(mild v moderate v high) 
0.214 0.086 0.364 
Apoptotic index 
(TUNEL) 
(low v high) 
0.086 0.264 0.093 
Proliferation index 
(Ki67) 
(low v high) 
0.215 0.746 0.007 
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7.1.2.1 Classical clinicopathological variables related to outcome measures 
As shown in Table 7.2 several clinical variables were associated with clinical 
outcome measures.  Increased age (p= 0.02, HR 3.2 (95% CI 1.4-7.3)), presence 
of CVD (p=0.036, HR 2.3 (95% CI 1.0-5.1)) and presence of a preoperative urinary 
catheter (p=0.024, HR 2.5 (95% CI 1.1-5.7)) were all associated with increased 
incidence of postoperative AUR >30 days after TUR (Figures 7.2, 7.3 and 7.4 
respectively). 
Figure 7.1 Kaplan Meier plot of age and time to postoperative AUR in BPH patients 
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Figure 7.2 Kaplan Meier plot of CVD and time to postoperative AUR in BPH patients 
 
Figure 7.3 Kaplan Meier plot of presence of preoperative urinary catheter and time to 
postoperative AUR in BPH patients 
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As shown in Table 7.2 and Figure 7.4 higher BMI was found to be associated with 
shorter time to failure of surgical management p=0.008, HR 1.6 (95% CI 1.2-2.1).  
Successful surgical management of BPH at 15 years was 69% in normal weight, 
56.6% in overweight and 24.6% in obese patients.  High serum PSA at diagnosis 
was also associated with shorter time to failure of surgical management p=0.010, 
HR 1.7 (95% CI 1.1-2.6) (Figure 7.5). 
Figure 7.4 Kaplan Meier plot of BMI and time to failure of surgical management in BPH 
patients 
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Figure 7.5 Kaplan Meier plot PSA at diagnosis and time to failure of surgical management in 
BPH patients 
 
Lower weight of chips resected at TUR was associated with shorter time to 
reoperation p=0.043, HR 0.62 (95% CI 0.39-0.99) (Figure 7.6). 
Chapter 7 BPH and clinicopathological factors  187 
 
Figure 7.6 Kaplan Meier plot weight of chips resected at TUR and time to reoperation in BPH 
patients 
 
7.1.2.2 Novel systemic and pathological variables related to outcome 
measures 
When considering the non-classical factors or novel factors for BPH there was a 
trend for higher apoptotic index to be associated with increased incidence of 
postoperative AUR (Table 7.2).  There was also a trend for higher levels of 
systemic inflammation to be associated with shorter time to failure of surgical 
management (Table 7.2).  Low proliferation index, as assessed by Ki67, was 
associated with a shorter time to reoperation p=0.007, HR 0.44 (95% CI 0.24-
0.81) (Figure 7.7) and a trend for low apoptotic index was observed to be 
associated with shorter time to reoperation but did not reach clinical 
significance (p=0.093, Table 7.2). 
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Figure 7.7 Kaplan Meier plot proliferation index and time to reoperation in BPH patients 
 
7.2 Discussion 
Several clinicopathological factors were associated with clinical outcome 
measures in BPH.  Regarding the clinical factors, increased age was associated 
with increased incidence of postoperative AUR.  It is likely that increased age 
corresponds to increased duration of symptoms and increased number of 
comorbidities, both of which may make postoperative AUR more likely.  
Presence of a preoperative indwelling urinary catheter was associated with 
increased incidence of postoperative AUR.  Although the clinical indication for 
the urinary catheter is unknown it can be assumed that a large majority would 
have had preoperative AUR.  Preoperative AUR has been demonstrated to be 
associated with a higher risk of complications following TUR in a large population 
study (220) and may explain the observed relationship. 
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As observed in the current study, CVD has been linked to BPH/LUTS previously.  
The Massachusetts Male Aging Study involving over 1000 men with a mean follow 
up of 9 years found that a history of heart disease at baseline more than doubled 
the odds of subsequent clinical BPH.(221)  Similarly the Flint Men’s Health Study 
found an increased risk of moderate to severe LUTS in patients with a history of 
heart disease.(222)  This may explain our finding that presence of CVD was 
associated with shorter time to postoperative AUR.  In addition patients with 
CVD are likely to be prescribed several medications that may worsen symptoms; 
the Massachusetts Male Aging Study found beta-blockers to be associated with an 
increased incidence of BPH, perhaps through effects on the sympathetic nervous 
system.(221)  Risk factors for CVD have also repeatedly been linked to BPH.  In a 
pre-clinical study where rats were fed high fat diets resulting in high serum 
concentrations of low density lipoprotein-cholesterol (a strong risk factor for 
cardiovascular disease), the animals were also noted to develop prostatic 
smooth muscle hypertrophy and bladder over-activity.(223)  In a population 
based study of 780 men risk factors for CVD were linked to progression of 
symptoms of BPH.(224)  Similarly factors that protect against CVD have been 
shown to protect against BPH/LUTS.  A systematic review and meta-analysis 
described a risk reduction of up to 25% with moderate to vigorous physical 
exercise.(225)  It is widely debated whether BPH is a risk factor for CVD or vice 
versa.(226)  The current study reinforces the link between the two conditions 
but further work is required in order to unpick this complex relationship. 
High serum PSA level at diagnosis was found to be an independent predictor on 
multivariate analysis with regards to failure of surgical management.  It is well 
recognised that serum PSA level in benign prostatic disease correlates strongly 
with prostatic volume.(227-229)  Increased prostate volume strongly predicts 
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adverse clinical outcomes associated with BPH.(46,230)  The correlation 
between prostate volume and severity of LUTS is not clear cut, however patients 
with larger volume prostates (and higher serum PSA levels) undergoing surgical 
management may not have adequate tissue removed thus resulting in 
ongoing/recurrent LUTS requiring further prescription of postoperative medical 
therapy.  This hypothesis is strengthened by the finding that a lower weight of 
chips resected at primary TUR is associated with a shorter time to reoperation.  
Data on grade of operating surgeon was not available for this cohort but it may 
be that junior trainees undertaking these procedures are more cautious with 
regards to the volume of tissue resected thus accounting for the observed 
relationships.  BMI was strongly associated with time to failure of surgical 
management in BPH patients undergoing TUR of prostate.  Few studies have 
examined the effect of obesity on response to treatment in BPH.  The Asian 
multinational prospective observational registry of patients with benign prostatic 
hyperplasia recorded data on BMI, treatment for BPH and IPSS but unfortunately 
did not examine this relationship.(218)  One study observed that high BMI and 
waist circumference were associated with greater response to medical 
treatment of LUTS as determined by IPSS.(231)  These results are contradictory 
to the current study’s findings that high BMI confers shorter time to failure of 
surgical management as it must be assumed that patients requiring treatment 
have worse symptoms.  This may be explained by the low rates of preoperative 
IPSS (38.8%) and maximum urine flow rate (Qmax) (56.6%) (data not shown) 
which is in line with the findings of the national prostatectomy audit.(232)  
Taken together, Lee’s work and the current study may suggest a strategy 
whereby medical treatment of BPH is instituted in preference to surgery in 
obese patients.(231)  Clearly this hypothesis requires investigation within the 
context of a randomised controlled trial. 
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Interestingly BMI was found to be associated with failure of surgical management 
but not associated with reoperation.  One explanation may be that high BMI 
patients are more likely to have significant comorbidities such as CVD and DM2.  
Significant comorbidities confer a higher perioperative risk and, on balance, 
repeat TUR may be evaluated as too hazardous to undertake in these patients. 
Obesity is known to be associated with a systemic, low-grade inflammatory 
state.  Pathological factors such as the role of inflammation in the development 
and progression of BPH is highly debated.  It is postulated that a chronic local 
inflammatory cell infiltrate creates a cytokine rich environment which can 
support the process of fibromuscular growth in BPH.(233)  Regarding the local 
inflammatory response previous work has demonstrated the presence of an 
inflammatory cell infiltrate in 98% of BPH specimens.(28)  The current study 
supports this work with inflammatory cells present in 100% of cases examined.  
The clinical significance of the inflammatory cell infiltrate remains speculative.  
This study is the first example of application of the Klintrup-Makinen scoring 
system in prostate disease.  Other studies have examined the local inflammatory 
cell infiltrate in BPH, with varying results.  The expression of CD4+ and CD8+ T 
cell lymphocytes in BPH diagnosed on prostate biopsies was not associated with 
progression of LUTS.(234)  Another histological study used a tissue microarray to 
review the inflammatory infiltrates on 275 BPH specimens.  Higher levels of 
inflammation were found to be associated with larger prostate volume and 
higher international prostate symptom score.(30)  Similarly Di Silverio examined 
3942 prostate specimens and found larger prostates to be positively associated 
with inflammation.(29)  Data was not available on prostate volume for this 
cohort however the relationship between IPSS and Klintrup-Makinen score was 
examined and demonstrated no association (data not shown). 
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The importance of tissue necrosis secondary to prostatic infarction in BPH is 
unclear.  This study reported a small amount (2.3%) of tissue necrosis in routine 
TUR prostate specimens.  These rates of necrosis are in line with previous 
studies, which showed rates of 0-9%.(235-237)  However, the presence of 
necrosis in other urological conditions has been well established.  In particular 
tissue necrosis in renal cancer specimens forms part of the risk stratification in 
these patients.(238,239)  Recent renal cancer studies have demonstrated that 
quantification of necrosis is superior to a basic presence/absence 
assessment.(240,241)  The prognostic significance of prostate tissue necrosis in 
BPH is largely unknown.  Prostate infarction has previously been associated with 
AUR which is a common complication of BPH.  Prostatic infarction was 85% and 
3% respectively when patients with AUR were compared with those undergoing 
elective surgery for BPH.(242)  However, the connection between AUR and 
prostate infarction has not been reproduced in recent studies.(235,236)  It is 
likely that the relationship between BPH and prostatic infarction is complex and 
subject to many confounders as BPH patients are likely to have larger prostates 
and therefore suffer AUR (with or without concurrent infection) requiring 
urethral instrumentation.  In addition BPH patients are likely to be older and 
therefore more at risk of atherosclerosis all of which may distort the 
intraglandular vascular supply leading to prostatic infarction.(243,244)  Some 
studies have linked prostate infarction to smoking and pre-existing 
cardiovascular disease (245), although this was not found in the current study.  
General anaesthesia and perioperative hypotension have also been suggested to 
play a role in prostate infarction due to reduced blood supply.  This has 
particularly been seen in those patients undergoing aortic aneurysm repair likely 
secondary to significant blood loss producing hypotension and the association 
with atherosclerosis of the iliac arteries further jeopardising blood flow to the 
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central part of the prostate gland.(246)  Previous general anaesthetic data was 
unavailable but this may account for the small proportion of prostate tissue 
necrosis seen in this study. 
Systemic inflammation as measured by circulating levels of CRP has been shown 
to be associated with development of BPH in a case matched prospective 
study.(247)  CRP has also been linked with irritative LUTS and decreased peak 
urinary flow rates in a population based study of 2115 men with BPH/LUTS.(33)  
CRP has been further validated in 205 men with BPH, whereby higher serum 
levels were found to be an independent predictor of on-going LUTS following 
medical treatment.(248)  Since the prognostic use of CRP has been previously 
studied it was assessed whether mGPS, an established systemic inflammatory 
scoring system utilising CRP in combination with albumin, could predict outcome 
in BPH.  mGPS has been associated with outcome in prostate cancer where it has 
recently been shown to predict poorer 5 year overall and relative survival in 
prostate cancer patients independent of Gleason score.(249)  Despite this 
significant relationship in neoplastic prostatic tissue mGPS was not found to be 
associated with clinical outcome measures in BPH.  To our knowledge this is the 
first investigation of mGPS in BPH patients and clearly further work is required in 
this field to validate the current study’s findings. 
The relationship between proliferation and apoptotic indices and clinical 
outcome measures was perhaps contrary to expectations.  We suggest that our 
results represent a shift in the normal balance of cells in BPH; a high 
proliferation index may result in more cells exhibiting mutations and therefore 
entering programmed cell death.  This could account for our finding that there 
was a trend for high apoptotic index to be associated with a shorter time to AUR 
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in BPH patients, which might contribute to the uncontrolled progression of the 
disease.  Both low proliferation index and low apoptotic index were associated 
with shorter time to reoperation.  The mechanisms behind this relationship are 
unclear however this could suggest that following primary surgery a reverse 
relationship may manifest.  It may also be true that too little tissue was 
removed to achieve symptomatic response or that the relationship is secondary 
to fast proliferation cells out growing their nutrient supply resulting in 
inflammation and necrosis causing a feedback pathway to shut down the overall 
growth of the gland.  These explanations represent hypotheses only and clearly 
there is a need for further investigation using mechanistic models, which is out 
with the scope of this project. 
In conclusion clinicopathological factors are of prognostic importance in BPH.  
However the role of some factors, such as inflammation and tissue necrosis, in 
BPH remains unclear.  Some of these factors provide an opportunity for 
intervention; high BMI was associated with worse outcome from primary TUR 
surgery therefore weight loss should form part of the routine management of 
BPH in obese patients.  This study was conducted retrospectively therefore 
prospective, randomised trials with appropriate length of follow up are required 
in order to definitively establish the impact of clinicopathological factors on the 
clinical manifestations of BPH and their role as prognostic indicators of disease 
progression. 
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8 Benign prostate hyperplasia and serine 
phosphorylation of the androgen receptor 
8.1 Androgen receptor expression 
Expression of AR and all phosphorylated forms investigated were observed at 
varying levels in the cytoplasm and nucleus of both stromal and epithelial cells 
(Figure 8.1).  Staining in epithelial cells was easily differentiated between the 
nucleus and the cytoplasm and thus both compartments were scored 
independently.  However, staining in the stromal and smooth muscle cells could 
only be confidently scored within the nuclear compartments therefore 
cytoplasmic scoring was not undertaken.  Protein expression was found to be 
heterogeneous throughout and, with the exception of pARS515 staining, less 
intense in the smooth muscle, stromal and cytoplasmic component of the 
epithelial cells compared to epithelial nuclear expression.  There was presence 
of benign prostatic tissue, adjacent to the BPH tissue, in some of the TMA cores.  
Only protein expression observed in the BPH tissue was scored. 
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Figure 8.1 Example high/low AR and pAR immunohistochemical staining in BPH 
 
ICCCs were performed to verify consistency between observers and all values 
were >0.80 (Table 8.1). 
Table 8.1 ICCC scores for AR and pAR protein expression analysis 
 Protein Nucleus Cytoplasm Smooth muscle Stroma 
AR 0.804 0.826 0.808 0.934 
pARS81 0.807 0.802 0.894 0.879 
pARS94 0.806 0.812 0.870 0.864 
pARS213 0.832 0.849 0.862 0.885 
pARS515 0.818 0.804 0.837 0.871 
pARS578 0.852 0.805 0.981 0.954 
pARS650 0.802 0.801 0.983 0.814 
Ki67 0.952 X X X 
TUNEL 0.920 X X X 
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Scatter plots for each antibody were used to display correlations between 
individual observers’ scores and to confirm there was no bias between observers 
Bland Altman plots were constructed.  Protein expression levels were subdivided 
into low (≤median) and high expression (>median) for analysis.  Median AR and 
pAR histoscore expression levels are shown in Table 8.2.  Proliferation and 
apoptotic indices were observed in 85.7% and 98.8%, respectively, of the BPH 
tissue examined and median cell counts (IQR) were 1.0% (0.3-1.7) and 2.0% (1.0-
4.0) respectively. 
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Table 8.2 Protein expression levels for AR and pAR sites 
Protein 
Subcellular 
Location 
Median Histoscore 
(Histoscore units) 
Interquartile Range 
(Histoscore units) 
AR 
Cytoplasm 5.0 1.7-10.0 
Nucleus 126.7 110-141.7 
Smooth muscle 38.3 18.3-58.3 
Stroma 63.3 38.3-91.7 
pARS81 
Cytoplasm 40.0 25.0-58.3 
Nucleus 175.0 155.0-195.0 
Smooth muscle 90.0 61.7-117.5 
Stroma 136.7 110.0-163.8 
pARS94 
Cytoplasm 60.0 43.3-75.0 
Nucleus 116.7 92.1-142.9 
Smooth muscle 40.0 21.7-63.3 
Stroma 65.0 40.0-86.3 
pARS213 
Cytoplasm 13.3 7.5-34.2 
Nucleus 125.0 106.7-141.7 
Smooth muscle 19.2 10.0-55.0 
Stroma 52.5 28.3-87.3 
pARS515 
Cytoplasm 16.7 10.0-26.7 
Nucleus 131.7 110.0-156.7 
Smooth muscle 133.3 110.0-160.0 
Stroma 156.7 136.7-184.6 
pARS578 
Cytoplasm 56.7 38.3-75.0 
Nucleus 35.0 15.0-60.0 
Smooth muscle 1.7 0-3.3 
Stroma 6.7 3.3-11.7 
pARS650 
Cytoplasm 43.3 30.0-56.7 
Nucleus 155.0 130.0-175.0 
Smooth muscle 66.7 38.3-90.0 
Stroma 103.3 73.3-130.0 
 
 
8.2 Correlation of cell-specific phosphorylated androgen 
receptor expression 
Continuous stromal-epithelial interactions are believed to be critical in prostatic 
development, homeostasis and disease.  The importance of stromal-epithelial 
cross talk has been demonstrated in co-culture experiments of primary human 
BPH stromal fibroblasts and epithelial cells in which cell growth was significantly 
Chapter 8 BPH and serine phosphorylation of the androgen receptor 199 
 
increased when compared to culture of either cell type separately.(24)  Given 
the wealth of data available the opportunity was taken to determine whether 
there was any relationship between cell-specific (stromal, smooth muscle or 
epithelial) expression of AR and AR phosphorylated at serine residues.  Pearson’s 
correlation coefficients were performed and the results are shown in Tables 8.3-
8.9. 
Table 8.3 Pearson's correlation coefficients total AR expression in epithelial, smooth muscle 
and stromal cells in BPH 
 
AR 
Total AR 
Nuclear 
Cytoplas
mic 
Smooth 
muscle 
Stroma 
Total AR 
Nuclear 
C.C.  0.200 0.248 0.304 
p 
value 
 <0.001 <0.001 <0.001 
Cytoplasmic 
C.C. 0.200  0.041 0.051 
p 
value 
<0.001  0.450 0.351 
Smooth 
muscle 
C.C. 0.248 0.041  0.607 
P 
value 
<0.001 0.450  <0.001 
Stroma 
C.C. 0.304 0.051 0.607  
P 
value 
<0.001 0.351 <0.001  
 
Siginicant values (highlighted bold) are denoted by Pearson’s correlation 
coefficient (C.C.) >0.400 and p value <0.05. 
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Table 8.4 Pearson's correlation coefficients pAR
S81
 expression in epithelial, smooth muscle 
and stromal cells in BPH 
 
AR phosphorylation sites 
Ser-81 
Nuclear 
Cytoplas
mic 
Smooth 
muscle 
Stroma 
Ser-81 
Nuclear 
C.C.  0.260 0.375 0.480 
p 
value 
 <0.001 <0.001 <0.001 
Cytoplasmic 
C.C. 0.260  0.262 0.150 
p 
value 
<0.001  <0.001 0.006 
Smooth 
muscle 
C.C. 0.375 0.262  0.582 
P 
value 
<0.001 <0.001  <0.001 
Stroma 
C.C. 0.480 0.150 0.582  
P 
value 
<0.001 0.006 <0.001  
 
Siginicant values (highlighted bold) are denoted by Pearson’s correlation 
coefficient (C.C.) >0.400 and p value <0.05. 
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Table 8.5 Pearson's correlation coefficients pAR
S94
 expression in epithelial, smooth muscle 
and stromal cells in BPH 
 
 
AR phosphorylation site 
Ser-94 
Nuclear 
Cytoplas
mic 
Smooth 
muscle 
Stroma 
Ser-94 
Nuclear 
C.C.  0.477 0.556 0.618 
p 
value 
 <0.001 <0.001 <0.001 
Cytoplasmic 
C.C. 0.477  0.333 0.331 
p 
value 
<0.001  <0.001 <0.001 
Smooth 
muscle 
C.C. 0.556 0.333  0.656 
P 
value 
<0.001 <0.001  <0.001 
Stroma 
C.C. 0.618 0.331 0.656  
P 
value 
<0.001 <0.001 <0.001  
 
Siginicant values (highlighted bold) are denoted by Pearson’s correlation 
coefficient (C.C.) >0.400 and p value <0.05. 
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Table 8.6 Pearson's correlation coefficients pAR
S213
 expression in epithelial, smooth muscle 
and stromal cells in BPH 
 
AR phosphorylation site 
Ser-213 
Nuclear 
Cytoplas
mic 
Smooth 
muscle 
Stroma 
Ser-213 
Nuclear 
C.C.  0.225 0.292 0.405 
p 
value 
 <0.001 <0.001 <0.001 
Cytoplasmic 
C.C. 0.225  0.439 0.407 
p 
value 
<0.001  <0.001 <0.001 
Smooth 
muscle 
C.C. 0.292 0.439  0.718 
P 
value 
<0.001 <0.001  <0.001 
Stroma 
C.C. 0.405 0.407 0.718  
P 
value 
<0.001 <0.001 <0.001  
 
Siginicant values (highlighted bold) are denoted by Pearson’s correlation 
coefficient (C.C.) >0.400 and p value <0.05. 
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Table 8.7 Pearson's correlation coefficients pAR
S515
 expression in epithelial, smooth muscle 
and stromal cells in BPH 
 
AR phosphorylation site 
Ser-515 
Nuclear 
Cytoplas
mic 
Smooth 
muscle 
Stroma 
Ser-515 
Nuclear 
C.C.  0.136 0.360 0.461 
p 
value 
 0.013 <0.001 <0.001 
Cytoplasmic 
C.C. 0.136  0.086 0.046 
p 
value 
0.013  0.121 0.407 
Smooth 
muscle 
C.C. 0.360 0.086  0.654 
P 
value 
<0.001 0.121  <0.001 
Stroma 
C.C. 0.461 0.046 0.654  
P 
value 
<0.001 0.407 <0.001  
 
Siginicant values (highlighted bold) are denoted by Pearson’s correlation 
coefficient (C.C.) >0.400 and p value <0.05. 
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Table 8.8 Pearson's correlation coefficients pAR
S578
 expression in epithelial, smooth muscle 
and stromal cells in BPH 
 
AR phosphorylation sites 
Ser-578 
Nuclear 
Cytoplas
mic 
Smooth 
muscle 
Stroma 
Ser-578 
Nuclear 
C.C.  0.568 0.413 0.490 
p 
value 
 <0.001 <0.001 <0.001 
Cytoplasmic 
C.C. 0.568  0.296 0.345 
p 
value 
<0.001  <0.001 <0.001 
Smooth 
muscle 
C.C. 0.413 0.296  0.665 
P 
value 
<0.001 <0.001  <0.001 
Stroma 
C.C. 0.490 0.345 0.665  
P 
value 
<0.001 <0.001 <0.001  
 
Siginicant values (highlighted bold) are denoted by Pearson’s correlation 
coefficient (C.C.) >0.400 and p value <0.05. 
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Table 8.9 Pearson's correlation coefficients pAR
S650
 expression in epithelial, smooth muscle 
and stromal cells in BPH 
 
AR phosphorylation sites 
Ser-650 
Nuclear 
Cytoplas
mic 
Smooth 
muscle 
Stroma 
Ser-650 
Nuclear 
C.C.  0.357 0.466 0.631 
p 
value 
 <0.001 <0.001 <0.001 
Cytoplasmic 
C.C. 0.357  0.216 0.182 
p 
value 
<0.001  <0.001 0.001 
Smooth 
muscle 
C.C. 0.466 0.216  0.702 
P 
value 
<0.001 <0.001  <0.001 
Stroma 
C.C. 0.631 0.182 0.702  
P 
value 
<0.001 0.001 <0.001  
 
Siginicant values (highlighted bold) are denoted by Pearson’s correlation 
coefficient (C.C.) >0.400 and p value <0.05. 
As shown in Table 8.3 there was a strong correlation between total AR stromal 
and smooth muscle cell expression.  Tables 8.4-8.9 illustrate that in all AR serine 
phosphorylation sites studied, there was a strong correlation between both 
stromal and smooth muscle cell expression and stromal and nuclear epithelial 
cell expression. 
8.3 Phosphorylated androgen receptor related to 
clinicopathological factors 
Environmental, host and local disease factors have been implicated in the 
progression of BPH, therefore the relationship between clinicopathological 
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factors and AR and phosphorylated AR expression was investigated in the BPH 
cohort using the chi-squared test (Table 8.10 and 8.11). 
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Table 8.10 Chi squared analysis of clinical factors as related to high/low AR and pAR expression in BPH patients 
 
Proteins 
Clinical Variables 
Age 
(<70 v 
≥70yrs) 
CVD 
(presence v 
absence) 
DM2 
(presence v 
absence) 
Aspirin 
Usage 
(yes vs no) 
Smoking History 
(non- v ex- v 
smoker) 
PSA at 
diagnosis 
(<4 v ≥4ng/ml) 
BMI 
(<25 v 25-29 
v ≥30kg/m2) 
Weight of chips 
resected 
(<11 v ≥11g) 
Catheter in 
situ preop 
(yes v no) 
AR 
Cytoplasm 0.239 0.220 0.359 0.179 0.350 0.329 0.170 0.017 0.259 
Nucleus 0.965 0.253 0.014 0.449 0.549 0.777 0.881 0.047 0.566 
Smooth Muscle 0.992 0.272 0.141 0.240 0.360 0.092 0.004 0.193 0.843 
Stroma 0.742 0.681 0.150 0.432 0.337 0.969 0.478 0.067 0.181 
pARS81 
Cytoplasm 0.397 0.585 0.542 0.338 0.510 0.820 0.542 0.200 0.932 
Nucleus 0.864 0.597 0.535 0.311 0.188 0.081 0.464 0.095 0.557 
Smooth Muscle 0.181 0.102 0.585 0.582 0.712 0.355 0.088 0.521 0.941 
Stroma 0.199 0.670 0.982 0.334 0.906 0.816 0.544 0.941 0.774 
pARS94 
Cytoplasm 0.606 0.229 0.098 0.864 0.840 0.482 0.994 0.161 0.656 
Nucleus 0.303 0.953 0.064 0.985 0.648 0.713 0.065 0.190 0.192 
Smooth Muscle 0.113 0.859 0.871 0.606 0.484 0.629 0.155 0.227 0.596 
Stroma 0.082 0.857 0.876 0.963 0.712 0.732 0.670 0.280 0.623 
pARS213 
Cytoplasm 0.411 0.686 1.000 0.665 0.853 0.733 0.124 0.144 0.569 
Nucleus 0.053 0.444 0.247 0.990 0.432 0.106 0.811 0.282 0.569 
Smooth Muscle 0.124 0.005 0.574 0.089 0.371 0.694 0.226 0.765 0.531 
Stroma 0.156 0.941 0.097 0.988 0.181 0.470 0.881 0.958 0.419 
pARS515 
Cytoplasm 0.648 0.264 0.109 0.156 0.759 0.069 0.201 0.037 0.110 
Nucleus 0.071 0.935 0.768 0.595 0.343 0.340 0.885 0.178 0.526 
Smooth Muscle 0.171 0.485 0.438 0.275 0.273 0.926 0.150 0.510 0.181 
Stroma 0.234 0.186 0.189 0.468 0.597 0.920 0.144 0.794 0.650 
pARS578 
Cytoplasm 0.092 0.425 0.350 0.393 0.454 0.832 0.227 0.505 0.842 
Nucleus 0.220 0.064 0.610 0.213 0.845 0.507 0.632 0.883 0.320 
Smooth Muscle 0.784 0.526 0.538 0.890 0.108 0.661 0.419 0.928 0.173 
Stroma 0.345 0.915 0.865 0.746 0.619 0.815 0.808 0.918 0.527 
pARS650 
Cytoplasm 0.974 0.902 0.763 0.204 0.143 0.510 0.892 0.788 0.710 
Nucleus 0.708 0.730 0.037 0.412 0.131 0.971 0.556 0.830 0.894 
Smooth Muscle 0.175 0.129 0.374 0.275 0.701 0.326 0.183 0.012 0.922 
Stroma 0.066 0.452 0.890 0.963 0.746 0.270 0.710 0.039 0.814 
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8.3.1 Clinical factors related to androgen receptor expression 
Low smooth muscle pARS213 expression was associated with an increased 
incidence of cardiovascular disease.  Low nuclear total AR and pARS650 expression 
was associated with increased incidence of DM2.  Low total AR expression in the 
smooth muscle cells was associated with higher BMI.  Low cytoplasmic and 
nuclear total AR expression was associated with increased weight of chips 
resected at TUR.  High expression of cytoplasmic pARS515 and both smooth 
muscle and stromal pARS650 were all associated with increased weight of chips 
resected at TUR (Table 8.10).  Age, aspirin usage, smoking history, PSA at 
diagnosis and presence of a preoperative urinary catheter were not associated 
with protein expression at any of the phosphorylated AR sites. 
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Table 8.11 Chi squared analysis of pathological factors as related to high/low AR and pAR 
expression in BPH patients 
 
Proteins 
Pathological Variables 
Proliferation 
Index (Ki67) 
Apoptotic 
Index 
(TUNEL) 
Local 
inflammation 
(Klintrup-
Makinen 
Tissue 
Necrosis 
Systemic 
inflammation 
(mGPS) 
AR 
Cytoplasm 0.499 0.177 0.076 0.009 0.244 
Nucleus 0.480 0.410 0.351 0.661 0.995 
Smooth 
Muscle 
0.119 0.006 0.463 0.280 0.192 
Stroma <0.001 0.002 0.007 0.252 0.971 
pARS81 
Cytoplasm <0.001 0.422 0.387 0.603 0.149 
Nucleus 0.002 0.301 0.161 0.263 0.312 
Smooth 
Muscle 
0.013 0.181 0.921 0.506 0.154 
Stroma 0.028 0.267 0.246 0.500 0.761 
pARS94 
Cytoplasm 0.935 0.116 0.091 0.199 0.680 
Nucleus 0.679 0.014 0.337 0.009 0.167 
Smooth 
Muscle 
0.292 0.702 0.526 0.256 0.267 
Stroma 0.611 0.916 0.344 0.063 0.968 
pARS213 
Cytoplasm 0.132 0.014 0.006 0.242 0.434 
Nucleus 0.496 0.013 0.962 0.291 0.048 
Smooth 
Muscle 
0.572 0.124 0.004 0.259 0.938 
Stroma 0.252 <0.001 0.002 0.252 0.526 
pARS515 
Cytoplasm 0.009 0.894 0.030 0.833 0.678 
Nucleus 0.742 0.090 0.337 0.062 0.271 
Smooth 
Muscle 
0.640 0.962 0.727 0.062 0.080 
Stroma 0.297 0.193 0.770 0.273 0.846 
pARS578 
Cytoplasm 0.138 0.847 0.458 0.879 0.580 
Nucleus 0.024 0.815 0.375 0.940 0.977 
Smooth 
Muscle 
0.467 0.821 0.390 0.845 0.684 
Stroma 0.401 0.413 0.248 0.983 0.540 
pARS650 
Cytoplasm 0.003 0.860 0.652 0.041 0.543 
Nucleus 0.730 0.873 0.170 0.062 0.026 
Smooth 
Muscle 
0.784 0.356 0.471 0.277 0.137 
Stroma 0.723 0.188 0.634 0.068 0.013 
 
8.3.2 Pathological factors related to androgen receptor 
expression 
High stromal total AR expression was associated with a low proliferation index.  
Low expression of pARS81 in the epithelia cell nucleus and cytoplasm and the 
smooth muscle and stromal cells was associated with a low proliferation index.  
Low cytoplasmic pARS650 expression was associated with a low proliferation 
index.  High expression of cytoplasmic pARS515 and nuclear pARS578 were 
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associated with a low proliferation index (Table 8.11).  Low smooth muscle and 
stromal total AR expression was associated with a high apoptotic index, p=0.006 
and 0.002 respectively.  High nuclear pARS94 expression was associated with a 
high apoptotic index p=0.014.  Low cytoplasmic, nuclear and stromal pARS213 
expression was associated with a high apoptotic index (Table 8.11).  Therefore 
expression of total AR in the stroma was directly linked, with cell turnover and 
depending on the phosphorylation site investigated was either directly (serine 81 
and 650) or inversely (serine 515 and 578) associated with proliferation.   
Suggesting that phosphorylation status of AR is important when considering its 
role in driving cellular proliferation.  It was interesting to note the 
phosphorylation sites associated with phosphorylation in response to androgens 
serine 81 and 650 were directly associated with proliferation in contrast to those 
phosphorylated by growth factor signalling pathways e.g. 515 being inversely 
associated with proliferation. 
Emerging evidence linking inflammation to AR expression in BPH (34,35) 
prompted the investigation of the relationship between the local (Klintrup-
Makinen) and systemic (mGPS) inflammatory responses and AR and 
phosphorylated AR expression (Table 8.11).  High stromal total AR expression 
was associated with increased levels of local inflammation, p=0.007.  High 
cytoplasmic, smooth muscle and stromal pARS213 expression was associated with 
increased levels of local inflammation (Table 8.11).  High cytoplasmic pARS515 
expression was associated with increased levels of local inflammation, p=0.030.  
High levels of tissue necrosis were associated with high cytoplasmic expression 
of total AR and pARS650, p=0.009 and p=0.041 respectively.  Low levels of tissue 
necrosis were associated with high nuclear expression of pARS94, p=0.009.  High 
stromal pARS650 expression was associated with increased levels of systemic 
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inflammation, p=0.013.  High nuclear pARS213 and pARS650 expression were 
associated with increased levels of systemic inflammation, p=0.048 and p=0.026 
respectively. 
Once again this illustrates different roles for the different serine phosphorylation 
sites in BPH.  In general high levels of AR and pAR were associated with 
increased inflammation and necrosis.  This is with the exception of the 
constitutively phosphorylated site Ser-94 in which an inverse relationship was 
observed.  It is likely that it is not only AR phosphorylation that is associated 
with inflammation and necrosis, but a concert of kinase and growth factor driven 
intracellular signalling pathways. 
8.4 Phosphorylated androgen receptor related to 
outcomes 
Univariate analysis of AR and pAR protein expression was carried out using 
Kaplan Meier methods with reference to the clinical outcome measures.  The 
results are shown in Table 8.12. 
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Table 8.12 Univariate analysis of AR and phosphorylated AR expression and clinical 
outcome measures in BPH 
Proteins 
Postoperative 
AUR 
Failure of 
Surgical 
management 
Reoperation 
AR 
Nucleus 0.290 0.929 0.746 
Cytoplasm 0.507 0.294 0.413 
Smooth Muscle 0.978 0.010 0.879 
Stroma 0.852 0.480 0.820 
pARS81 
Nucleus 0.148 0.290 0.027 
Cytoplasm 0.951 0.182 0.183 
Smooth Muscle 0.578 0.392 0.358 
Stroma 0.282 0.721 0.194 
pARS94 
Nucleus 0.494 0.600 0.230 
Cytoplasm 0.523 0.341 0.340 
Smooth Muscle 0.344 0.729 0.152 
Stroma 0.802 0.844 0.514 
pARS213 
Nucleus 0.494 0.205 0.306 
Cytoplasm 0.232 0.176 0.927 
Smooth Muscle 0.760 0.094 0.755 
Stroma 0.756 0.052 0.143 
pARS515 
Nucleus 0.216 0.022 0.373 
Cytoplasm 0.850 0.010 0.294 
Smooth Muscle 0.017 0.646 0.682 
Stroma 0.441 0.556 0.533 
pARS578 
Nucleus 0.267 0.861 0.293 
Cytoplasm 0.674 0.801 0.357 
Smooth Muscle 0.324 0.553 0.945 
Stroma 0.692 0.681 0.449 
pARS650 
Nucleus 0.780 0.016 0.022 
Cytoplasm 0.874 0.023 0.752 
Smooth Muscle 0.317 0.698 0.750 
Stroma 0.992 0.091 0.081 
 
 
8.4.1 Postoperative acute urinary retention 
Only low pARS515 smooth muscle cell expression was associated with shorter time 
to postoperative AUR, HR 0.34 (95% CI 0.15-0.86) (Figure 8.2). 
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Figure 8.2 Kaplan Meier plot of smooth muscle pAR
S515
 expression and time to 
postoperative AUR in BPH patients 
 
8.4.2 Failure of surgical management 
Several proteins were associated with time to failure of surgical management of 
BPH.  Specifically low smooth muscle total AR expression was associated with 
shorter time to failure of surgical management, HR 0.59 (95% CI 0.39-0.88) 
(Figure 8.3). 
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Figure 8.3 Kaplan Meier plot of smooth muscle total AR expression and time to failure of 
surgical management in BPH patients 
 
Low cytoplasmic and nuclear pARS515 expression (HR 0.58 (95% CI 0.38-0.88) and 
(HR 0.62 (95% CI 0.41-0.94) respectively) were associated with shorter time to 
failure of surgical management (Figure 8.4 and 8.5). 
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Figure 8.4 Kaplan Meier plot of cytoplasmic expression and time to failure of surgical 
management in BPH patients 
 
Figure 8.5 Kaplan Meier plot of nuclear pAR
S515
 expression and time to failure of surgical 
management in BPH patients 
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Similarly low cytoplasmic and nuclear pARS650 expression (HR 0.62 (95% CI 0.41-
0.94) and HR 0.61 (95% CI 0.40-0.92) respectively) were also associated with 
shorter time to failure of surgical management of BPH (Figure 8.6 and 8.7). 
Figure 8.6 Kaplan Meier plot of cytoplasmic pAR
S650
 expression and time to failure of 
surgical management in BPH patients 
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Figure 8.7 Kaplan Meier plot of nuclear pAR
S650
 expression and time to failure of surgical 
management in BPH patients 
 
Given the inverse relationship with proliferation the relationships of total AR and 
pARS515 are not wholly unexpected.  However slowly proliferating prostates as 
demonstrated by low cytoplasmic pARS650 expression are more difficult to explain 
and compounding influences are likely to be at play. 
8.4.3 Reoperation 
Both low nuclear pARS81 and pARS650 expression were associated with shorter time 
to reoperation, HR 0.57 (95% CI 0.34-0.94) and HR 0.56 (95% CI 0.34-0.93) 
respectively (Figure 8.8 and 8.9). 
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Figure 8.8 Kaplan Meier plots of nuclear pAR
S81
 expression and time to reoperation in BPH 
patients 
 
Figure 8.9 Kaplan Meier plot of nuclear pAR
S650
 expression and time to reoperation in BPH 
patients 
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8.5 Multivariate analysis 
Significant univariate results were included in a backwards conditional cox-
regression model to determine independence from significant clinical 
parameters. 
Smooth muscle pARS515 expression was combined with age, CVD and presence of 
a preoperative catheter in a multivariate cox regression analysis.  Both smooth 
muscle pARS515 (p=0.029, HR 0.31 (95% CI 0.10-0.94)) and age (p=0.004, HR 5.13 
(95% CI 1.43-18.41)) were independently associated with postoperative AUR.  As 
these variables were deemed independent it was investigated whether smooth 
muscle pARS515 expression could inform on the likelihood of postoperative AUR in 
patients older than 70 years at diagnosis.  Low expression of pARS515 in the 
smooth muscle was associated with increased incidence of postoperative AUR in 
patients over 70 years old (25.1% vs 2.8% at 10 years post TUR), (p=0.002, HR 
0.20 (95% CI 0.06-0.62)) (Figure 8.10).  This may have important clinical 
implications in postoperative counselling and prophylactic medical treatment of 
these patients. 
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Figure 8.10 Kaplan Meier plot of smooth muscle pAR
S515
 expression and time to 
postoperative AUR in BPH patients over 70 years old 
 
Nuclear and cytoplasmic pARS515 and pARS650 expression were combined with 
smooth muscle AR expression, BMI and PSA at diagnosis in a multivariate cox 
regression analysis.  BMI (p=0.038, HR 1.43 (95% CI 1.01-2.00)), PSA at diagnosis 
(p=0.018, HR 1.89 (95% CI 1.11-3.16)), smooth muscle AR (p=0.016, HR 0.51 (95% 
CI 0.29-0.89)) and cytoplasmic pARS650 expression (p=0.010, HR 0.50 (95% CI 0.29-
0.86)) were independently associated with time to failure of operative 
management.  As these variables were deemed independent it was investigated 
whether cytoplasmic pARS650 expression could inform on the likelihood of failure 
of operative management in patients with PSA ≥4ng/ml at diagnosis.  Low 
expression of pARS650 in the cytoplasm was associated with increased failure of 
operative management in patients with PSA ≥4ng/ml at diagnosis (45.5% vs 13% 
at 5 years post TUR), (p=0.026, HR 0.52 (95% CI 0.29-0.93)) (Figure 8.11). 
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Figure 8.11 Kaplan Meier plot of cytoplasmic pAR
S650
 expression and time to failure of 
surgical management in BPH patients with PSA ≥4ng/ml at diagnosis 
 
When nuclear pARS81 and pARS650 expression were combined with proliferation 
index and weight of chips resected in a multivariate cox regression analysis, 
nuclear pARS650 expression (p=0.020, HR 0.54 (95% CI 0.32-0.91)), proliferation 
index (p<0.001, HR 0.33 (95% CI 0.17-0.65)) and weight of chips resected 
(p=0.013, HR 0.52 (95% CI 0.31-0.87) were independently associated with time to 
reoperation. 
8.6 Discussion 
Serine phosphorylated AR expression has been shown to have relevance with 
regards to clinical outcome in BPH.  Interestingly these results are both 
overlapping and subtly different to those seen in the pilot prostate cancer and 
active surveillance cohorts. 
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Protein expression was observed at all serine phosphorylation sites, in all cell 
types and subcellular locations in the BPH tissue which is consistent with 
previous work.(250)  A strong correlation was observed between stromal and 
smooth muscle total AR and phosphorylated AR expression at all serine sites.  
Interestingly nuclear epithelial AR expression was associated with stromal AR in 
all serine phosphorylation sites but not with regards to total AR expression.  BPH 
has been reported to comprise of 88.4% stromal cells and 9.0% epithelial cells 
(251) it is therefore logical that the stromal compartment may be the central 
communicating cell type perhaps influencing actions of the others.  These 
results suggest that expression levels and site specific phosphorylation status of 
AR in one cell type could affect or be linked to AR expression in other cell type, 
adding weight to the growing body of evidence regarding androgen-driven 
stromal-epithelial cell interactions in prostate disease.(252) 
In contrast to prostate cancer the expression levels of AR in human BPH tissue 
and their relationship to clinicopathological factors and clinical outcome has not 
been widely explored.  This study comprises the most extensive investigation 
into the clinical relevance of AR and AR serine phosphorylation expression levels 
in BPH to date. 
Regarding the clinical factors, low expression of AR and AR phosphorylated at 
serine residues were associated with CVD, DM2 and BMI.  As discussed previously 
CVD has been linked to BPH.  This study has observed, for the first time, that the 
androgen receptor may directly link these two diseases.  From the current study 
it is unclear whether it is the underlying heart disease itself or the commonly 
used drugs to treat CVD that underpin this relationship.  Work in prostate cancer 
cell lines has shown that statins (cholesterol-lowering drugs) decreased AR 
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protein levels by proteolysis resulting in a reduction in androgen sensitivity and 
cell proliferation (in AR positive cells).(253)  The metabolic consequences of 
DM2 (hyperglycaemia/ hyperinsulinaemia/ insulin resistance) have been 
demonstrated to promote production of insulin growth factor (IGF) 1 by prostate 
stromal (fibroblast) cells and it is hypothesised that this might have an impact on 
other intracellular signalling pathways involving the AR.(254)  Another element 
of the metabolic syndrome, high BMI, was shown to be associated with low 
smooth muscle AR expression; this is in agreement with the well-established 
observations that androgen insensitivity is associated with the number of CAG 
trinucleotide repeats in the AR, which in turn decreases AR-mediated gene 
transcription and results in elevated visceral fat.(255)  In addition, male mice 
lacking AR develop late onset visceral obesity with increased lipogenesis in white 
adipose tissue and liver.(256,257)  This result may be viewed alongside that 
described previously whereby high BMI was associated with shorter time to 
failure of surgical management in BPH patients.  Low smooth muscle AR 
expression was also associated with shorter time to failure of surgical 
management of BPH in the current study.  Selective smooth muscle AR ablation 
in mice leads to significant histological abnormalities such as hyperplasia, 
inflammation and fibrosis and it may be that even after surgery in patients with 
low smooth muscle AR expression these histological abnormalities translate into 
symptom recurrence requiring medical intervention at a faster rate.(21)  The 
relationship between smooth muscle AR expression, BMI and failure of surgical 
management in BPH patients requires further investigation to discern whether 
low smooth muscle AR expression is the cause or result of high BMI and indeed 
whether failure of surgical management is due to high BMI and/or low smooth 
muscle AR expression.  Taken together, these results suggest that BPH patients 
with low smooth muscle AR expression and/or high BMI may not respond 
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favourably to surgical management.  These patients could represent an exciting 
opportunity for the development of novel cell-specific AR targeted drug therapy. 
There was a variable relationship between AR and pAR expression and weight of 
chips resected at TUR.  This may be explained by the differing roles of AR at 
different phosphorylation sites.(100)  In general AR serine phosphorylation 
activates AR and is associated with increased gene transcription and cellular 
proliferation.  However, phosphorylation at Ser-650 is associated with nuclear 
export and negative regulation of gene transcription, the results in the current 
study whereby cytoplasmic levels of Ser-650 were associated with proliferation 
and therefore difficult to explain especially as cytoplasmic expression trended 
towards a direct relationship with nuclear expression.  Phosphorylation at Ser-
515 is associated with transcriptional activity and receptor stability.(100)  
However an inverse relationship was seen with proliferation and it may be the 
case that in BPH cells the primary role of Ser-515 phosphorylation is receptor 
stabilisation.  Increased receptor stability (Ser-515) may translate into larger 
prostates which have more tissue available for surgical resection and this may 
account for the results in this study.  It is also worth noting that no data was 
available for grade of surgeon performing the surgery and this may have 
confounded the results. 
In keeping with previous studies in prostate cancer cell lines pARS81 expression 
was strongly associated with proliferation in all cellular locations.(100,116)  In 
the current study high apoptotic index was associated with both low stromal and 
smooth muscle AR expression.  This agrees with previous work in double stromal 
AR knockout mouse models which exhibited increased levels of apoptosis.(23)  In 
addition, stromal fibroblast selective AR knockout mice showed increased 
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apoptosis (22) whilst smooth muscle selective AR knockout mice showed no 
change in apoptosis.(258)  We suggest that our results represent a shift in the 
normal balance of cells in BPH; a high proliferation index may result in more 
cells exhibiting mutations and therefore entering programmed cell death.  This 
could account for our finding that stromal AR expression was associated with 
both increased apoptosis and proliferation in BPH patients which might 
contribute to the uncontrolled progression of the disease.  Ser-578 
phosphorylation has been implicated in gene transcription and nuclear-
cytoplasmic shuttling of the AR, however its role in non-neoplastic prostatic 
tissue has not been previously studied.  Differing roles of AR serine 
phosphorylation sites in benign disease and neoplastic tissue may explain the 
relationship of Ser-578 phosphorylation with low levels of proliferation in BPH.  
Interestingly low expression levels of cytoplasmic, nuclear and stromal pARS213 
expression were associated with high levels of apoptosis.  This novel finding in 
BPH tissue is in line with previous work by the host laboratory in matched 
hormone naïve and castrate resistant prostate cancer samples whereby an 
increase in pARS213 expression was associated with decreased disease specific 
survival.  Uncontrolled cellular proliferation with associated 
dysregulation/inhibition of apoptosis may be driven by pARS213 in castrate 
resistant prostate cancer.  The current study suggests that the role of pARS213 
may be similar in benign and neoplastic prostatic disease.  Further work is 
required to substantiate this relationship. 
In line with previous work, evidence of local inflammation was found in all 
samples.(28)  The association of prostatic stromal cells with the immune 
response is supported by Penna and colleagues who demonstrated that human 
fibromuscular stromal BPH cells can behave as antigen presenting cells and 
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activate alloantigen-specific CD4+ T cells to produce IFN-γ and IL-17, thereby 
inducing and sustaining an autoimmune response.(259)  Unfortunately, AR 
expression levels in Penna’s work were not characterised and it is therefore 
difficult to draw direct comparisons.  Phosphorylation at Ser-213 was also 
strongly associated with local inflammation in the cytoplasm (along with pARS515) 
and smooth muscle cells.  This is in contrast to previous work whereby smooth 
muscle AR activation has been shown to mediate a direct anti-inflammatory 
effect via the use of the selective AR ligand DHT.(35)  Furthermore selective 
ablation of AR in murine prostate smooth muscle cells results in diffuse stromal 
hyperplasia, characterised by an infiltration of leukocytes.(21)  One explanation 
for these seemingly conflicting results may be AR phosphorylation status which 
augments its activation state and was not investigated in the previous studies. 
Patchy areas of necrosis are not infrequently seen in routine prostate pathology 
specimens with concurrent BPH.  In line with previous work our study reported a 
small amount of tissue necrosis in routine TUR prostate specimens.(236)  High 
epithelial AR and pARS650 expression in the cytoplasm were associated with tissue 
necrosis.  This may be explained by an increase in the host inflammatory 
response, which is known to be influenced by the presence of tissue necrosis.  If 
the local inflammatory response is increased this may lead to increased 
epithelial AR expression as supported by previous work.(260)  This is supported 
by the trend for high cytoplasmic AR expression to be associated with high levels 
of local inflammation.  Interestingly, low levels of pARS94 were associated with 
high levels of tissue necrosis.  These findings may illustrate the individual roles 
for serine phosphorylation sites in BPH.  These results require verification in a 
large, prospectively collected, independent cohort. 
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Overall low protein expression was generally associated with worse outcome in 
BPH patients.  Effects on clinical outcome measures were mediated by different 
phosphorylation sites of the AR in different cellular locations.  This suggests a 
differing role for androgen signalling in each cellular location and also highlights 
the importance of considering these cellular compartments individually in the 
development of new treatments for BPH. 
Low smooth muscle AR expression was associated with shorter time to failure of 
surgical management of BPH in the current study.  Selective smooth muscle AR 
ablation in mice leads to significant histological abnormalities such as 
hyperplasia, inflammation and fibrosis and it may be that even after surgery in 
patients with low smooth muscle AR expression these histological abnormalities 
translate into symptom recurrence requiring medical intervention at a faster 
rate.(21)  Low expression of Ser-515 and Ser-650 were also associated with 
shorter time to failure of surgical management in BPH patients.  Phosphorylation 
of AR at Ser-650 by JNK1 and p38 is associated with nuclear export of the 
receptor to the cytoplasm and subsequently antagonises AR transcription.(132)  
Low levels of Ser-650 may equate to uninhibited AR transcription and disease 
progression.  Ser-515 nuclear expression correlated strongly with Ser-650 nuclear 
expression (c.c. 0.419, p<0.001) and it may be that the expression of these two 
phosphorylation sites is linked.  This is further substantiated by the results in 
this study that they are both associated with the candidate upstream kinase 
Cdk1/pCdk1.  The low expression of Ser-515 as an adverse prognostic marker is 
in stark contrast to the findings in prostate cancer whereby high expression was 
associated with a poorer clinical outcome.  This adds weight to the long argued 
point that despite often occurring concurrently, BPH behaves as a separate 
disease process from prostatic carcinogenesis.(261)  Further functional cell line 
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studies coupled with prospective clinical trials would clarify the role and clinical 
application of these serine phosphorylation sites in BPH. 
Low expression of smooth muscle pARS515 expression was found to inform on the 
risk of AUR after primary TUR surgery in older patients with BPH.  The role of 
Ser-515 phosphorylation in AR stability may explain this relationship.  Low 
expression of pARS515 may result in instability in the receptor making it more 
vulnerable to modulation by other growth factors.  This may result in increased 
unregulated activity within the smooth muscle compartment of the prostate 
eventually leading to the clinical consequence of AUR.  This has potential 
clinical relevance in counselling of patients postoperatively with regards to the 
increased risk of AUR and in addition may provide an opportunity for 
intervention with current medical treatment for BPH and/or a novel targeted 
drug following further investigative work as to the mechanistic consequences of 
pARS515 smooth muscle expression with regards to disease progression.  In 
addition low levels of cytoplasmic pARS650 were found to inform on patients with 
high/abnormal PSA at diagnosis associated with increased failure of operative 
management in patients with PSA ≥4ng/ml at diagnosis.  Once again this has 
potential clinical utility with regards to the pre and post operative counselling of 
these patients and the targeted use of prophylactic medical treatment.
229 
 
9 Benign prostate hyperplasia and kinases 
mediating androgen receptor serine 
phosphorylation 
In the previous chapter it was demonstrated that phosphorylation of the AR at 
specific serine residues is associated with clinical outcome in BPH patients.  As 
in prostate cancer AR serine phosphorylation in BPH is thought to be controlled 
by kinases.  To our knowledge there are no previous studies investigating the 
kinases responsible for AR serine phosphorylation in BPH therefore this chapter is 
the first thorough exploration of kinases mediating AR phosphorylation at clinical 
relevant serine sites.  The aim was to explore whether these candidate kinases 
may represent novel therapeutic targets for treatment of BPH. 
9.1 Kinase protein expression 
Scansite 2.0 was utilised to identify the candidate kinases mediating AR 
phosphorylation on the clinically relevant sites; Ser-81, Ser-515, and Ser-
650.(154)  Scansite 2.0 predicted Cdk1 and ERK1/2 as strong candidates 
mediating phosphorylation of Ser-81, 515 and 650. 
Expression of all proteins was observed at varying levels in the cytoplasm and 
nucleus of both stromal and epithelial cells (Figure 9.1) 
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Figure 9.1 Example high/low candidate kinase immunohistochemical staining in BPH 
 
Only protein expression observed in the BPH tissue was scored.  ICCCs were 
performed to verify consistency between scorers, all values were >0.70 and are 
shown in Table 9.1.  Scatter plots for each antibody were used to display this 
data and to confirm there was no bias between scorers Bland-Altman plots were 
constructed. 
Table 9.1 ICCC scores for candidate kinase protein expression analysis in BPH 
 Protein Nucleus Cytoplasm Smooth muscle Stroma 
Cdk1 0.809 0.871 0.818 0.820 
pCdk1161 0.812 0.804 0.979 0.951 
pERK1/2 0.917 0.940 0.796 0.748 
 
Chapter 9 BPH and kinases mediating AR serine phosphorylation 231 
 
Protein expression levels were subdivided into low (≤median) and high 
expression (>median) for analysis.  Median kinase histoscore expression levels 
are shown in Table 9.2. 
Table 9.2 Protein expression levels for kinases in BPH cohort 
 
9.2 Candidate kinase expression related to 
clinicopathological factors 
The relationship between clinicopathological factors and high/low expression 
levels of the candidate kinases phosphorylating AR at clinically significant serine 
residues was investigated in the BPH cohort using the chi-squared test (Table 9.3 
and 9.4). 
9.2.1 Clinical factors related to candidate kinase expression 
As shown in Table 9.3 high expression of stromal Cdk1 was associated with 
increased age.  Low expression of nuclear pERK1/2 was associated with 
increased incidence of DM2.  Low expression of stromal pERK1/2 and smooth 
muscle Cdk1 was associated with a higher BMI. 
Protein 
Subcellular 
Location 
Median Histoscore 
(Histoscore units) 
Interquartile Range 
(Histoscore units) 
Cdk1 
Cytoplasm 125.0 102.5-150.0 
Nucleus 130.0 101.7-162.5 
Smooth muscle 38.3 20.0-65.0 
Stroma 71.7 45.0-100.0 
pCdk1 
Cytoplasm 30.0 20.0-50.0 
Nucleus 121.7 78.3-155.8 
Smooth muscle 95.0 86.7-98.3 
Stroma 96.7 87.7-100.0 
pERK1/2 
Cytoplasm 13.3 1.7-33.3 
Nucleus 14.2 2.2-35.0 
Smooth muscle 6.7 0-30.0 
Stroma 0 0-3.3 
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Table 9.3 Clinical factors as related to high/low candidate kinase expression in BPH cohort 
  
Proteins 
Clinical Variables 
Age 
(<70 v 
≥70yrs) 
CVD 
(presence v 
absence) 
DM2 
(presence v 
absence) 
Aspirin 
Usage 
(yes vs no) 
Smoking History 
(non- v ex- v 
smoker) 
PSA at 
diagnosis 
(<4 v ≥4ng/ml) 
BMI 
(<25 v 25-29 
v ≥30kg/m2) 
Weight of chips 
resected 
(<11 v ≥11g) 
Catheter in 
situ preop 
(yes v no) 
Cdk1 
Cytoplasm 0.341 0.564 0.718 0.545 0.575 0.091 0.847 0.277 0.914 
Nucleus 0.874 0.738 0.524 0.728 0.222 0.193 0.690 0.220 0.881 
Smooth Muscle 0.855 0.587 0.237 0.246 0.822 0.676 0.004 0.423 0.233 
Stroma 0.033 0.105 0.789 0.885 0.688 0.319 0.080 0.184 0.328 
pCdk1161 
Cytoplasm 0.629 0.481 0.442 0.871 0.623 0.058 0.753 0.438 0.507 
Nucleus 0.410 0.907 0.128 0.972 0.090 0.795 0.283 0.823 0.705 
Smooth Muscle 0.430 0.677 0.510 0.296 0.300 0.699 0.656 0.375 0.687 
Stroma 0.526 0.698 0.479 0.645 0.477 0.796 0.015 0.316 0.953 
pERK1/2 
Cytoplasm 0.191 0.235 0.217 0.290 0.729 0.349 0.896 0.870 0.757 
Nucleus 0.099 0.245 0.042 0.661 0.566 0.555 0.532 0.332 0.786 
Smooth Muscle 0.919 0.149 0.239 0.595 0.785 0.142 0.136 0.785 0.430 
Stroma 0.279 0.641 0.801 0.970 0.227 0.659 0.990 0.091 0.582 
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9.2.2 Pathological factors related to candidate kinase expression 
As shown in Table 9.4 low expression of nuclear pCdk1161 and stromal pERK1/2 
were associated with a high proliferation index.  Low expression levels of 
nuclear Cdk1 and pERK1/2 were associated with a higher level of tissue necrosis.  
High expression of cytoplasmic and smooth muscle pERK1/2 were associated 
with increased levels of systemic inflammation.  Low expression of smooth 
muscle pCdk1161 and stromal pCdk1161 and pERK1/2 were associated with a high 
apoptotic index. 
Table 9.4 Pathological factors as related to high/low candidate kinase expression in BPH 
cohort 
 
Proteins 
Pathological Variables 
Proliferation 
index 
(Ki67) 
Apoptotic 
index 
(TUNEL) 
Local 
inflammation 
(Klintrup-
Makinen) 
Tissue 
Necrosis 
Systemic 
inflammation 
(mGPS) 
Cdk1 
Cytoplasm 0.285 0.631 0.232 0.460 0.402 
Nucleus 0.659 0.250 0.323 0.014 0.761 
Smooth 
Muscle 
0.204 
0.460 0.691 0.469 0.846 
Stroma 0.157 0.299 0.825 0.058 0.102 
pCdk1161 
Cytoplasm 0.385 0.165 0.735 0.945 0.601 
Nucleus 0.005 0.137 0.309 0.994 0.060 
Smooth 
Muscle 
0.722 0.005 0.181 0.580 0.284 
Stroma 0.223 0.001 0.207 0.800 0.112 
pERK1/2 
Cytoplasm 0.757 0.575 0.462 0.113 0.018 
Nucleus 0.428 0.509 0.536 0.014 0.124 
Smooth 
Muscle 
0.330 0.189 0.499 0.266 0.048 
Stroma 0.045 0.002 0.913 0.930 0.092 
 
9.3 Kinases related to outcomes 
Univariate analysis of the candidate kinases (Cdk1, pCdk1161 and pERK1/2) with 
regards to the four clinical outcome measures is shown in Table 9.5. 
Table 9.5 Univariate analysis of candidate kinase expression and clinical outcome measures 
in BPH 
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Proteins 
Postoperative 
AUR 
Failure of 
Surgical 
Management 
Reoperation 
Cdk1 
Nuclear 0.983 0.718 0.431 
Cytoplasm 0.272 0.102 0.016 
Smooth Muscle 0.081 0.511 0.558 
Stroma 0.780 0.244 0.742 
pCdk1161 
Nuclear 0.023 0.597 0.668 
Cytoplasm 0.227 0.398 0.179 
Smooth Muscle 0.884 0.027 0.584 
Stroma 0.659 0.866 0.308 
pERK1/2 
Nuclear 0.637 0.492 0.773 
Cytoplasm 0.784 0.538 0.690 
Smooth Muscle 0.554 0.099 0.978 
Stroma 0.437 0.446 0.056 
 
9.3.1 Postoperative acute urinary retention 
High nuclear pCdk1161 was associated with shorter time to postoperative acute 
urinary retention HR 2.79 (95% CI 1.12-7.04) (Figure 9.2). 
Figure 9.2 Kaplan Meier plot nuclear pCdk1
161
 expression and time to postoperative AUR in 
BPH patients 
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9.3.2 Failure of surgical management 
High stromal pCdk1161 was associated with shorter time to failure of surgical 
management of BPH HR 1.58 (95% CI 1.05-2.39) (Figure 9.3). 
Figure 9.3 Kaplan Meier plot stromal pCdk1
161
 expression and time to failure of operative 
management in BPH patients 
 
9.3.3 Reoperation 
Low cytoplasmic Cdk1 expression was associated with shorter time to 
reoperation HR 0.53 (95% CI 0.31-0.90) (Figure 9.4). 
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Figure 9.4 Kaplan Meier plot cytoplasmic Cdk1 expression and time to reoperation in BPH 
patients 
 
9.4 Multivariate analysis 
As with AR and pAR expression significant univariate candidate kinase results 
were included in a backwards conditional cox-regression model to determine 
independence from significant clinical parameters. 
When nuclear pCdk1161 expression was combined with age, CVD and presence of 
a preoperative catheter in a multivariate cox regression analysis, age (p=0.016, 
HR 20.51 (95% CI 1.13-372.41)) was independently associated with postoperative 
AUR. 
No independent variables were found when significant clinicopathological factors 
were combined with protein expression in a cox regression analysis with regards 
to failure of surgical management and reoperation. 
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9.5 Association of candidate kinases to phosphorylated 
AR sites 
Once the clinical significance of the candidate kinases had been established, 
their association with AR phosphorylation was then investigated in order to 
establish whether the predicted kinase was observed to correlate with clinically 
relevant AR phosphorylation sites in the clinical samples. 
As shown in Table 9.6 pERK1/2 expression was not significantly associated with 
any of the clinically relevant AR phosphorylation sites, however Cdk1 and/or 
pCdk1161 were significantly associated with pARS81, pARS515 and pARS650 as 
predicted by Scansite 2.0 (Table 9.6). 
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Table 9.6 Pearson's correlation of significant AR serine phosphorylation sites and candidate kinases in BPH 
 
AR phosphorylation sites 
Cdk1 pCdk1
161
 pERK1/2 
Nuclear Cytoplasmic 
Smooth 
muscle 
Stroma Nuclear Cytoplasmic 
Smooth 
muscle 
Stroma Nuclear Cytoplasmic 
Smooth 
muscle 
Stroma 
Ser-81 
Nuclear 
C.C. 0.517 0.225 0.104 0.050 0.145 0.064 -0.65 -0.100 0.247 0.158 0.027 -0.180 
p value <0.001 <0.001 0.061 0.361 0.008 0.247 0.240 0.069 <0.001 0.004 0.626 0.001 
Cytoplasmic 
C.C. 0.060 0.385 -0.005 -0.083 -0.075 0.431 -0.97 -0.066 0.047 0.077 0.074 -0.104 
p value 0.279 <0.001 0.922 0.133 0.175 <0.001 0.077 0.233 0.390 0.162 0.176 0.057 
Smooth 
muscle 
C.C. 0.223 0.240 0.267 0.189 0.114 0.360 0.178 0.146 0.144 0.173 0.020 -0.124 
P value <0.001 <0.001 <0.001 0.001 0.038 <0.001 0.001 0.008 0.009 0.002 0.714 0.024 
Stroma 
C.C. 0.224 0.227 0.157 0.183 0.121 0.162 0.029 0.087 0.147 0.128 0.077 -0.190 
P value <0.001 <0.001 0.005 0.001 0.029 0.003 0.595 0.111 0.008 0.021 0.161 <0.001 
Ser-515 
Nuclear 
C.C. 0.452 0.385 0.143 0.194 0.208 0.074 -0.123 -0.089 0.200 0.141 0.106 -0.059 
p value <0.001 <0.001 0.010 <0.001 <0.001 0.183 0.026 0.108 <0.001 0.011 0.055 0.287 
Cytoplasmic 
C.C. 0.005 0.218 0.108 0.237 0.291 0.266 0.025 0.103 0.255 0.217 0.214 0.189 
p value 0.932 <0.001 0.050 <0.001 <0.001 <0.001 0.649 0.062 <0.001 <0.001 <0.001 0.001 
Smooth 
Muscle 
C.C. 0.344 0.283 0.370 0.353 0.193 0.204 0.082 0.106 0.090 0.090 0.021 -0.086 
p value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.139 0.055 0.106 0.104 0.702 0.119 
Stroma 
C.C. 0.404 0.279 0.297 0.385 0.182 0.093 -0.034 0.029 0.097 0.068 0.095 0.004 
p value <0.001 <0.001 <0.001 <0.001 0.001 0.091 0.540 0.597 0.079 0.216 0.082 0.939 
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Table 9.6 continued Pearson's correlation of significant AR serine phosphorylation sites and candidate kinases in BPH 
 
AR phosphorylation sites 
Cdk1 pCdk1
161
 pERK1/2 
Nuclear Cytoplasmic 
Smooth 
muscle 
Stroma Nuclear Cytoplasmic 
Smooth 
muscle 
Stroma Nuclear Cytoplasmic 
Smooth 
muscle 
Stroma 
Ser-650 
Nuclear 
C.C. 0.343 0.119 0.138 0.283 0.506 0.128 0.011 -0.040 0.263 0.240 0.301 0.190 
p value <0.001 0.031 0.012 <0.001 <0.001 0.020 0.839 0.470 <0.001 <0.001 <0.001 <0.001 
Cytoplasmic 
C.C. 0.175 0.344 0.141 0.094 0.040 0.331 0.015 -0.095 0.097 0.087 0.056 0.048 
p value 0.001 <0.001 0.011 0.086 0.465 <0.001 0.784 0.082 0.079 0.113 0.308 0.386 
Smooth 
Muscle 
C.C. 0.145 0.178 0.430 0.434 0.366 0.271 0.205 0.200 0.127 0.172 0.315 0.071 
p value 0.009 0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.021 0.002 <0.001 0.199 
Stroma 
C.C. 0.244 0.144 0.374 0.521 0.495 0.230 0.104 0.207 0.194 0.191 0.309 0.119 
p value <0.001 0.009 <0.001 <0.001 <0.001 <0.001 0.059 <0.001 <0.001 <0.001 <0.001 0.030 
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9.6 Discussion 
Kinases hypothesised to be responsible for AR phosphorylation were identified 
via Scansite.  These were Cdk1 for Ser-81, Ser-515 and Ser-650 and ERK1/2 for 
Ser-515 and Ser-650.  The expression of these candidate kinases was observed to 
be associated with clinicopathological factors in the BPH cohort.  Specifically, 
high expression of Cdk1 in the stroma was associated with increased age.  
Previous work has demonstrated an inverse link between the Cdk inhibitor 
p27(Kip1) and age in BPH tissue (200), which supports the results of the current 
study. 
Low expression of nuclear and stromal pERK1/2 was associated with increased 
incidence of DM2 and increased BMI respectively.  DM2 and obesity are 
interlinked diseases forming part of the metabolic syndrome.  These 
relationships are in contrast to previous work which has shown that activation of 
the ERK pathway is strongly associated with whole-body insulin resistance, and 
also indicated that ERK is likely a key modulator of the development of insulin 
resistance.(262)  Furthermore the inhibition of ERK phosphorylation by 
administration of a MEK inhibitor (U0126) decreased the blood glucose levels of a 
mouse model for metabolic syndrome (db/db knockouts).(263)  The explanation 
for these results is unclear and may reflect tissue specificity, however requires 
further investigation in a prospective cohort of BPH patients and mechanistic 
work in BPH cell lines. 
Low proliferation index and low apoptotic index were associated with high 
expression of pCdk1161 and pERK1/2.  This relationship is perhaps contrary to 
expectations and could suggest that following primary surgery a reverse 
relationship may manifest.  As previously discussed, fast proliferating cells that 
out grow their nutrient supply could result in inflammation and necrosis causing 
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a feedback pathway to shut down the overall growth of the gland.  To add 
weight to this theory low expression levels of Cdk1 and pERK1/2 were also 
associated with increased levels of tissue necrosis and high cytoplasmic pERK1/2 
(suggesting low nuclear expression) was associated with increased systemic 
inflammation.   These explanations represent hypotheses only and clearly there 
is a need for further investigation using mechanistic models, which is out with 
the scope of this project. 
Interestingly pERK1/2 expression was not found to be associated with any of the 
clinical outcome measures, as was the case in the pilot prostate cancer cohort.  
Previous studies comparing pERK1/2 expression in normal, hyperplastic and 
cancerous human prostate specimens has shown increased overall pERK1/2 
expression in prostate cancer > BPH > normal prostate.(264)  This relationship 
was replicated in the current study with regards to BPH and prostate cancer.  
pERK1/2 likely has downstream consequences in BPH however the current study 
infers that these may be operating primarily via different pathways than via AR.  
The clinical relevance of pERK1/2 expression and downstream signaling in BPH 
requires further investigation. 
Similar to the pilot prostate cancer cohort, expression of both Cdk1 and pCdk1161 
were associated with clinical outcome measures suggesting that Cdk1 may be of 
functional importance.  This is reinforced by previous work in which p27(Kip1) 
knock out mice develop histological BPH (265).  Studies have demonstrated the 
complete absence of p27(Kip1) expression in human BPH nodules.(266)  In 
contrast, diffuse p27(Kip1) expression was observed in normal prostate tissue 
with reduced expression in prostate cancer.(266)  This points towards a pivotal 
role of Cdk signalling in the development and progression of BPH. 
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pERK1/2 was not related to any of the AR serine phosphorylation sites observed 
to be clinically relevant in the previous chapter.  However, Cdk1 and pCdk1161 
were associated with pARS81, pARS515 and pARS650 in at least one subcellular 
location. 
In the previous chapter low expression of smooth muscle pARS515 expression was 
found to inform on the risk of AUR after primary TUR surgery in older patients 
with BPH.  Although correlation of smooth muscle pARS515 expression with 
Cdk1/pCdk1161 did not reach significance there was a trend for association of 
Cdk1 in all cell types/subcellular locations. 
In addition low levels of cytoplasmic pARS650, which trended towards a 
correlation with expression of cytoplasmic Cdk1 and pCdk1161, were found to 
inform on patients with high/abnormal PSA at diagnosis associated with 
increased failure of operative management in patients with PSA ≥4ng/ml at 
diagnosis.  Once again this has potential clinical utility with regards to the pre 
and post operative counselling of these patients and the targeted use of 
prophylactic medical treatment.  Over 20 Cdk inhibitors are already in use in 
clinical trials in monotherapy and in combination therapy for other 
diseases.(267-270)  Inhibition of cell cycle Cdks is thought to inhibit cellular 
proliferation and therefore disease progression.  Both broad Cdk inhibitors (e.g. 
Cdk 1, 2, 4, 5 and 9) and Cdk specific inhibitors (Cdk4 and 6) are available.  
Their potential use in BPH is as yet unexplored.  In the context of the current 
study high pCdk1161 expression was associated with shorter time to failure of 
surgical management and postoperative AUR which may benefit from direct 
inhibition.  However, low expression of pAR at serine residues was associated 
with poorer clinical outcome and these sites were directly associated with 
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Cdk1/pCdk1161 in this case a Cdk inhibitor may actually prove to be detrimental.  
Further work is required in order to unpick the modulation of pAR expression by 
Cdk1 in BPH prior to an investigation into the usefulness of Cdk inhibitors in this 
disease. 
Serine phosphorylation of the androgen receptor has been shown to be 
associated with Cdk1/pCdk1161 in BPH patients.  Future work will include the 
undertaking of mechanistic cell line studies in order to clarify these 
relationships, this is unfortunately out with the scope of the current study. 
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Conclusion 
In conclusion the work presented comprises the first fully comprehensive 
examination of the relevance of AR serine phosphorylation, and associated 
kinases, in prostatic disease in the clinical setting. 
Key findings 
The key findings in study were: 
1. AR serine phosphorylation may have clinical relevance in both BPH and 
prostate cancer. 
2. High levels of AR phosphorylation at serine residues is generally associated 
with worse outcome in prostate cancer, whilst low expression is associated with 
worse outcome in BPH. 
3. Upstream kinases mediating AR serine phosphorylation, in particular Cdk1, 
may also have clinical relevance in BPH and prostate cancer. 
Key advancement in science 
The current study has demonstrated for the first time the significance of AR 
serine phosphorylation in prostate cancer and BPH human tissue specimens in 
relation to clinical outcome.  In addition, the Cdk1/pAR axis may have potential 
as a new target for therapeutic intervention.  AR serine phosphorylation has 
been identified as a worthwhile avenue for future investigation as a prognostic 
and predictive biomarker in prostatic disease. 
Potential clinical applications 
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AR serine phosphorylation has been demonstrated to have potential as a 
predictive and prognostic biomarker in both prostate cancer and BPH. 
Furthermore, the primary experimental technique utilised 
(immunohistochemistry) is currently employed in every diagnostic pathology lab 
in the UK and it is for this reason that this is considered a fully translational 
research study. 
Areas of future research 
Although the results presented are exciting they are far from conclusive and this 
study lays the foundation for further investigation. Future work will firstly 
include the additional validation of the phosphospecific antibodies utilised in 
this study via siRNA and knockout mice, phosphatase assays, kinase and 
phosphatase inhibitors, cell transfectants and site specific mutagenesis. Once 
further antibody specificity has been established immunohistochemistry on a 
large, multicentre, prospectively collected cohort of both BPH and prostate 
cancer patients should be undertaken. In parallel mechanistic cell line work via 
silencing and functional assays would further clarify the nature of the 
kinase/pAR axis. 
AR serine phosphorylation in prostatic disease represents a potential diagnostic 
tool to aid the differentiation of indolent from aggressive disease. In the future 
this may translate as increased survival and reduction of potential harm to 
patients from overtreatment of both prostate cancer and BPH. 
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